| Role of probiotics VSL#3 in prevention of suspected sepsis in low birthweight infants in India: a randomised controlled trial 2015 · Probiotics · Low-birthweight infants weighing 1500–2500 g, enrolled at 3–7 days of life | 10 billion CFU | 30 days | 668 |
| Clostridium butyricum MIYAIRI 588 Reduces Colorectal Adenomatous Polyp Recurrence: A Randomized Crossover Trial 2025 · CBM588 treatment phase (Groups A and B) · Adults with a history of colorectal adenomas removed within the previous three years and recurrent colorectal polyps | 2 g | 1 year | 398 |
| Bifidobacterium and Lactobacillus Probiotics and Gut Dysbiosis in Preterm Infants: The PRIMAL Randomized Clinical Trial 2024 · Verum · Preterm infants born at 28 weeks 0 days to 32 weeks 6 days of gestation | 1.5 billion CFU | 4 weeks | 306 |
| Dietary supplementation with lactobacilli and bifidobacteria is well tolerated and not associated with adverse events during late pregnancy and early infancy 2010 · treatment group · Women in the last month of pregnancy and their infants aged 0–6 months | 10 billion CFU | 26 weeks | 220 |
| [A multicenter randomized controlled study of Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea in infants and young children] 2017 · prevention group · Hospitalized children aged 1 month to 3 years with non-gastrointestinal infections requiring antibiotic therapy | 250 mg | — | 213 |
| Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial 2017 · HN001 · Pregnant women enrolled at 14–16 weeks’ gestation; participants were eligible if they or the unborn child’s biological father had a history of asthma, hayfever or eczema requiring medication. | 6 billion CFU | — | 212 |
| Effect of Lactobacillus rhamnosus Probiotic in Early Pregnancy on Plasma Conjugated Bile Acids in a Randomised Controlled Trial 2021 · HN001 group · Pregnant women recruited at 14–16 weeks’ gestation whose own or unborn child’s biological father had a history of asthma, hay fever, or eczema requiring medication | 6 billion CFU | — | 212 |
| [Multicenter, randomized, controlled clinical trial on preventing antibiotic-associated diarrhea in children with pneumonia using the live Clostridium butyricum and Bifidobacterium combined Powder] 2012 · treatment group · Hospitalized children aged 3 months to 3 years with pneumonia | 5 billion CFU | 7 days | 193 |
| Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study 2014 · high-dose · Adult hospital in-patients requiring antibiotic therapy; age and sex ranges not reported | 17 billion CFU | — | 168 |
| Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study 2014 · low-dose · Adult hospital in-patients requiring antibiotic therapy; age and sex ranges not reported | 4.17 billion CFU | — | 168 |
| Effect of Limosilactobacillus reuteri DSM17938 to prevent antibiotic-associated diarrhea in children: prospective, multi-center, randomized, placebo-controlled clinical trial (PEARL Study) 2025 · Group 1a (14 days) · Children aged 6 months to 10 years with acute otitis media or acute rhinosinusitis receiving amoxicillin-clavulanate | 0.2 billion CFU | 2 weeks | 168 |
| Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine 2004 · Escherichia coli Nissle 1917 group · Patients with ulcerative colitis in remission | 200 mg | 1 year | 162 |
| Effect of Limosilactobacillus reuteri DSM17938 to prevent antibiotic-associated diarrhea in children: prospective, multi-center, randomized, placebo-controlled clinical trial (PEARL Study) 2025 · Group 1b (21 days) · Children aged 6 months to 10 years with acute otitis media or acute rhinosinusitis receiving amoxicillin-clavulanate | 0.2 billion CFU | 3 weeks | 162 |
| Multispecies Probiotic for the Prevention of Antibiotic-Associated Diarrhea in Children: A Randomized Clinical Trial 2022 · probiotic · Children aged 3 months to 18 years receiving broad-spectrum systemic antibiotics | 10 billion CFU | — | 158 |
| Oxygen-driven nebulization of Clostridium butyricum prevents drug-resistant bacterial pneumonia 2026 · Control group · Patients aged 6–85 years with chronic respiratory disease and a history of multiple infections with drug-resistant bacteria | 0.0063 billion CFU | 13 days | 155 |
| Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial 2022 · Probiotic · Adults aged 18–60 with symptomatic, RT-qPCR-confirmed Covid-19; both sexes, including participants with and without metabolic risk factors | 2 billion CFU | 30 days | 150 |
| Efficacy of proprietary Lactobacillus casei for anti-tuberculosis associated gastrointestinal adverse reactions in adult patients: a randomized, open-label, dose-response trial 2020 · high-dose group · Adults undergoing intensive-phase anti-tuberculosis therapy | 20 billion CFU | 60 days | 143 |
| Efficacy of proprietary Lactobacillus casei for anti-tuberculosis associated gastrointestinal adverse reactions in adult patients: a randomized, open-label, dose-response trial 2020 · low-dose group · Adults undergoing intensive-phase anti-tuberculosis therapy | 10 billion CFU | 60 days | 142 |
| Randomised, double-blind and placebo-controlled study using new probiotic lactobacilli for strengthening the body immune defence against viral infections 2011 · Probiotic group · Healthy subjects; age and sex not stated | 1 billion CFU | 12 weeks | 135 |
| Saccharomyces boulardii for prevention of necrotizing enterocolitis in preterm infants: a randomized, controlled study 2013 · study group · Very low-birth-weight infants with gestational age ≤32 weeks and birth weight ≤1500 g | 250 mg | — | 135 |
| Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children 2008 · probiotic group · children aged 3 months to 14 years with common infections receiving antibiotic treatment | 40 billion CFU | — | 120 |
| [Clinical effect of triple therapy combined with Saccharomyces boulardii in the treatment of Helicobacter pylori infection in children] 2014 · probiotics group · Children with confirmed Helicobacter pylori infection | 500 mg | 2 weeks | 120 |
| Supplementation of standard antibiotic therapy with oral probiotics for bacterial vaginosis and aerobic vaginitis: a randomised, double-blind, placebo-controlled trial 2015 · prOVag group · Women aged 18–50 with recurrent bacterial vaginosis, including women with bacterial vaginosis or aerobic vaginitis | 0.2 billion CFU | 100 days | 118 |
| Yogurt supplemented with probiotics can protect the healthy elderly from respiratory infections: A randomized controlled open-label trial 2017 · intervention group · Healthy men and women aged 45 years or older | 10.8 billion CFU | 12 weeks | 115 |
| Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in intensive care unit patients 2008 · Probiotic group · Adults aged 18 years or older admitted to an intensive care unit, with a stay longer than 48 hours and a nasogastric feeding tube; mixed medical, surgical and trauma patients | 2 billion CFU | 2 weeks | 102 |
| Prevention of recurrence with epirubicin and lactobacillus casei after transurethral resection of bladder cancer 2008 · epirubicin plus Lactobacillus casei group · Patients with histologically confirmed superficial bladder cancer after transurethral resection | 3 g | 1 year | 100 |
| Prenatal and postnatal probiotics reduces maternal but not childhood allergic diseases: a randomized, double-blind, placebo-controlled trial 2012 · LGG group · Pregnant women with atopic diseases, elevated total IgE and/or positive specific IgE | 10 billion CFU | — | 95 |
| Effect of perioperative probiotic intervention on postoperative cognitive dysfunction in elderly patients: a randomized double- blinded and placebo-controlled trial 2025 · probiotic group · Adults aged 65 years or older undergoing elective lower-extremity orthopedic surgery | 420 mg | 7 days | 90 |
| The Effect of Probiotics on Health in Pregnancy and Infants: A Randomized, Double-Blind, Placebo-Controlled Trial 2025 · probiotic group · Healthy pregnant women aged 18–39 years, less than 28 weeks pregnant, planning to breastfeed | 5 billion CFU | 18 weeks | 90 |
| Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial 2014 · probiotics · Adults with cirrhosis without overt hepatic encephalopathy; mean age 48.6 years; 96 men and 64 women overall | 0.3 billion CFU | 90 days | 86 |
| Effects of Lactobacillus paracasei N1115 on gut microbial imbalance and liver function in patients with hepatitis B-related cirrhosis 2024 · intervention group · Adults with hepatitis B-related cirrhosis; age and sex not restricted | 100 billion CFU | 90 days | 86 |
| Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients 2010 · Pro-1 · Adult inpatients receiving antibiotics | 50 billion CFU | — | 85 |
| Role of probiotics in the prevention of the enteric colonization by Candida in preterm newborns: incidence of late-onset sepsis and neurological outcome 2011 · group I (L. reuteri) · Preterm newborns with birth weight <2500 g and gestational age <37 weeks | 0.1 billion CFU | 6 weeks | 83 |
| Role of probiotics in the prevention of the enteric colonization by Candida in preterm newborns: incidence of late-onset sepsis and neurological outcome 2011 · group II (L. rhamnosus) · Preterm newborns with birth weight <2500 g and gestational age <37 weeks | 6 billion CFU | 6 weeks | 83 |
| [A prospective control study of Saccharomyces boulardii in prevention of antibiotic-associated diarrhea in the older inpatients] 2017 · study group · older inpatients treated with broad-spectrum antibiotics for at least three days | 1 g | 3 weeks | 81 |
| Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection 2012 · POCA group · H. pylori-positive gastritis patients | 0.03 billion CFU | 2 weeks | 78 |
| Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy 2012 · Gp-P · Adults with cirrhosis who had recovered from hepatic encephalopathy | 338 billion CFU | 1 year | 77 |
| Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection 2012 · OCAP group · H. pylori-positive gastritis patients | 0.03 billion CFU | 2 weeks | 77 |
| Double-blind, randomised clinical assay to evaluate the efficacy of probiotics in preterm newborns weighing less than 1500 g in the prevention of necrotising enterocolitis 2013 · probiotic group · Preterm newborns weighing less than 1500 g | 1 g | — | 75 |
| Preventive Effect of Cow's Milk Fermented with Lactobacillus paracasei CBA L74 on Common Infectious Diseases in Children: A Multicenter Randomized Controlled Trial 2017 · group A · Healthy children aged 12–48 months attending day care or preschool at least 5 days a week | 7 g | 90 days | 73 |
| Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates 2005 · Probiotic-supplemented infants · Preterm neonates with birth weight ≤1500 g | 1 billion CFU | — | 72 |
| Probiotics Prevent Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt: A Randomised Controlled Trial 2025 · probiotics group · Patients with cirrhosis receiving TIPS for variceal bleeding, without previous overt hepatic encephalopathy | 6 g | 24 weeks | 72 |
| Streptococcus salivarius K12 Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors: A Randomized Controlled Trial 2024 · SsK12 · Adults aged 18–80 with nonmetastatic malignant head and neck tumors undergoing definitive or postoperative radiotherapy, with or without concurrent chemotherapy | 3 billion CFU | 46 days | 71 |
| Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy 2006 · yogurt-plus-quadruple therapy group · Patients with residual Helicobacter pylori infection after failed triple therapy | 400 mL | 4 weeks | 69 |
| A Randomised, Controlled Trial: Effect of a Multi-Strain Fermented Milk on the Gut Microbiota Recovery after Helicobacter pylori Therapy 2021 · Test group · Adults aged 18–65 with dyspepsia and Helicobacter pylori infection receiving eradication therapy | 200 g | 4 weeks | 68 |
| Beneficial effect of probiotics supplements in reflux esophagitis treated with esomeprazole: A randomized controlled trial 2019 · probiotics group · Adults aged 18–65 with reflux esophagitis | 1.5 g | 8 weeks | 67 |
| Positive regulatory effects of perioperative probiotic treatment on postoperative liver complications after colorectal liver metastases surgery: a double-center and double-blind randomized clinical trial 2015 · PRO group · Adults aged 25–75 with colorectal cancer and liver metastases undergoing surgery | 2 g | 16 days | 66 |
| Efficacy and Safety of Postbiotic Contained Inactivated Lactobacillus reuteri ( Limosilactobacillus reuteri ) DSM 17648 as Adjuvant Therapy in the Eradication of Helicobacter pylori in Adults With Functional Dyspepsia: A Randomized Double-Blind Placebo-Controlled Trial 2024 · Postbiotic group · Adults aged 18–65 with functional dyspepsia and Helicobacter pylori infection | 400 mg | 4 weeks | 66 |
| Evaluation of the efficacy of Lactobacillus plantarum HEAL9 and Lactobacillus paracasei 8700:2 on aspects of common cold infections in children attending day care: a randomised, double-blind, placebo-controlled clinical study 2020 · Probi Defendum® (probiotic group) · Healthy boys and girls aged 1–6 years attending day care | 1 billion CFU | 90 days | 63 |
| Effectiveness and safety of vonoprazan and amoxicillin dual regimen with Saccharomyces boulardii supplements on eradication of Helicobacter pylori 2024 · VAS group · Adults aged 18–75 with confirmed Helicobacter pylori infection and no prior eradication therapy | 500 mg | 10 days | 63 |
| The influence of probiotics on genital high-risk human papilloma virus clearance and quality of cervical smear: a randomized placebo-controlled trial 2019 · study group · Women aged 30–65 with high-risk human papillomavirus infection and a cervical smear negative for intraepithelial lesion or malignancy; not pregnant | 5.4 billion CFU | 1 year | 62 |
| Probiotics prophylaxis in children with persistent primary vesicoureteral reflux 2007 · probiotics group · children with persistent primary vesicoureteral reflux after one year of antibiotic prophylaxis | 2 g | 1 year | 60 |
| Probiotic Supplementation Reduces RRTIs and Enhances Gut Microbial and Immunity in Children: A Randomized Controlled Trial 2026 · probiotic group · boys and girls aged 0–14 years with recurrent respiratory tract infections (RRTIs) | 10 billion CFU | 180 days | 60 |
| Efficacy and safety of Saccharomyces boulardii as adjunct therapy with Vancomycin in treating Clostridioides difficile infection: A randomized controlled trial 2025 · S. boulardii and vancomycin · Hospitalized adults aged 20 years or older with mild to moderate Clostridioides difficile infection | 500 mg | 10 days | 59 |
| Pregnancy outcomes in pregnant women taking oral probiotic undergoing cerclage compared to placebo: two blinded randomized controlled trial 2024 · Group A: Oral probiotic (probiotic group) · Pregnant women aged 18–45 years, at 14–24 weeks’ gestation, who underwent cerclage | 500 mg | 21 weeks | 58 |
| Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial 2007 · probiotic group · Hospital patients taking antibiotics, mean age 74; both sexes and a diagnosed condition not specified | 200 g | — | 57 |
| Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy 2011 · probiotic group · healthy infants enrolled at 1 month of age | 10 billion CFU | 26 weeks | 55 |
| [Study on the efficacy of combination therapy with rifaximin and Saccharomyces boulardii CNCM I-745 in patients with small intestinal bacterial overgrowth associated with long-term use of proton pump inhibitors] 2025 · Group 2 · Adults with confirmed small intestinal bacterial overgrowth (SIBO) associated with long-term proton pump inhibitor use | 1 g | 7 days | 55 |
| Effect of probiotic chewing tablets on early childhood caries--a randomized controlled trial 2015 · test group · Healthy children aged 2–3 years from a multicultural, low-socioeconomic area | 0.1 billion CFU | 1 year | 54 |
| Effect of Lactobacillus rhamnosus HN001 on carriage of Staphylococcus aureus: results of the impact of probiotics for reducing infections in veterans (IMPROVE) study 2018 · Probiotic · Adults aged 18 years or older, predominantly older men, colonized with Staphylococcus aureus | 10 billion CFU | 4 weeks | 52 |
| Saccharomyces boulardii Allows Partial Patients to Avoid Reusing Bismuth Quadruple for Helicobacter pylori Rescue Therapy: A Single-Center Randomized Controlled Study 2022 · study group · Adults aged 18–65, male and female, with H. pylori infection after failed treatment | 1 g | 2 weeks | 50 |
| Lactobacillus casei Shirota probiotic drinks reduce antibiotic associated diarrhoea in patients with spinal cord injuries who regularly consume proton pump inhibitors: a subgroup analysis of the ECLISP multicentre RCT 2024 · LcS group · Adults aged 18 years or older with spinal cord injury, taking regular proton pump inhibitors and prescribed antibiotics | 6.5 billion CFU | 2 weeks | 50 |
| A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children 2009 · Intervention group · Children aged 3–18 years with Helicobacter pylori infection | 500 mg | 4 weeks | 48 |
| Intelligent Algorithm-Based Gastrointestinal X-Ray Examination in Evaluating the Therapeutic Effect of Probiotics Combined with Triple Therapy on Children with Helicobacter Infection 2022 · group B · Children aged 3–11 years with Helicobacter pylori infection | 1.5 g | 6 weeks | 48 |
| Saccharomyces boulardii combined with triple therapy alter the microbiota in the eradication of Helicobacter pylori infection 2024 · Group SRAC · Adults aged 18–65 with Helicobacter pylori-positive non-ulcerative dyspepsia | 1 g | 2 weeks | 48 |
| Kefir improves the efficacy and tolerability of triple therapy in eradicating Helicobacter pylori 2011 · triple therapy + kefir · Patients with dyspepsia symptoms and Helicobacter pylori infection | 500 mL | 2 weeks | 46 |
| Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants 2001 · LGG · Children aged 1 to 36 months hospitalized for reasons other than diarrhea | 12 billion CFU | — | 45 |
| The efficacy of lactobacillus reuteri in conjunction with racecadotril in managing pediatric rotavirus enteritis and its impact on intestinal mucosa and immune function 2025 · observation group · Children aged 3 months to 6 years with rotavirus enteritis | 0.1 billion CFU | 7 days | 42 |
| Do Probiotics During In-Hospital Antibiotic Treatment Prevent Colonization of Gut Microbiota With Multi-Drug-Resistant Bacteria? A Randomized Placebo-Controlled Trial Comparing Saccharomyces to a Mixture of Lactobacillus, Bifidobacterium, and Saccharomyces 2020 · Saccharomyces · Adults aged 35–97 hospitalized with infectious diseases and treated with antibiotics; mostly older adults with comorbidities | 12 billion CFU | 30 days | 40 |
| Oral Lactobacillus fermentum CECT5716 in the patients with lactational abscess treated by needle aspiration: The late follow-up of a randomized controlled trial 2022 · Experimental group · Lactating women aged 20–45 with a breast abscess during lactation, treated by needle aspiration | 3 billion CFU | 4 weeks | 40 |
| Assessment of the role of probiotics in prevention of ventilator-associated pneumonia in neonates 2025 · probiotic group · Full-term neonates aged 37 to 42 weeks who required mechanical ventilation for more than 48 hours | 2 billion CFU | — | 40 |
| Effect of orally administered L. crispatus M247 in favoring HR-HPV clearance and CST shift: results from a randomized, multi-center, placebo-controlled trial 2025 · Probiotic group · Women aged 18–69 with newly diagnosed high-risk HPV infection and no visible cervical lesions at colposcopy | 20 billion CFU | 120 days | 40 |
| Evaluation of efficacy and safety of Lacticaseibacillus rhamnosus LRa05 in the eradication of Helicobacter pylori: a randomized, double-blind, placebo-controlled trial 2024 · LRa05 group · Adults aged 18–65 with Helicobacter pylori infection | 10 billion CFU | 4 weeks | 36 |
| The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: An open-label, randomized clinical trial 2018 · Group B · Adults aged 18–70 with H. pylori-positive gastritis | 120 mg | 2 weeks | 35 |
| Effect of Lactobacillus casei supplementation on the effectiveness and tolerability of a new second-line 10-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection 2004 · group A · Adults with persistent Helicobacter pylori infection after failure of a first eradication attempt | 750 mg | 10 days | 34 |
| Evaluation of Helicobacter Pylori eradication in pediatric patients by triple therapy plus lactoferrin and probiotics compared to triple therapy alone 2012 · Group B (triple therapy plus probiotic) · Children with Helicobacter pylori-positive gastritis, mean age 8.3 ± 3.4 years | 5 g | 7 days | 34 |
| An evaluation of the ability of the probiotic strain Lactobacillus rhamnosus GG to eliminate the gastrointestinal carrier state of vancomycin-resistant enterococci in colonized children 2011 · LGG treatment group · Children aged 0–18 years with gastrointestinal carriage of vancomycin-resistant enterococci, hospitalized in a children's hospital | 3 billion CFU | 3 weeks | 32 |
| Remission of peanut allergy is associated with rewiring of allergen-driven T helper 2-related gene networks 2022 · Probiotic Peanut Oral Immunotherapy (PPOIT) · Peanut-allergic children aged 1–10 years | 20 billion CFU | 548 days | 31 |
| [Effects of probiotics on feeding intolerance in low birth weight premature infants] 2010 · probiotics treatment group · Low birth weight premature infants | 500 mg | — | 30 |
| Lactobacillus reuteri ATCC55730 in cystic fibrosis 2014 · LR · Patients with cystic fibrosis and mild-to-moderate lung disease | 10 billion CFU | 26 weeks | 30 |
| [Dynamics of contamination and persistence of Clostridium difficile in intestinal microbiota in newborn infants during antibiotic therapy and use of probiotic strain enterococcus faecium L3] 2013 · main group (premature newborn infants) · Premature newborn infants with very low body weight receiving inpatient antibiotic therapy | 2 mL | 10 days | 29 |
| VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial 2023 · low-dose VE303 · Adults aged 18 years or older with prior Clostridioides difficile infection (CDI) and at least one prior CDI episode in the last 6 months, or primary CDI and high risk for recurrence | 1.6 billion CFU | 2 weeks | 27 |
| Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3 2014 · Group A = “6Tx/6-” · Infertile men aged 19–46 with bacteriologically cured chronic bacterial prostatitis and diarrhea-predominant IBS | 450 billion CFU | 26 weeks | 26 |
| Probiotic mitigates gut hypoperfusion-associated acute gastrointestinal injury in patients undergoing cardiopulmonary bypass: a randomized controlled trial 2025 · Lac group · Adults aged 18–70 with moderate to severe congestive heart failure and heart valve disease undergoing valve replacement with cardiopulmonary bypass | 6 billion CFU | 7 days | 26 |
| High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study 2019 · 7-day high dose PPI-bismuth-containing quadruple therapy with probiotics · Adults older than 18 with Helicobacter pylori infection and non-ulcer dyspepsia | 75 mg | 7 days | 25 |
| High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study 2019 · 14-day high dose PPI-bismuth-containing quadruple therapy with probiotics · Adults older than 18 with Helicobacter pylori infection and non-ulcer dyspepsia | 75 mg | 2 weeks | 25 |
| Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3 2014 · Group C = “6-/6Tx” · Infertile men aged 19–46 with bacteriologically cured chronic bacterial prostatitis and diarrhea-predominant IBS | 450 billion CFU | 26 weeks | 23 |
| Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3 2014 · Group B = “12Tx” · Infertile men aged 19–46 with bacteriologically cured chronic bacterial prostatitis and diarrhea-predominant IBS | 450 billion CFU | 1 year | 22 |
| Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial 2000 · VSL#3 group · Adults with chronic pouchitis in clinical and endoscopic remission after ileal pouch-anal anastomosis for ulcerative colitis | 6 g | 270 days | 20 |
| Effects of probiotic on intestinal mucosa of patients with ulcerative colitis 2004 · BIFICO group · Patients with ulcerative colitis; age and sex not reported | 1.26 g | 8 weeks | 15 |
| Lactobacillus brevis CD2 attenuates traumatic oral lesions induced by fixed orthodontic appliance: A randomized phase 2 trial 2021 · Lactobacillus brevis CD2 · Orthodontic patients aged 14–57 years using a fixed orthodontic appliance | 12 billion CFU | 3 weeks | 10 |
| Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study 1999 · Lactobacillus GG group · Children aged 2 weeks to 12.8 years with acute respiratory infections receiving antimicrobial treatment | 40 billion CFU | — | — |
| [The effects of bifidobacterium on the intestinal mucosa of the patients with ulcerative colitis] 2003 · BIFICO group · Patients with ulcerative colitis in clinical and endoscopic remission while receiving sulphasalazine and glucocorticoid; ages and sex not reported | 420 mg | 8 weeks | — |
| Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial 2007 · Lactobacillus reuteri group · Mothers from families with a history of allergic disease and their infants; mothers began supplementation at gestational week 36, and infants continued from birth | 0.1 billion CFU | 1 year | — |
| Modulation of Helicobacter pylori colonization with cranberry juice and Lactobacillus johnsonii La1 in children 2008 · placebo juice/La1 (La1) · Children aged 6–16 with asymptomatic Helicobacter pylori colonization | 80 mL | 3 weeks | — |
| Reducing the risk of infection in the elderly by dietary intake of yoghurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 2010 · yoghurt group · healthy elderly individuals; median ages 74.5 and 67.7 years in the two studies; sex not specified | 90 g | 12 weeks | — |
| Comparative efficacy of probiotic yoghurt and clindamycin in treatment of bacterial vaginosis in pregnant women: a randomized clinical trial 2012 · probiotic yoghurt · pregnant women in the third trimester with symptomatic bacterial vaginosis | 200 g | 7 days | — |
| A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years 2012 · Lactobacillus rhamnosus HN001 (HN001) · High-risk birth cohort; mothers from 35 weeks’ gestation and infants from birth | 6 billion CFU | 2 years | — |
| A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years 2012 · Bifidobacterium animalis subsp lactis HN019 (HN019) · High-risk birth cohort; mothers from 35 weeks’ gestation and infants from birth | 9 billion CFU | 2 years | — |
| Prophylactic probiotics to prevent death and nosocomial infection in preterm infants 2012 · probiotic group · Preterm infants weighing ≤2000 g | 0.1 billion CFU | — | — |
| A randomized double-blind controlled trial: impact of probiotics on diarrhea in patients treated with pelvic radiation 2014 · standard dose group · Patients with pelvic cancers receiving pelvic radiotherapy; some had prior surgery and some received chemotherapy; age and sex not stated | 2.6 billion CFU | — | — |
| A randomized double-blind controlled trial: impact of probiotics on diarrhea in patients treated with pelvic radiation 2014 · high dose group · Patients with pelvic cancers receiving pelvic radiotherapy; some had prior surgery and some received chemotherapy; age and sex not stated | 30 billion CFU | — | — |
| Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals 2014 · Group 1 - Bifidobacterium animalis subsp. lactis Bl-04 (Bl-04) · Healthy physically active men and women; ages not specified for this arm | 2 billion CFU | — | — |
| Lactobacillus Reuteri for the prevention of necrotising enterocolitis in very low birthweight infants: a randomised controlled trial 2014 · first group · Preterm infants with gestational age ≤32 weeks and birth weight ≤1500 g | 0.1 billion CFU | — | — |
| Probiotics Reduce Necrotizing Enterocolitis Severity in HIV-exposed Premature Infants 2015 · probiotic group · Premature infants born to HIV-positive or HIV-negative women | 1 billion CFU | — | — |
| Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: a randomized controlled multicenter trial 2016 · probiotics group · critically ill adults expected to receive mechanical ventilation for at least 48 hours | 1.5 g | 2 weeks | — |
| Effects of Lactobacillus rhamnosus HN001 in early life on the cumulative prevalence of allergic disease to 11 years 2018 · Lactobacillus rhamnosus HN001 (HN001) · Mothers from 35 weeks' gestation while breastfeeding and their infants from birth to age 2 years | 6 billion CFU | 2 years | — |
| Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial 2019 · Experimental group · Moroccan patients with confirmed Helicobacter pylori infection; age and sex range not specified | 500 mg | 10 days | — |
| [Influence of different timing of Saccharomyces boulardii combined with bismuth quadruple therapy for Helicobacter pylori eradication] 2019 · simultaneous probiotic group · H. pylori-infected patients | 1 g | 2 weeks | — |
| [Influence of different timing of Saccharomyces boulardii combined with bismuth quadruple therapy for Helicobacter pylori eradication] 2019 · there after probiotic group · H. pylori-infected patients | 1 g | 2 weeks | — |
| Safety and tolerance of Lacticaseibacillus paracasei N1115 in caesarean-born young children: a randomised, placebo-controlled trial 2022 · L. paracasei N1115 group · Children aged 6–24 months born by caesarean section | 2 g | 12 weeks | — |
| Randomised clinical trial: efficacy and safety of H. pylori eradication treatment with and without Saccharomyces boulardii supplementation 2024 · Saccharomyces boulardii, 10-day regimen · Healthy individuals aged 40–64 years | 1 g | 10 days | — |
| Randomised clinical trial: efficacy and safety of H. pylori eradication treatment with and without Saccharomyces boulardii supplementation 2024 · Saccharomyces boulardii, 14-day regimen · Healthy individuals aged 40–64 years | 1 g | 2 weeks | — |
| Prebiotic and probiotic fortified milk in prevention of morbidities among children: community-based, randomized, double-blind, controlled trial 2010 · Prebiotic and probiotic fortified milk (PP) · Children aged 1–4 years in a community setting in India, with no specific diagnosed condition required | 0.019 billion CFU | 1 year | 312 |
| Bovine lactoferrin supplementation for prevention of necrotizing enterocolitis in very-low-birth-weight neonates: a randomized clinical trial 2014 · group BLF + LGG · Very-low-birth-weight neonates (<1500 g at birth), born prematurely | 6 billion CFU | 45 days | 238 |
| Perinatal probiotic supplementation in the prevention of allergy related disease: 6 year follow up of a randomised controlled trial 2015 · Probiotic · Pregnant women in a general population in Trondheim, Norway; maternal supplementation from 36 weeks’ gestation until 3 months postpartum | 55 billion CFU | — | 211 |
| Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial 2009 · BLF plus LGG · Very low-birth-weight infants (<1500 g) enrolled from birth; preterm neonates at risk of sepsis | 6 billion CFU | 45 days | 151 |
| Role of short-term use of L. acidophilus DDS-1 and B. lactis UABLA-12 in acute respiratory infections in children: a randomized controlled trial 2016 · probiotic group · Otherwise healthy children of both sexes aged 3–12 years, exposed to a sick household member | 5 billion CFU | 2 weeks | 113 |
| Filaggrin Mutation Status and Prevention of Atopic Dermatitis with Maternal Probiotic Supplementation 2024 · Probiotic group · Pregnant women from a non-selected population, receiving the intervention from 36 weeks of gestation while breastfeeding after delivery | 105 billion CFU | — | 111 |
| Effect of a Short-Term Intervention with Lactobacillus salivarius Probiotic on Early Childhood Caries-An Open Label Randomized Controlled Trial 2022 · probiotic test group · Healthy children aged 3–6 years, either sex, with or without early childhood caries; recruited from a region with high caries prevalence | 20 mg | 2 weeks | 70 |
| Effects of synbiotics on necrotizing enterocolitis and full enteral feeding in very low birth weight infants: A double-blind, randomized controlled trial 2024 · Synbiotic group · Preterm neonates with very low birth weight under 1500 g and gestational age under 34 weeks | 2 billion CFU | — | 59 |
| Probiotics and magnesium orotate for the treatment of major depressive disorder: a randomised double blind controlled trial 2024 · Intervention · Adults over 18 with current major depressive disorder | 40 billion CFU | 8 weeks | 58 |
| Probiotics in septic acute kidney injury, a double blind, randomized control trial 2023 · intervention group (probiotics) · Adults with sepsis-induced acute kidney injury; mean age 55.5 years in this arm, both sexes | 90 billion CFU | 7 days | 48 |
| Synbiotics modulate gut microbiota and reduce enteritis and ventilator-associated pneumonia in patients with sepsis: a randomized controlled trial 2018 · Synbiotics group · Patients older than 16 years with sepsis requiring mechanical ventilation in the ICU | 3 g | 20 days | 35 |
| Long-term use of probiotics Lactobacillus and Bifidobacterium has a prophylactic effect on the occurrence and severity of pouchitis: a randomized prospective study 2014 · probiotic group · Adults aged 21–68 years after restorative proctocolectomy for ulcerative colitis or familial adenomatous polyposis, without acute pouchitis at entry | 4.8 billion CFU | 270 days | 19 |
| D-Mannose Plus Saccharomyces boulardii to Prevent Urinary Tract Infections and Discomfort after Cystoscopy: A Single-Center Prospective Randomized Pilot Study 2023 · Group A · Patients undergoing cystoscopy for suspected bladder cancer or follow-up after transurethral resection, with negative urine culture | 6 billion CFU | 6 days | 16 |
| Modulation of Helicobacter pylori colonization with cranberry juice and Lactobacillus johnsonii La1 in children 2008 · cranberry juice/La1 (CB/La1) · Children aged 6–16 with asymptomatic Helicobacter pylori colonization | 80 mL | 3 weeks | — |
| Modulation of Helicobacter pylori colonization with cranberry juice and Lactobacillus johnsonii La1 in children 2008 · cranberry juice/heat-killed La1 (CB) · Children aged 6–16 with asymptomatic Helicobacter pylori colonization | 80 mL | 3 weeks | — |
| Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial 2012 · group A2 · Preterm very low birth weight neonates | 0.001 billion CFU | 6 weeks | — |
| Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals 2014 · Group 2 - Lactobacillus acidophilus NCFM and Bifidobacterium animalis subsp. lactis Bi-07 (NCFM & Bi-07) · Healthy physically active men and women; ages not specified for this arm | 10 billion CFU | — | — |
| Specific probiotics and virological findings in symptomatic conscripts attending military service in Finland 2014 · probiotic group · Healthy male military conscripts aged 18–28; symptomatic conscripts were included in the virological analysis | 14 billion CFU | 150 days | — |
| Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis 2015 · Bio-Three group · Outpatients with ulcerative colitis in remission; age and sex not reported | 198 mg | 1 year | — |
| Maternal fish oil and/or probiotics intervention: Allergic diseases in children up to two years old 2023 · probiotics + placebo · Women in early pregnancy | 20 billion CFU | — | — |
| Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial 2015 · 10 billion CFU · Healthy men and women aged 18–70 with low defecation frequency (2–4 days per week) and abdominal discomfort | 10 billion CFU | 4 weeks | 452 |
| Fewer Community-Acquired Colds with Daily Consumption of Lactiplantibacillus plantarum HEAL9 and Lacticaseibacillus paracasei 8700:2. A Randomized, Placebo-Controlled Clinical Trial 2021 · Probiotic · Healthy men and women aged 18–70 years with susceptibility to the common cold (at least 4 colds in the previous 12 months) | 1 billion CFU | 12 weeks | 448 |
| Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial 2015 · 1 billion CFU · Healthy men and women aged 18–70 with low defecation frequency (2–4 days per week) and abdominal discomfort | 1 billion CFU | 4 weeks | 343 |
| Saccharomyces cerevisiae I-3856 in irritable bowel syndrome with predominant constipation 2022 · Probiotic group · Females and males aged 18–75 with irritable bowel syndrome with predominant constipation (IBS-C) | 8 billion CFU | 8 weeks | 230 |
| Effect of Lactobacillus rhamnosus HN001 in Pregnancy on Postpartum Symptoms of Depression and Anxiety: A Randomised Double-blind Placebo-controlled Trial 2017 · HN001 · Pregnant women recruited at 14–16 weeks’ gestation with a parental or fetal biological-parent history of asthma, hayfever, or eczema requiring medication; planned to breastfeed | 6 billion CFU | — | 212 |
| Effect of Probiotics on Diarrhea in Children With Severe Acute Malnutrition: A Randomized Controlled Study in Uganda 2017 · probiotic group · Children admitted with severe acute malnutrition | 10 billion CFU | 12 weeks | 200 |
| Probiotics for children with uncomplicated severe acute malnutrition (PruSAM study): A randomized controlled trial in the Democratic Republic of Congo 2023 · probiotic group · Children with uncomplicated severe acute malnutrition | 2 billion CFU | 30 days | 200 |
| Perioperative administration of CBM588 in colorectal cancer radical surgery: A single-center, randomized controlled trial 2025 · CBM588-treated group · Adults aged 18–80 with colorectal adenocarcinoma undergoing radical surgery | 120 mg | 13 days | 200 |
| Efficacy of high-dose Lactobacillus rhamnosus GG in controlling acute watery diarrhea in Indian children: a randomized controlled trial 2009 · group B · Indian children with acute watery diarrhea | 20 billion CFU | 7 days | 188 |
| Efficacy of high-dose Lactobacillus rhamnosus GG in controlling acute watery diarrhea in Indian children: a randomized controlled trial 2009 · group C · Indian children with acute watery diarrhea | 2,000 billion CFU | 7 days | 186 |
| Prevention and treatment of diarrhoea with Saccharomyces boulardii in children with acute lower respiratory tract infections 2013 · group A · Hospitalised children with acute lower respiratory tract infection receiving intravenous antibiotics | 500 mg | 2 weeks | 167 |
| Randomized, direct comparison study of Saccharomyces boulardii CNCM I-745 versus multi-strained Bacillus clausii probiotics for the treatment of pediatric acute gastroenteritis 2022 · Bacillus clausii O/C, SIN, N/R, T mixture · Children aged 6 months to 5 years with mild-to-moderate acute diarrhea | 4 billion CFU | 5 days | 158 |
| Randomized, direct comparison study of Saccharomyces boulardii CNCM I-745 versus multi-strained Bacillus clausii probiotics for the treatment of pediatric acute gastroenteritis 2022 · Saccharomyces boulardii CNCM I-745 · Children aged 6 months to 5 years with mild-to-moderate acute diarrhea | 500 mg | 5 days | 157 |
| Effects of Lactobacillus fermentum CECT5716 Lc40 on infant growth and health: a randomised clinical trial in nursing women 2020 · Lc40 group · Nursing women who were breastfeeding; mothers of infants | 3 billion CFU | 16 weeks | 139 |
| Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial 2005 · experimental group · Children aged 6 months to 14 years with otitis media and/or respiratory tract infections receiving antibiotic treatment | 500 mg | — | 132 |
| Increasing work-place healthiness with the probiotic Lactobacillus reuteri: a randomised, double-blind placebo-controlled study 2005 · L. reuteri group · Healthy employees aged 18–65; the study also included shift-workers | 0.1 billion CFU | 80 days | 132 |
| Irritable bowel syndrome symptom severity improves equally with probiotic and placebo 2016 · High-dose · Adults aged 18–65 with irritable bowel syndrome diagnosed according to Rome III criteria | 10 billion CFU | 12 weeks | 131 |
| Probiotics improve bowel movements in hospitalized elderly patients--the PROAGE study 2011 · study group · Hospitalized orthopedic rehabilitation patients aged 65 years and older, including patients recovering from orthopedic surgery or bone fracture | 450 billion CFU | 45 days | 129 |
| Irritable bowel syndrome symptom severity improves equally with probiotic and placebo 2016 · Low-dose · Adults aged 18–65 with irritable bowel syndrome diagnosed according to Rome III criteria | 1 billion CFU | 12 weeks | 129 |
| Efficacy of a yeast postbiotic on cold/flu symptoms in healthy children: A randomized-controlled trial 2024 · EpiCor · Healthy boys and girls aged 4–12 years attending school or daycare | 500 mg | 12 weeks | 128 |
| Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial 2020 · L. acidophilus DDS-1 group · Adults aged 18–70 with irritable bowel syndrome meeting Rome IV criteria | 10 billion CFU | 6 weeks | 111 |
| Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial 2020 · B. lactis UABla-12 group · Adults aged 18–70 with irritable bowel syndrome meeting Rome IV criteria | 10 billion CFU | 6 weeks | 110 |
| The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial 2018 · Clostridium butyricum group · Adults aged 18–65, male and female, with diarrhea-dominant irritable bowel syndrome (IBS-D) | 1.26 g | 4 weeks | 105 |
| Efficacy and dose response of Lactiplantibacillus plantarum in diarrhea-predominant irritable bowel syndrome 2023 · L. plantarum 1B · Adults aged 18–70 years, females and males, with Rome IV diarrhea-predominant irritable bowel syndrome | 1 billion CFU | 8 weeks | 104 |
| Effect of probiotic Lactobacillus (Lacidofil® cap) for the prevention of antibiotic-associated diarrhea: a prospective, randomized, double-blind, multicenter study 2010 · Lactobacillus group · Korean adults aged over 18 years with respiratory tract infection receiving antibiotic therapy | 4 billion CFU | 2 weeks | 103 |
| Effect of a Multi-Strain Probiotic on Growth and Time to Reach Full Feeds in Preterm Neonates 2022 · probiotic (intervention) group · Male and female preterm neonates with birth weight 750–1500 g and gestational age under 37 weeks | 0.2 mL | 4 weeks | 100 |
| The Effects of Perioperative Probiotics on Postoperative Gastrointestinal Function in Patients with Brain Tumors: A Randomized, Placebo-Controlled Study 2023 · probiotics group · Patients with brain tumors undergoing elective craniotomy; age and sex not reported | 8 g | 15 days | 100 |
| Efficacy and dose response of Lactiplantibacillus plantarum in diarrhea-predominant irritable bowel syndrome 2023 · L. plantarum 10B · Adults aged 18–70 years, females and males, with Rome IV diarrhea-predominant irritable bowel syndrome | 10 billion CFU | 8 weeks | 99 |
| Effects of phototherapy combined with Lactobacillus salivarius AP-32 or Bifidobacterium animalis subsp. lactis CP-9 on improving neonatal jaundice and gut microbiome health: a randomized double-blind clinical study 2025 · CP-9 group · Full-term neonates (≥37 weeks gestation) with bilirubin levels exceeding 15 mg/dL on postnatal day 4 | 10 billion CFU | — | 96 |
| Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study 2020 · Lactobacillus paracasei group · Adults aged 18 years or older with IBS diagnosed according to Rome III criteria; all IBS subtypes were eligible. | 10 billion CFU | 8 weeks | 95 |
| Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study 2020 · Bifidobacterium longum group · Adults aged 18 years or older with IBS diagnosed according to Rome III criteria; all IBS subtypes were eligible. | 10 billion CFU | 8 weeks | 95 |
| Lactiplantibacillus plantarum P9 for chronic diarrhea in young adults: a large double-blind, randomized, placebo-controlled trial 2024 · P9 (probiotic) · Adults aged 18–65 with chronic diarrhea | 100 billion CFU | 4 weeks | 93 |
| Treatment of acute diarrhea with Saccharomyces boulardii in infants 2011 · Saccharomyces boulardii group · Infants aged 6 to 48 months hospitalized with acute diarrhea | 400 mg | 5 days | 90 |
| Impact of probiotic supplements on behavioural and gastrointestinal symptoms in children with autism spectrum disorder: A randomised controlled trial 2025 · probiotic group · Children aged 2–9 years with medically diagnosed autism spectrum disorder | 18 billion CFU | 90 days | 90 |
| Effects of phototherapy combined with Lactobacillus salivarius AP-32 or Bifidobacterium animalis subsp. lactis CP-9 on improving neonatal jaundice and gut microbiome health: a randomized double-blind clinical study 2025 · AP-32 group · Full-term neonates (≥37 weeks gestation) with bilirubin levels exceeding 15 mg/dL on postnatal day 4 | 10 billion CFU | — | 89 |
| Multistrain probiotics alleviate gastrointestinal symptoms during bismuth quadruple therapy for Helicobacter pylori infection 2025 · intervention group · Adults aged 18–60 with untreated Helicobacter pylori infection | 40 billion CFU | 4 weeks | 89 |
| The efficacy of the prenatal administration of Lactobacillus reuteri LR92 DSM 26866 on the prevention of infantile colic: a randomized control trial 2020 · case group · Healthy pregnant women; infants were followed for colic after birth | 0.1 billion CFU | 4 weeks | 87 |
| A Double-Blind, Randomized, Placebo-Controlled Trial of Heat-Killed Pediococcus acidilactici K15 for Prevention of Respiratory Tract Infections among Preschool Children 2020 · K15 group · Healthy preschool children aged 3–6 years | 9.1 mg | 16 weeks | 87 |
| Effect of single versus multistrain probiotic in extremely preterm infants: a randomised trial 2022 · SS probiotic group · Extremely preterm infants born before 28 weeks’ gestation, ready to commence feeds or on feeds for less than 12 hours | 3 billion CFU | 10 weeks | 87 |
| The Beneficial Effects of Regular Intake of Lactobacillus paragasseri OLL2716 on Gastric Discomfort in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Study 2024 · OLL2716 group · Healthy Japanese men and women aged 20–64 years with mild to slightly severe postprandial fullness or early satiety | 1 billion CFU | 12 weeks | 87 |
| A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome 2015 · Saccharomyces cerevisiae group · Adults with irritable bowel syndrome meeting Rome III criteria; age range not reported | 500 mg | 8 weeks | 86 |
| Effect of single versus multistrain probiotic in extremely preterm infants: a randomised trial 2022 · TS probiotic group · Extremely preterm infants born before 28 weeks’ gestation, ready to commence feeds or on feeds for less than 12 hours | 3 billion CFU | 71 days | 86 |
| Effectiveness of Sterilized Symbiotic Drink Containing Lactobacillus helveticus Comparable to Probiotic Alone in Patients with Constipation-Predominant Irritable Bowel Syndrome 2020 · Group B (probiotic group) · Adults with constipation-predominant irritable bowel syndrome; age range not reported; both sexes | 350 mL | 7 days | 84 |
| Impact of probiotics on the course of indirect hyperbilirubinemia and phototherapy duration in very low birth weight infants 2013 · study group · Very low birth weight infants with gestational age ≤32 weeks and birth weight ≤1500 g | 250 mg | — | 81 |
| Fish Oil And/Or Probiotics Intervention in Overweight/Obese Pregnant Women and Overweight Risk in 24-Month-Old Children 2023 · Probiotics + placebo · Pregnant women with overweight or obesity, enrolled before 18 gestational weeks; no chronic diseases stated | 10 billion CFU | — | 81 |
| Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial 2022 · PPOIT (probiotic and peanut oral immunotherapy) · Children aged 1–10 years with confirmed peanut allergy | 20 billion CFU | 548 days | 79 |
| Weizmannia coagulans BC01 supplementation improved functional constipation by regulating gut microbiota: A randomized, placebo-controlled, clinical study 2025 · probiotic group · Adults aged 18–65 with functional constipation | 5 billion CFU | 3 weeks | 79 |
| Effect of the probiotic strain, Lactiplantibacillus plantarum P9, on chronic constipation: A randomized, double-blind, placebo-controlled study 2023 · probiotic group · Patients diagnosed with chronic constipation following Rome IV criteria; age and sex not stated | 100 billion CFU | 6 weeks | 78 |
| The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis 2009 · VSL#3 group · Adults with mild-to-moderately active ulcerative colitis | 7,200 billion CFU | 12 weeks | 77 |
| Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial 2018 · high-dose group · Adults aged 18–70 with functional constipation diagnosed by Rome III criteria | 10 billion CFU | 4 weeks | 76 |
| Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial 2018 · low-dose group · Adults aged 18–70 with functional constipation diagnosed by Rome III criteria | 1 billion CFU | 4 weeks | 76 |
| The Effect of the Lacticaseibacillus paracasei BEPC22 and Lactiplantibacillus plantarum BELP53 Combination (BN-202M) on Body Fat Percentage Loss in Overweight Individuals: A Randomized, Double-Blind, Placebo-Controlled Study 2024 · BN-202M group · Adults aged 19–60 years with overweight (BMI 25–29.9 kg/m²) | 50 billion CFU | 12 weeks | 75 |
| Collinsella aerofaciens as a predictive marker of response to probiotic treatment in non-constipated irritable bowel syndrome 2024 · probiotic arm · Adults with non-constipated irritable bowel syndrome, IBS-D or IBS-M; mean age 35 years | 48 billion CFU | 12 weeks | 72 |
| Bacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial 2025 · B. coagulans Unique IS2 · Healthy adults with infrequent bowel movements, averaging at least 3.0 and fewer than 7.0 complete spontaneous bowel movements per week during the run-in | 2 billion CFU | 4 weeks | 72 |
| Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study 2010 · VSL#3 group · Adults with relapsing mild-to-moderate ulcerative colitis | 3,600 billion CFU | 8 weeks | 71 |
| Psychobiotic Effects on Anxiety Are Modulated by Lifestyle Behaviors: A Randomized Placebo-Controlled Trial on Healthy Adults 2023 · Probiotic intake · Healthy adults aged 20–66 years in Santiago, Chile; both sexes | 3 billion CFU | 4 weeks | 71 |
| Lactiplantibacillus plantarum Lp815 improves sleep and increases urinary GABA in a randomized, double-blind, placebo-controlled study of sleep disturbance 2026 · GABA Probiotic Lp815 (5 billion CFU Lp815/dose/day) · Adults aged 18 years or older with at least moderate symptoms of sleep disturbance, including difficulty falling asleep | 5 billion CFU | 6 weeks | 70 |
| A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome 2024 · HT-ES1 · Adults aged 18–65 with diarrhea-predominant irritable bowel syndrome (IBS-D) | 50 mg | 12 weeks | 68 |
| Neurodevelopment and Growth 2 Years After Probiotic Supplementation in Extremely Preterm Infants: A Randomised Trial 2025 · L. reuteri group · Extremely preterm newborn infants born at postmenstrual week 23+0–27+6 with birth weight under 1000 g | 0.125 billion CFU | — | 68 |
| Randomized Clinical Trial to Evaluate the Effect of Probiotic Intake on Androgenic Alopecia 2024 · probiotic · Adults aged 18–65, men and women with androgenetic alopecia | 0.5 billion CFU | 16 weeks | 67 |
| Probiotic Formulation for Patients With Bipolar or Schizophrenia Spectrum Disorder: A Double-Blind, Randomized Placebo-Controlled Trial 2025 · probiotics · Adults aged 18 years or older with bipolar disorder or a schizophrenia spectrum disorder | 4 g | 12 weeks | 67 |
| The Effectiveness of Probiotic Lactobacillus rhamnosus and Lactobacillus casei Strains in Children with Atopic Dermatitis and Cow's Milk Protein Allergy: A Multicenter, Randomized, Double Blind, Placebo Controlled Study 2021 · probiotic group · Children under 2 years old with atopic dermatitis and cow’s milk protein allergy; mean age 8.2 months | 1 billion CFU | 90 days | 66 |
| Intake of Lactiplantibacillus plantarum HEAL9 Improves Cognition in Moderately Stressed Subjects: A Randomized Controlled Study 2023 · LPHEAL9 group · Healthy males and females aged 21–50 years with moderate stress | 10 billion CFU | 12 weeks | 66 |
| Adjunctive efficacy of Bifidobacterium animalis subsp. lactis XLTG11 for functional constipation in children 2024 · intervention group (IG) · Children aged 0–6 years, both sexes, with functional constipation | 10 billion CFU | 4 weeks | 65 |
| A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome 2024 · ES1 · Adults aged 18–65 with diarrhea-predominant irritable bowel syndrome (IBS-D) | 1 billion CFU | 12 weeks | 65 |
| A double-blinded randomized trial on growth and feeding tolerance with Saccharomyces boulardii CNCM I-745 in formula-fed preterm infants 2016 · treatment group · Preterm newborns with gestational age 30–37 weeks and birth weight 1500–2500 g | 100 mg/kg | — | 63 |
| Effects of Probiotic NVP-1704 on Mental Health and Sleep in Healthy Adults: An 8-Week Randomized, Double-Blind, Placebo-Controlled Trial 2021 · experimental group receiving the probiotic NVP-1704 · Healthy adults aged 19–65 with psychological stress and subclinical symptoms of depression or anxiety | 2.5 billion CFU | 8 weeks | 63 |
| Probiotic Supplement Preparation Relieves Test Anxiety by Regulating Intestinal Microbiota in College Students 2021 · AP group · College students aged 18–24 with test anxiety | 2 billion CFU | 15 days | 60 |
| Effect of a Probiotic and a Synbiotic on Body Fat Mass, Body Weight and Traits of Metabolic Syndrome in Individuals with Abdominal Overweight: A Human, Double-Blind, Randomised, Controlled Clinical Study 2023 · Probiotic · Adults aged 18 years or older, women and men with abdominal overweight or obesity (BMI ≥25 and elevated waist circumference) | 10 billion CFU | 12 weeks | 60 |
| Adjudicative efficacy of Bifidobacterium animalis subsp. lactis BLa80 in treating acute diarrhea in children: a randomized, double-blinded, placebo-controlled study 2024 · intervention group (IG) · Children aged 0–3 years, both sexes, with acute watery diarrhea | 5 billion CFU | 7 days | 60 |
| Effects of Lacticaseibacillus rhamnosus HN001 on Happiness and Mental Well-Being: Findings from a Randomized Controlled Trial 2024 · probiotic arm · Healthy men and women aged 18 years or older with PSS-10 scores of 14 or higher and no current mental health diagnosis | 6 billion CFU | 4 weeks | 59 |
| Imaging and Microorganism Analyses of the Effects of Oral Bifidobacterium breve Intake on Facial Skin in Females: A Randomized, Double-Blind, Placebo-Controlled Study 2025 · B. breve group · Women aged 30–79 years; healthy, with no skin disease or other stated qualifying condition | 20 billion CFU | 12 weeks | 59 |
| A randomized trial of Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitis 2012 · Lactobacillus plantarum CJLP133 group · Children aged 12 months to 13 years with atopic dermatitis | 10 billion CFU | 12 weeks | 58 |
| Effects of Probiotics on Malnutrition and Health-Related Quality of Life in Patients Undergoing Peritoneal Dialysis: A Randomized Controlled Trial 2021 · intervention group · Patients undergoing peritoneal dialysis; age and sex not specified | 1 billion CFU | 60 days | 58 |
| Metabolic Status Influences Probiotic Efficacy for Depression-PRO-DEMET Randomized Clinical Trial Results 2024 · probiotic (PRO) group · Adults aged 18 years or older with depressive disorders and MADRS score ≥13 | 3 billion CFU | 60 days | 58 |
| Probiotic enhanced immunity and mental wellbeing of generally healthy women: a randomised, placebo-controlled and double-blind study 2025 · probiotic group · Generally healthy women; mean age 38.38 ± 0.85 years | 1 billion CFU | 12 weeks | 58 |
| Safety and Tolerance of Bifidobacterium longum subsp. Infantis YLGB-1496 in Toddlers with Respiratory Symptoms 2025 · YLGB-1496 group · Toddlers aged 1–3 years with at least two kinds of respiratory symptoms | 10 billion CFU | 12 weeks | 58 |
| Effect of Lactobacillus sakei, a Probiotic Derived from Kimchi, on Body Fat in Koreans with Obesity: A Randomized Controlled Study 2020 · L. sakei (CJLS03) group · Men and women aged 20–65 years with obesity (BMI ≥25 kg/m²) | 10 billion CFU | 12 weeks | 57 |
| Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with constipation-predominant IBS: a 4-week randomized double-blinded placebo-controlled intervention trial 2024 · Probiotic BLa80 · Adults aged 18–70 with constipation-predominant irritable bowel syndrome (IBS-C) | 4 g | 4 weeks | 57 |
| Comparative efficacy of probiotic mixture Bifidobacterium longum KABP042 plus Pediococcus pentosaceus KABP041 vs. Limosilactobacillus reuteri DSM17938 in the management of infant colic: a randomized clinical trial 2024 · LR group · Infants aged 2 to 12 weeks diagnosed with infant colic; both sexes, otherwise healthy | 0.1 billion CFU | 3 weeks | 57 |
| Lactobacillus plantarum DR7 alleviates stress and anxiety in adults: a randomised, double-blind, placebo-controlled study 2019 · DR7 · Adults with moderate stress levels | 1 billion CFU | 12 weeks | 56 |
| Lactobacillus plantarum DR7 improved upper respiratory tract infections via enhancing immune and inflammatory parameters: A randomized, double-blind, placebo-controlled study 2019 · DR7 · Adults; the abstract does not state a diagnosed condition | 1 billion CFU | 12 weeks | 56 |
| Validity and safety of ID-JPL934 in lower gastrointestinal symptom improvement 2021 · ID-JPL934 group · Adults aged 18–80 with abnormal bowel movement symptoms, including abdominal pain or discomfort, not meeting IBS criteria | 10 billion CFU | 8 weeks | 56 |
| Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in early childhood 2016 · probiotic group · Healthy infants assigned at 1 month of age | 10 billion CFU | 2 years | 55 |
| Effect of Probiotic Bifidobacterium breve in Improving Cognitive Function and Preventing Brain Atrophy in Older Patients with Suspected Mild Cognitive Impairment: Results of a 24-Week Randomized, Double-Blind, Placebo-Controlled Trial 2022 · Probiotics · Adults aged 65–89 with suspected mild cognitive impairment | 20 billion CFU | 24 weeks | 55 |
| Therapeutic Evaluation of Bifidobacterium animalis subsp. lactis MH-02 as an Adjunctive Treatment in Patients with Reflux Esophagitis: A Randomized, Double-Blind, Placebo-Controlled Trial 2024 · probiotics group (Probio) · Adults aged 18–65 with reflux esophagitis | 2 billion CFU | 8 weeks | 55 |
| Comparative efficacy of probiotic mixture Bifidobacterium longum KABP042 plus Pediococcus pentosaceus KABP041 vs. Limosilactobacillus reuteri DSM17938 in the management of infant colic: a randomized clinical trial 2024 · BL + PP group · Infants aged 2 to 12 weeks diagnosed with infant colic; both sexes, otherwise healthy | 1 billion CFU | 3 weeks | 55 |
| Add-On Bifidobacterium Bifidum Supplement in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Week Randomized Double-Blind Placebo-Controlled Clinical Trial 2024 · Bf-688 group · Children aged 6–12 with ADHD receiving stable pharmacotherapy | 5 billion CFU | 12 weeks | 54 |
| Effect of functional yogurt NY-YP901 in improving the trait of metabolic syndrome 2011 · Treatment group · Healthy adults aged 20–65 years | 300 mL | 8 weeks | 53 |
| Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults 2019 · B. coagulans Unique IS2 · Adults aged 18–60 years with irritable bowel syndrome; both sexes | 2 billion CFU | 8 weeks | 53 |
| A double blinded randomized placebo trial of Bifidobacterium animalis subsp. lactis BLa80 on sleep quality and gut microbiota in healthy adults 2025 · BLa80 group · Healthy adults aged 19–45 with PSQI scores >6 and <18 and ISI scores >8 and <23 | 10 billion CFU | 8 weeks | 53 |
| A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lactobacillus plantarum LMT1-48 on Body Fat Loss 2025 · experimental group (LMT1-48) · Adults aged 19 to under 70 with BMI 25 to under 30 kg/m²; middle-aged Korean participants, average age 44.6 years | 5 billion CFU | 12 weeks | 53 |
| Probiotic Lactobacillus plantarum P8 alleviated stress and anxiety while enhancing memory and cognition in stressed adults: A randomised, double-blind, placebo-controlled study 2019 · P8 · Adults with moderate stress; mean age 31.7 ± 11.1 years; sex not specified | 10 billion CFU | 12 weeks | 52 |
| A multistrain probiotic improves handgrip strength and functional capacity in patients with COPD: A randomized controlled trial 2022 · probiotic group · men aged 63–73 with COPD | 112 billion CFU | 16 weeks | 51 |
| Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea 2006 · S. boulardii group · Children aged 2 months to 12 years with acute diarrhoea | 500 mg | 5 days | 50 |
| Bifidobacterium bifidum YIT 10347 fermented milk exerts beneficial effects on gastrointestinal discomfort and symptoms in healthy adults: A double-blind, randomized, placebo-controlled study 2018 · YIT10347 group · Healthy Japanese adults | 100 mL | 4 weeks | 50 |
| Efficacy and Safety of Lactobacillus Plantarum C29-Fermented Soybean (DW2009) in Individuals with Mild Cognitive Impairment: A 12-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial 2019 · DW2009 · Men and women aged 55–85 with mild cognitive impairment | 800 mg | 12 weeks | 50 |
| Effect of Lactobacillus plantarum LMT1-48 on Body Fat in Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial 2023 · LMT1-48 group · Middle-aged Korean adults with overweight (BMI ≥25 to <30 kg/m²); men and women | 10 billion CFU | 12 weeks | 50 |
| Therapeutic effects elicited by the probiotic Lacticaseibacillus rhamnosus GG in children with atopic dermatitis. The results of the ProPAD trial 2022 · Group B · Children aged 6–36 months, both sexes, with atopic dermatitis | 10 billion CFU | 12 weeks | 50 |
| Effect of Lactobacillus sakei OK67 in Reducing Body and Visceral Fat in Lifestyle-Modified Overweight Individuals: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Clinical Trial 2023 · DW2010 group · Men and women aged 20–60 years with BMI ≥25 and <30 kg/m² | 10 billion CFU | 12 weeks | 50 |
| Efficacy of Bifidobacterium animalis subsp. lactis BL-99 in the treatment of functional dyspepsia: a randomized placebo-controlled clinical trial 2024 · BL-99_low · Adults aged 18–60 with functional dyspepsia | 10 billion CFU | 8 weeks | 50 |
| Efficacy of Bifidobacterium animalis subsp. lactis BL-99 in the treatment of functional dyspepsia: a randomized placebo-controlled clinical trial 2024 · BL-99_high · Adults aged 18–60 with functional dyspepsia | 50 billion CFU | 8 weeks | 50 |
| A 12-Week, Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Design Clinical Trial for the Evaluation of the Efficacy and Safety of Lactiplantibacillus plantarum SKO-001 in Reducing Body Fat 2024 · SKO-001 group · Adults aged 19–60 years with BMI ≥25 and <30 kg/m² | 20 billion CFU | 12 weeks | 50 |
| Effectiveness of Psychobiotic Bifidobacterium breve BB05 in Managing Psychosomatic Diarrhea in College Students by Regulating Gut Microbiota: A Randomized, Double-Blind, Placebo-Controlled Trial 2024 · MB group (probiotic group) · College students aged 18–30 with diarrhea associated with travel for the new semester, a new environment, or dietary changes; males and females | 20 billion CFU | 2 weeks | 50 |
| Role of Bacillus coagulans (Heyndrickxia coagulans)BCP92 in managing irritable bowel syndrome: A randomized, double-blind, multicenter, placebo-controlled clinical trial 2024 · test arm (IP) · Adults aged 18–70 with irritable bowel syndrome diagnosed using Rome IV criteria | 2 billion CFU | 12 weeks | 50 |
| Effect of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and nutritional status 2025 · observation group · Children aged 3–14 years with bacterial peritonitis | 3 g | 7 days | 50 |
| Efficacy and safety of Latilactobacillus sakei LB-P12 in patients with knee osteoarthritis: an exploratory randomized, double-blind, placebo-controlled clinical trial 2025 · LB-P12 group · Adults aged 40–75 years with mild knee osteoarthritis (Kellgren–Lawrence grade 1 or 2) and knee pain; men and women | 10 billion CFU | 12 weeks | 50 |
| High-dose multi-strain Bacillus probiotics enhance treatment and reduce antibiotic usage in children with persistent diarrhea through immune and microbiota modulation 2025 · Dia30 group · Children aged 3–24 months with persistent diarrhea | 15 billion CFU | 10 days | 50 |
| Effects of Two Compound Probiotic Formulations on Gastrointestinal Symptoms and Gut Microbiota: A 4-Week Randomized, Double-Blind Intervention Trial 2025 · Wec120B group · Adults aged 18–65 with functional gastrointestinal disorders and gastrointestinal discomfort | 240 billion CFU | 4 weeks | 50 |
| Effects of Two Compound Probiotic Formulations on Gastrointestinal Symptoms and Gut Microbiota: A 4-Week Randomized, Double-Blind Intervention Trial 2025 · Wec300B group · Adults aged 18–65 with functional gastrointestinal disorders and gastrointestinal discomfort | 600 billion CFU | 4 weeks | 50 |
| Efficacy and Safety of Lactobacillus delbrueckii subsp. lactis CKDB001 Supplementation on Cognitive Function in Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial 2025 · LL group · Men and women aged 55–80 years with mild cognitive impairment | 5 billion CFU | 12 weeks | 50 |
| Improvement of Post-Surgery Constipation in Patients with Fractures by Lactobacillus rhamnosus JYLR-127: A Single-Blind Randomized Controlled Trial 2024 · TRE group · Adults aged 18–70 of either sex with fractures and post-surgery constipation | 4 billion CFU | 7 days | 49 |
| Bifidobacterium lactis IDCC 4301 (B. lactis Fit™) supplementation effects on body fat, serum triglyceride, and adipokine ratio in obese women: a randomized clinical trial 2024 · probiotics · Obese women with BMI 25–30 kg/m²; age range not reported | 5 billion CFU | 12 weeks | 49 |
| A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome 2008 · probiotic combination · Adults with irritable bowel syndrome fulfilling Rome II criteria | 10 billion CFU | 4 weeks | 48 |
| Investigation of the Efficacy of Lactobacillus rhamnosus GG in Infants With Cow's Milk Protein Allergy: a Randomised Double-Blind Placebo-Controlled Trial 2020 · probiotic group · Infants aged 0–12 months diagnosed with cow's milk protein allergy | 1 billion CFU | 4 weeks | 48 |
| Impact of a probiotic product on bowel habits and microbial profile in participants with functional constipation: A randomized controlled trial 2019 · probiotic group · Adults aged 18–65 with functional constipation | 15 billion CFU | 4 weeks | 48 |
| Improvement Effect of Bifidobacterium animalis subsp. lactis MH-02 in Patients Receiving Resection of Colorectal Polyps: A Randomized, Double-Blind, Placebo-Controlled Trial 2022 · probiotic group (P-Bb) · Adults aged 18 or older with at least three endoscopically resected colorectal polyps | 2 billion CFU | 7 days | 48 |
| Lactobacillus fermentum (PCC®) supplementation and gastrointestinal and respiratory-tract illness symptoms: a randomised control trial in athletes 2011 · probiotic group · Adult male and female cyclists and triathletes meeting the study fitness criteria; healthy, physically active athletes | 1 billion CFU | 11 weeks | 47 |
| Probiotics in diverticular disease of the colon: an open label study 2010 · SCM-III symbiotic mixture · Adults aged 49–77 with previously symptomatic uncomplicated diverticular disease of the colon | 30 mL | 26 weeks | 46 |
| PROBIOTICS AS AN ADJUNCTIVE THERAPY FOR CELIAC DISEASE: SYMPTOM RELIEF AND QUALITY OF LIFE IMPROVEMENT 2025 · Probiotic · Adults aged 18–65 with celiac disease | 1 billion CFU | 90 days | 46 |
| Effects of Lactobacillus reuteri DSM 17938 in preterm infants: a double-blinded randomized controlled study 2019 · intervention group · Formula-fed preterm infants born at 30 to under 37 weeks’ gestation, weighing 1500–2000 g | 0.1 billion CFU | — | 45 |
| Impact of Probiotic Formula (Lacto-5X) on Constipation: Improvements in Gastrointestinal Symptoms, Gut Microbiome, and Metabolites 2025 · Probiotic group · Adults aged 19–69 with mild constipation | 2 billion CFU | 4 weeks | 45 |
| Lactobacillus GG (LGG) and smectite versus LGG alone for acute gastroenteritis: a double-blind, randomized controlled trial 2013 · LGG/placebo · Children aged 4–60 months with acute gastroenteritis | 6 billion CFU | 7 days | 44 |
| Probiotic NVP-1703 Alleviates Allergic Rhinitis by Inducing IL-10 Expression: A Four-week Clinical Trial 2020 · NVP-1703 group · Adults aged 19–65 with perennial allergic rhinitis | 10 billion CFU | 4 weeks | 44 |
| Effects of probiotics on selected anthropometrics and biochemical measures in overweight or obese Saudi subjects: a double-blind, placebo-controlled, randomised clinical trial 2024 · Probiotic · Saudi adults aged 19–40, male and female, who were overweight, obese and/or abdominally obese | 60 billion CFU | 12 weeks | 44 |
| A double-blind, randomized, placebo-controlled trial studying the effects of Saccharomyces boulardii on the gastrointestinal tolerability, safety, and pharmacokinetics of miglustat 2015 · miglustat + S. boulardii · Healthy male and female adults aged 18–55 years | 1 g | 16 days | 42 |
| Probiotic Lactobacillus casei: Effective for Managing Childhood Diarrhea by Altering Gut Microbiota and Attenuating Fecal Inflammatory Markers 2019 · Lactobacillus casei variety rhamnosus treatment · Hospitalized children aged 6 months to 6 years with suspected infectious acute diarrhea of less than 72 hours’ duration | 0.4 billion CFU | 7 days | 42 |
| Bacillus Subtilis (BG01-4(TM)) Improves Self-Reported Symptoms for Constipation, Indigestion, and Dyspepsia: A Phase 1/2A Randomized Controlled Trial 2023 · BG01-4™ group · Adults aged 18–75 with self-reported functional gastrointestinal disorder symptoms | 5 billion CFU | 4 weeks | 42 |
| Oral compound probiotic supplements can improve the quality of life for patients with lung cancer during chemotherapy: A randomized placebo-controlled study 2024 · Group BP-1 (compound probiotic supplements group) · Adults aged 18–75 with lung cancer, chemotherapy-naive and receiving platinum-based doublet chemotherapy | 4 g | — | 42 |
| A Randomized Clinical Trial to Evaluate the Efficacy of an Oral Probiotic in Acne Vulgaris 2024 · PROBIOTIC group · People aged 12–30 with mild or greater acne vulgaris | 1 billion CFU | 12 weeks | 42 |
| The effect of probiotic administration on the severity of menopausal symptoms and mental health of postmenopausal women: a triple-blind randomized controlled trial in the West of Iran 2025 · intervention group · Postmenopausal women in Hamadan, Iran | 200 mg | 6 weeks | 42 |
| Diversity and Dosage Determine the Efficacy of the Probiotic SYN-53 in Allergic Rhinoconjunctivitis: A Randomized, Double-Blind, Placebo-Controlled Trial 2025 · SYN-53 · Adults aged 18–65 with grass-pollen allergic rhinoconjunctivitis and moderate-to-severe symptoms during allergen exposure | 150 billion CFU | 3 weeks | 42 |
| Diversity and Dosage Determine the Efficacy of the Probiotic SYN-53 in Allergic Rhinoconjunctivitis: A Randomized, Double-Blind, Placebo-Controlled Trial 2025 · SYN-4 · Adults aged 18–65 with grass-pollen allergic rhinoconjunctivitis and moderate-to-severe symptoms during allergen exposure | 120 billion CFU | 3 weeks | 42 |
| Efficacy and Safety of Lactobacillus plantarum K50 on Lipids in Koreans With Obesity: A Randomized, Double-Blind Controlled Clinical Trial 2021 · LPK group · Men and women aged 20–65 years with obesity, BMI 25–30 kg/m² | 4 billion CFU | 12 weeks | 41 |
| Efficacy of Bifidobacterium longum and Lactobacillus plantarum (NVP-1703) in Children With Allergic Rhinitis: A Randomized Controlled Trial 2024 · NVP-1703 group · Children and adolescents aged 6–19 years with perennial allergic rhinitis | 10 billion CFU | 4 weeks | 41 |
| Diversity and Dosage Determine the Efficacy of the Probiotic SYN-53 in Allergic Rhinoconjunctivitis: A Randomized, Double-Blind, Placebo-Controlled Trial 2025 · SYN-53-LD · Adults aged 18–65 with grass-pollen allergic rhinoconjunctivitis and moderate-to-severe symptoms during allergen exposure | 18 billion CFU | 3 weeks | 41 |
| The Impact of Weizmannia coagulans BC99 on Anxiety and Depression: An 8-Week Clinical Pilot Study Through the Gut Microbiota-Brain Axis 2025 · BC99 intervention group · Adults aged 18–65 with depressive symptoms (HAMD-17 ≥ 8) or anxiety symptoms (HAMA-14 ≥ 7); predominantly young adults under research, employment, or job pressure | 5 billion CFU | 8 weeks | 41 |
| A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy 2011 · GpC (probiotics) · Patients with cirrhosis and minimal hepatic encephalopathy | 220 billion CFU | 90 days | 40 |
| Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial 2013 · Lactobacillus reuteri DSM 17938 group · Infants with infantile colic who were breastfed exclusively or predominantly; ages not specified | 0.1 billion CFU | 3 weeks | 40 |
| The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB-12(®) in infant colic: A randomised, double blind, placebo-controlled trial 2020 · Group 1 BB-12 · Exclusively breastfed infants aged 7 weeks or younger with signs and symptoms of infant colic | 1 billion CFU | 4 weeks | 40 |
| Probiotic Bifidobacterium breve in Improving Cognitive Functions of Older Adults with Suspected Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial 2020 · Probiotic · Adults aged 50–79 with suspected mild cognitive impairment and lower RBANS total scores | 20 billion CFU | 16 weeks | 40 |
| Assessment of probiotic strain Lactobacillus acidophilus LB supplementation as adjunctive management of attention-deficit hyperactivity disorder in children and adolescents: a randomized controlled clinical trial 2023 · Probiotic group · Children and adolescents aged 6–16 with ADHD | 20 billion CFU | 12 weeks | 40 |
| Lactobacillus paragasseri OLL2809 Improves Premenstrual Psychological Symptoms in Healthy Women: A Randomized, Double-Blind, Placebo-Controlled Study 2023 · OLL2809 group · Healthy women aged 25–40 with menstrual-related symptoms before and during menstruation, without the specified gynecologic disorders | 100 mg | 12 weeks | 40 |
| Promising clinical and immunological efficacy of Bacillus clausii spore probiotics for supportive treatment of persistent diarrhea in children 2024 · Clausy group · Children aged 3–24 months, male and female, with persistent diarrhea | 12 billion CFU | 10 days | 40 |
| Evaluating the Effectiveness of Probiotic Supplementation in Combination With Doxycycline for the Treatment of Moderate Acne: A Randomized Double-Blind Controlled Clinical Trial 2025 · Doxycycline + probiotic · People aged 15–35 with moderate acne | 2 billion CFU | 120 days | 40 |
| Impact of probiotic Lactobacillus plantarum GKM3 on gastrointestinal health in overweight and obese individuals: A randomized clinical trial 2025 · probiotics group · Overweight and obese adults aged 20–40 years with BMI 25.0–29.9 and body fat over 25% for males or 30% for females | 1 g | 4 weeks | 40 |
| The role of probiotics and dietary interventions in the treatment of periodontitis: a pilot randomized controlled clinical trial 2025 · Probiotic group · Women aged 20–60 with periodontitis, probing depths of 3–7 mm, at least 20 natural teeth, and no systemic diseases | 1 billion CFU | 6 weeks | 40 |
| The role of probiotics and dietary interventions in the treatment of periodontitis: a pilot randomized controlled clinical trial 2025 · Diet + probiotic group · Women aged 20–60 with periodontitis, probing depths of 3–7 mm, at least 20 natural teeth, and no systemic diseases | 1 billion CFU | 6 weeks | 40 |
| The effect of probiotic consumption on fatigue severity and sexual function among postmenopausal women: a double-blind randomized controlled trial in the west of Iran 2026 · probiotic group · postmenopausal women | 200 mg | 6 weeks | 40 |
| Weizmannia coagulans BC99 regulates oxidative stress and serum metabolic pathways to improve allergic rhinitis: a randomized, double-blind, placebo-controlled trial 2025 · probiotic group (BC99) · Adults aged 18–65 years with diagnosed allergic rhinitis | 2 billion CFU | 8 weeks | 40 |
| Probiotics Plus Dietary Fiber Supplements Attenuate Olanzapine-Induced Weight Gain in Drug-Naïve First-Episode Schizophrenia Patients: Two Randomized Clinical Trials 2022 · Olanzapine plus probiotics (Study 1) · Adults aged 18–50 with drug-naïve first-episode schizophrenia | 1.68 g | 12 weeks | 39 |
| Usefulness of Bifidobacterium longum BB536 in Elderly Individuals With Chronic Constipation: A Randomized Controlled Trial 2023 · probiotic (BB536) group · Men and women aged 65 years or older with functional constipation or constipated irritable bowel syndrome, and a Constipation Scoring System score of 6 or higher | 50 billion CFU | 4 weeks | 39 |
| The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial 2022 · BS50 · Healthy adults aged 30–65 years, female and male, with at least minimal abdominal bloating, burping, or flatulence and no stated functional GI disorder | 2 billion CFU | 6 weeks | 38 |
| Live and Heat-Killed Probiotic Lactobacillus paracasei PS23 Accelerated the Improvement and Recovery of Strength and Damage Biomarkers after Exercise-Induced Muscle Damage 2022 · L. paracasei PS23 live bacteria group (L-PS23) · Males and females aged 20–40 years, without recent sports or resistance-training experience and without the listed exclusion conditions | 20 billion CFU | 6 weeks | 38 |
| The Effects of Limosilactobacillus reuteri LR-99 Supplementation on Body Mass Index, Social Communication, Fine Motor Function, and Gut Microbiome Composition in Individuals with Prader-Willi Syndrome: a Randomized Double-Blinded Placebo-Controlled Trial 2021 · active probiotic · Individuals aged 6–264 months with genetically confirmed Prader–Willi syndrome; both sexes | 60 billion CFU | 12 weeks | 37 |
| The effect of probiotic supplementation on episiotomy wound healing among primiparous women: a triple-blind randomized clinical trial 2023 · probiotic group · Primiparous women after delivery with a mediolateral episiotomy | 1.5 billion CFU | 2 weeks | 37 |
| A probiotic containing L. plantarum and P. acidilactici strains for treating upper respiratory infection in children aged 6 months to 5 years: a randomized, double-blind trial 2025 · Probiotic · Children aged 6 months to 5 years with pediatrician-diagnosed upper respiratory infection, concurrent fever and pharyngitis | 4 billion CFU | 15 days | 37 |
| Evaluation of the Efficacy of Probiotics (MCP® BCMC® Strains) Treating Constipation in Elderly Patients with Multiple Chronic Co-Morbidities: A Randomized Control Trial 2020 · Treatment group (MCP® BCMC® strains; sample labelled A or B) · Adults aged 60 years and older with constipation and at least two chronic medical conditions | 60 billion CFU | 7 days | 36 |
| Bifidobacterium lactis Probio-M8 Adjuvant Treatment Confers Added Benefits to Patients with Coronary Artery Disease via Target Modulation of the Gut-Heart/-Brain Axes 2022 · probiotic group · men and women with diagnosed coronary artery disease (CAD); age range not reported | 30 billion CFU | 180 days | 36 |
| The effect of probiotic-fortified kefir on depression, appetite, oxidative stress, and inflammatory parameters in Iranian overweight and obese elderly: a randomized, double-blind, placebo-controlled clinical trial 2025 · fortified kefir group · Men older than 65 years with BMI greater than 25, overweight or obese, without the listed excluded medical conditions | 3 billion CFU | 8 weeks | 36 |
| Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhoea--a double-blind study 2012 · L. reuteri group · Children aged 6–36 months hospitalised with acute diarrhoea and clinical signs of dehydration | 0.4 billion CFU | — | 35 |
| Bifidobacteriumbreve Bif195 Protects Against Small-Intestinal Damage Caused by Acetylsalicylic Acid in Healthy Volunteers 2019 · Bif195 group · Healthy volunteers exposed to acetylsalicylic acid; age and sex not specified | 50 billion CFU | 8 weeks | 35 |
| Daily supplementation with the Lab4P probiotic consortium induces significant weight loss in overweight adults 2021 · Active Lab4P group · Healthy overweight adults aged 45–65 years, men and women, with BMI 25–29.9 kg/m² and elevated waist circumference | 50 billion CFU | 270 days | 35 |
| Multispecies probiotic administration reduces emotional salience and improves mood in subjects with moderate depression: a randomised, double-blind, placebo-controlled study 2023 · probiotic group · Adults aged 18–55 with untreated mild to moderate depression (PHQ-9 scores 5–19) | 8 billion CFU | 4 weeks | 35 |
| Adjunctive efficacy of Lactis XLTG11 for Acute diarrhea in children: A randomized, blinded, placebo-controlled study 2023 · intervention group (IG) · Children with acute watery diarrhea | 10 billion CFU | — | 35 |
| Comparison of Rifaximin Monotherapy and Rifaximin Combined with Probiotics in Patients with Irritable Bowel Syndrome: A Randomized Controlled Trial 2025 · combination therapy group · Adults older than 19 years with irritable bowel syndrome diagnosed according to Rome IV criteria | 10 billion CFU | 4 weeks | 35 |
| Safety and tolerability of Bifidobacterium longum subspecies infantis EVC001 supplementation in healthy term breastfed infants: a phase I clinical trial 2017 · BiLS (lactation support plus B. infantis supplementation) · Healthy term breastfed infants, born at least 37 weeks’ gestation, without medical complications | 18 billion CFU | 3 weeks | 34 |
| Lactobacillus reuteri V3401 Reduces Inflammatory Biomarkers and Modifies the Gastrointestinal Microbiome in Adults with Metabolic Syndrome: The PROSIR Study 2019 · Lactobacillus reuteri V3401 · Adults with a new diagnosis of metabolic syndrome; age and sex distribution not specified | 5 billion CFU | 12 weeks | 34 |
| The effects of probiotics plus dietary fiber on antipsychotic-induced weight gain: a randomized clinical trial 2022 · Probiotics · Adults aged 18–45 with schizophrenia or bipolar disorder, receiving atypical antipsychotics and with more than 10% weight gain | 1.68 g | 12 weeks | 34 |
| Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults 2011 · high dose · Adults aged 25–65 with functional gastrointestinal symptoms, including an average of 1–3 bowel movements per week | 17.2 billion CFU | 2 weeks | 33 |
| Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults 2011 · low dose · Adults aged 25–65 with functional gastrointestinal symptoms, including an average of 1–3 bowel movements per week | 1.8 billion CFU | 2 weeks | 33 |
| Effectiveness and Safety of a Probiotic-Mixture for the Treatment of Infantile Colic: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial with Fecal Real-Time PCR and NMR-Based Metabolomics Analysis 2018 · probiotics group · Exclusively breastfed, healthy term infants aged 30–90 days with infantile colic | 5 billion CFU | 3 weeks | 33 |
| The effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults: A randomized, double-blind, placebo-controlled study 2023 · B coagulans MTCC 5856 · Adults aged 18–65, male and female, with functional abdominal bloating/distension | 2 billion CFU | 4 weeks | 33 |
| Cognitive and Emotional Effect of a Multi-species Probiotic Containing Lactobacillus rhamnosus and Bifidobacterium lactis in Healthy Older Adults: A Double-Blind Randomized Placebo-Controlled Crossover Trial 2025 · Probiotic condition (Placebo-Probiotic and Probiotic-Placebo sequences) · Adults aged 55 years or older; healthy older adults, with some participants reporting chronic or digestive conditions | 3.3 billion CFU | 10 weeks | 33 |
| Cognitive and Emotional Effect of a Multi-species Probiotic Containing Lactobacillus rhamnosus and Bifidobacterium lactis in Healthy Older Adults: A Double-Blind Randomized Placebo-Controlled Crossover Trial 2025 · Probiotic condition (Placebo-Probiotic and Probiotic-Placebo sequences) · Adults aged 55 years or older; healthy older adults, with some participants reporting chronic or digestive conditions | 3.3 billion CFU | 10 weeks | 33 |
| Gut Microbiome and Metabolome Alterations in Overweight or Obese Adult Population after Weight-Loss Bifidobacterium breve BBr60 Intervention: A Randomized Controlled Trial 2024 · BBr60 group · Adults aged 19–45 with BMI ≥28 kg/m² who were overweight or obese | 10 billion CFU | 12 weeks | 33 |
| Enhancement of Lower Limb Muscle Strength and Reduction of Inflammation in the Elderly: A Randomized, Double-Blind Clinical Trial Comparing Lacticaseibacillus paracasei PS23 Probiotic with Heat-Treated Supplementation 2025 · live L-PS23 group · Adults aged 65–85 years, without a stated diagnosed condition | 20 billion CFU | 12 weeks | 33 |
| Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial 2014 · DRUG-3 (Velgut probiotics) · Adults with cirrhosis and minimal hepatic encephalopathy | 5 billion CFU | 60 days | 32 |
| Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial 2021 · probiotics · Adults aged 18 years or older with functional dyspepsia, on or off proton-pump inhibitors | 5 billion CFU | 16 weeks | 32 |
| Evaluating the Effect of Lacticaseibacillus paracasei Strain Shirota on the Physical Consistency of Stool in Healthy Participants with Hard or Lumpy Stools: A Double-Blind, Randomized, Placebo-Controlled Study 2024 · LcS group · Healthy women and men aged 18–65 years who frequently produced hard or lumpy stools | 6.5 billion CFU | 8 weeks | 32 |
| Probiotic Supplementation Enhances the Effects of a Nutritional Intervention on Quality of Life in Women with Hashimoto's Thyroiditis-A Double-Blind Randomised Study 2025 · NE+Lp299v (probiotic group) · Women aged 18–64 years with Hashimoto’s thyroiditis and euthyroid thyroid function | 10 billion CFU | 12 weeks | 32 |
| The effect of probiotic supplementation on sexual function in premenopausal and menopausal women: a randomized controlled clinical trial 2025 · Probiotic group · Women aged 40–60 with sexual dysfunction who were premenopausal or menopausal | 3 billion CFU | 8 weeks | 32 |
| A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis 2009 · probiotic group · Adults with ulcerative colitis | 2 billion CFU | 4 weeks | 31 |
| Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study 2011 · active probiotic arm · Men and women aged 18–65 with non-constipation irritable bowel syndrome, functional diarrhea, or functional bloating | 200 billion CFU | 8 weeks | 31 |
| Lacticaseibacillus paracasei GM-080 Ameliorates Allergic Airway Inflammation in Children with Allergic Rhinitis: From an Animal Model to a Double-Blind, Randomized, Placebo-Controlled Trial 2023 · Group B (middle dose) · Children aged 5–16 years with perennial allergic rhinitis | 2 billion CFU | 90 days | 31 |
| Lacticaseibacillus paracasei GM-080 Ameliorates Allergic Airway Inflammation in Children with Allergic Rhinitis: From an Animal Model to a Double-Blind, Randomized, Placebo-Controlled Trial 2023 · Group C (high dose) · Children aged 5–16 years with perennial allergic rhinitis | 10 billion CFU | 90 days | 31 |
| Antigingivitis and Antiplaque Effects of Oral Probiotic Containing the Streptococcus salivarius M18 Strain: A Randomized Clinical Trial 2023 · Group 1 (probiotic group) · Men and women aged 18–25 with clinically diagnosed gingivitis and no stated systemic or chronic disease | 0.5 billion CFU | 4 weeks | 31 |
| Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis 2004 · group A · Adults with acute mild-to-moderate active ulcerative colitis | 3 g | 8 weeks | 30 |
| Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study 2006 · L. casei DG (group L) · Adults aged 39–84 with previously treated symptomatic uncomplicated diverticular disease of the colon | 16 billion CFU | 1 year | 30 |
| Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study 2006 · Mesalazine plus L. casei DG (group LM) · Adults aged 39–84 with previously treated symptomatic uncomplicated diverticular disease of the colon | 16 billion CFU | 1 year | 30 |
| Efficacy and Safety of Saccharomyces boulardii in Acute Rotavirus Diarrhea: Double Blind Randomized Controlled Trial from a Developing Country 2016 · intervention group · Children aged 3 months to 5 years with WHO-defined acute watery diarrhea and rotavirus-positive stool | 500 mg | 5 days | 30 |
| Role of probiotics in the treatment of minimal hepatic encephalopathy in patients with HBV-induced liver cirrhosis 2018 · probiotic treatment · Adults with HBV-induced liver cirrhosis and minimal hepatic encephalopathy; age and sex range not stated | 4.5 g | 90 days | 30 |
| Clinical and metabolic response to probiotic administration in people with Parkinson's disease: A randomized, double-blind, placebo-controlled trial 2019 · probiotic · people with Parkinson's disease | 8 billion CFU | 12 weeks | 30 |
| Effect of probiotic Lactobacillus plantarum Dad-13 powder consumption on the gut microbiota and intestinal health of overweight adults 2021 · Probiotic-treated group · Adults aged 35–56 years, men and women, with overweight (BMI ≥25) | 2 billion CFU | 90 days | 30 |
| Plant-Derived Lactobacillus paracasei IJH-SONE68 Improves Chronic Allergy Status: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial 2021 · IJH-SONE68-intake group · Adults aged 21–70 with perennial allergy symptoms and difficulty in daily activities; healthy male and female volunteers | 1.04 g | 12 weeks | 30 |
| Probiotic Bifidobacterium longum BB68S Improves Cognitive Functions in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial 2022 · probiotic group · Healthy adults aged 60–75 years with cognitive function screened as healthy | 50 billion CFU | 8 weeks | 30 |
| Psychobiotic Lactobacillus plantarum JYLP-326 relieves anxiety, depression, and insomnia symptoms in test anxious college via modulating the gut microbiota and its metabolism 2023 · PB group · Senior college students preparing for the UNGEE, screened for anxiety and depression symptoms; healthy-range BMI | 30 billion CFU | 3 weeks | 30 |
| Effect of Postbiotic Bifidobacterium longum CECT 7347 on Gastrointestinal Symptoms, Serum Biochemistry, and Intestinal Microbiota in Healthy Adults: A Randomised, Parallel, Double-Blind, Placebo-Controlled Pilot Study 2024 · intervention group (HT-ES1) · Healthy adults aged 18–65 with mild gastrointestinal symptoms | 50 mg | 8 weeks | 30 |
| Exploring the acute and chronic effects of a multistrain probiotic supplement on cognitive function and mood in healthy older adults: a randomized controlled trial 2025 · probiotic condition · Healthy men and women aged 65–80 years | 5 billion CFU | 8 weeks | 30 |
| Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting 2015 · probiotic group · children with acute watery infectious diarrhea treated in outpatient clinics | 0.1 billion CFU | 5 days | 29 |
| Adjunctive Probiotics Alleviates Asthmatic Symptoms via Modulating the Gut Microbiome and Serum Metabolome 2021 · probiotic group · Adults aged 18–75, male and female, with stable bronchial asthma | 30 billion CFU | 90 days | 29 |
| Randomized Controlled Trial of Probiotic PS128 in Children with Tourette Syndrome 2021 · PS128 group · Children aged 5–18 years with Tourette syndrome | 60 billion CFU | 60 days | 29 |
| Effect of Heat-Killed Lactobacillus paracasei KW3110 Ingestion on Ocular Disorders Caused by Visual Display Terminal (VDT) Loads: A Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study 2018 · L. paracasei KW3110-treated group · Healthy Japanese men and women aged 35–45 who used VDTs daily and reported VDT-induced eye fatigue | 50 mg | 8 weeks | 28 |
| Lactobacillus plantarum CCFM1143 Alleviates Chronic Diarrhea via Inflammation Regulation and Gut Microbiota Modulation: A Double-Blind, Randomized, Placebo-Controlled Study 2021 · L. plantarum CCFM1143 intervention group · Adults aged 18–65 with chronic diarrhea | 3.52 billion CFU | 30 days | 28 |
| The effect of multistrain probiotics on functional constipation in the elderly: a randomized controlled trial 2022 · probiotic · Nursing-home residents aged 65 years or older with functional constipation | 1 billion CFU | 12 weeks | 28 |
| Lacticaseibacillus paracasei GM-080 Ameliorates Allergic Airway Inflammation in Children with Allergic Rhinitis: From an Animal Model to a Double-Blind, Randomized, Placebo-Controlled Trial 2023 · Group A (low dose) · Children aged 5–16 years with perennial allergic rhinitis | 0.2 billion CFU | 90 days | 28 |
| A randomized, double-blinded, placebo-controlled clinical trial on Lactobacillus-containing cultured milk drink as adjuvant therapy for depression in irritable bowel syndrome 2024 · IBS-NM probiotic · Adults aged 18–65 with IBS meeting Rome IV criteria and normal mood (CESD-R score <16) | 2 billion CFU | 12 weeks | 28 |
| Efficacy of saccharomyces boulardii with antibiotics in acute amoebiasis 2003 · Regimen 2 (Group 2) · Adults with acute intestinal amoebiasis | 750 mg | 10 days | 27 |
| Effect of the Intake of a Traditional Mexican Beverage Fermented with Lactic Acid Bacteria on Academic Stress in Medical Students 2021 · experimental group (EXP) · Male and female medical students aged 20–25 with academic stress | 100 mL | 60 days | 27 |
| Evaluating probiotic efficacy on weight loss in adults with overweight through a double-blind, placebo-controlled randomized trial 2023 · Single dose probiotics · Adults aged 18–45 with overweight (BMI 26.0 to <30 kg/m²), willing to lose weight | 0.0104 billion CFU | 90 days | 27 |
| Evaluating probiotic efficacy on weight loss in adults with overweight through a double-blind, placebo-controlled randomized trial 2023 · Double dose probiotics · Adults aged 18–45 with overweight (BMI 26.0 to <30 kg/m²), willing to lose weight | 0.0208 billion CFU | 90 days | 27 |
| Lactobacillus reuteri DSM 17938 in the Treatment of Functional Abdominal Pain in Children: RCT Study 2017 · Lactobacillus reuteri DSM 17938 group · Children aged 4–18 years with functional abdominal pain or irritable bowel syndrome | 0.1 billion CFU | 120 days | 26 |
| Efficacy and Safety of New Lactobacilli Probiotics for Unconstipated Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial 2019 · probiotics group · Vietnamese adults aged 19–60 living in Korea with unconstipated irritable bowel syndrome | 1 billion CFU | 4 weeks | 26 |
| Lactobacillus rhamnosus GG (ATCC 53103) for the Management of Infantile Colic: A Randomized Controlled Trial 2020 · Lactobacillus rhamnosus group · Breastfed term infants aged 10–60 days with infantile colic | 5 billion CFU | 4 weeks | 26 |
| Probiotic effects on sperm parameters, oxidative stress index, inflammatory factors and sex hormones in infertile men 2022 · Intervention group · Men with idiopathic oligoasthenoteratozoospermia; age and sex beyond male not specified | 500 mg | 10 weeks | 26 |
| A randomized, double-blinded, placebo-controlled clinical trial on Lactobacillus-containing cultured milk drink as adjuvant therapy for depression in irritable bowel syndrome 2024 · IBS-SD probiotic · Adults aged 18–65 with IBS meeting Rome IV criteria and subthreshold depression (CESD-R score ≥16) | 2 billion CFU | 12 weeks | 26 |
| Clinical efficacy of Saccharomyces boulardii and metronidazole compared to metronidazole alone in children with acute bloody diarrhea caused by amebiasis: a prospective, randomized, open label study 2009 · Group B · Children with acute bloody diarrhea caused by Entameba histolytica | 500 mg | 7 days | 25 |
| Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial 2010 · L reuteri group · Exclusively breastfed infants with infantile colic | 0.1 billion CFU | 3 weeks | 25 |
| Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: a randomized, double-blind study 2012 · LCR35 · Patients with irritable bowel syndrome meeting Rome III criteria; age and sex not reported | 0.6 billion CFU | 4 weeks | 25 |
| Hypocaloric diet supplemented with probiotic cheese improves body mass index and blood pressure indices of obese hypertensive patients--a randomized double-blind placebo-controlled pilot study 2013 · Probiotic cheese group · Adults aged 30–69 with obesity and hypertension/metabolic syndrome | 50 g | 3 weeks | 25 |
| The effects of probiotics on mental health and hypothalamic-pituitary-adrenal axis: A randomized, double-blind, placebo-controlled trial in petrochemical workers 2016 · probiotic yogurt · petrochemical workers | 100 g | 6 weeks | 25 |
| The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study 2021 · probiotic group · Adults aged 18–70, female and male, with moderate or severe diarrhea-predominant irritable bowel syndrome (IBS-D) | 5 billion CFU | 8 weeks | 25 |
| Effects of oral administration of Bifidobacterium animalis subsp. lactis HN019 on the treatment of plaque-induced generalized gingivitis 2023 · Test (probiotic therapy) · Systemically healthy adults with plaque-induced generalized gingivitis; ages 18 and older, both sexes | 2 billion CFU | 8 weeks | 25 |
| The effect of oral probiotics on CD4 count in patients with HIV infection undergoing treatment with ART who have had an immunological failure 2023 · Probiotic group (Groups A and B during their probiotic periods) · Adults with HIV infection, aged 41.4 years on average, receiving ART and with immunological failure despite viral suppression | 2 billion CFU | 90 days | 25 |
| The effect of probiotic supplementation on the clinical and para-clinical findings of multiple sclerosis: a randomized clinical trial 2023 · Case (probiotic supplement group) · Adults aged 18–55, men and women with relapsing–remitting multiple sclerosis and EDSS score ≥4.5 | 250 mg | 120 days | 25 |
| Microbiological profile of patients with generalized gingivitis undergoing periodontal therapy and administration of Bifidobacterium animalis subsp. lactis HN019: A randomized clinical trial 2024 · Probiotic group · Adults with untreated generalized plaque-induced gingivitis; the probiotic group had a mean age of 23.92 years and included 16 women and 9 men | 2 billion CFU | 8 weeks | 25 |
| Can psychobiotics intake modulate psychological profile and body composition of women affected by normal weight obese syndrome and obesity? A double blind randomized clinical trial 2017 · Intervention group (psychobiotics oral suspension; crossover phase) · Adult women aged 20–65, including normal-weight lean, normal-weight obese, and pre-obese/obese women | 3 g | 3 weeks | 24 |
| Bifidobacterium longum subsp. longum Reduces Perceived Psychological Stress in Healthy Adults: An Exploratory Clinical Trial 2023 · probiotic · Healthy adults aged 25–65 with mild-to-moderate psychological stress | 10 billion CFU | 6 weeks | 24 |
| Multispecies Probiotic Supplementation Favorably Affects Vascular Function and Reduces Arterial Stiffness in Obese Postmenopausal Women-A 12-Week Placebo-Controlled and Randomized Clinical Study 2018 · high dose of the probiotic (HD) group · Women aged 45–70 years who were postmenopausal and had obesity | 4 g | 12 weeks | 23 |
| Effect of a seven-strain probiotic on dietary intake, inflammatory markers, and T-cells in severe traumatic brain injury patients: A randomized, double-blind, placebo-controlled trial 2024 · Probiotic group · Adults aged 18–60 with severe traumatic brain injury admitted to an ICU, receiving enteral nutrition | 40 billion CFU | 2 weeks | 23 |
| Multi-species probiotic supplement enhances vagal nerve function - results of a randomized controlled trial in patients with depression and healthy controls 2025 · Probiotic group — healthy controls · Healthy adults aged 18–65 without a psychiatric diagnosis | 30 billion CFU | 90 days | 23 |
| Efficacy of Lactococcus lactis subsp. lactis LY-66 and Lactobacillus plantarum PL-02 in Enhancing Explosive Strength and Endurance: A Randomized, Double-Blinded Clinical Trial 2024 · PL-02 probiotic group · Healthy non-athlete adults aged 20–40, men and women | 15 billion CFU | 6 weeks | 22 |
| Efficacy of Lactococcus lactis subsp. lactis LY-66 and Lactobacillus plantarum PL-02 in Enhancing Explosive Strength and Endurance: A Randomized, Double-Blinded Clinical Trial 2024 · LY-66 probiotic group · Healthy non-athlete adults aged 20–40, men and women | 15 billion CFU | 6 weeks | 22 |
| Efficacy of Lactococcus lactis subsp. lactis LY-66 and Lactobacillus plantarum PL-02 in Enhancing Explosive Strength and Endurance: A Randomized, Double-Blinded Clinical Trial 2024 · PL-02+LY-66 combined bacteria probiotic group · Healthy non-athlete adults aged 20–40, men and women | 15 billion CFU | 6 weeks | 22 |
| A randomized cross-over trial of prebiotics and probiotics in multiple sclerosis: Trial feasibility, supplement tolerability and symptom abatement 2024 · Probiotic (cross-over arm) · Adults aged 18 or older with relapsing-remitting multiple sclerosis receiving anti-CD20 therapy | 7,200 billion CFU | 6 weeks | 22 |
| Decreased gum bleeding and reduced gingivitis by the probiotic Lactobacillus reuteri 2006 · LR-2 · Patients with moderate to severe gingivitis | 0.2 billion CFU | 2 weeks | 21 |
| [Dynamics of contamination and persistence of Clostridium difficile in intestinal microbiota in newborn infants during antibiotic therapy and use of probiotic strain enterococcus faecium L3] 2013 · main group (mature neonates) · Mature neonates receiving inpatient antibiotic therapy | 2 mL | 10 days | 21 |
| The additional effects of a probiotic mix on abdominal adiposity and antioxidant Status: A double-blind, randomized trial 2017 · Dietary intervention + probiotic mix · Women with excess weight or obesity | 20 billion CFU | 8 weeks | 21 |
| Effects of Lactobacillus plantarum PS128 on Depressive Symptoms and Sleep Quality in Self-Reported Insomniacs: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial 2021 · PS128 group · Adults aged 20–40 with self-reported chronic primary insomnia | 60 billion CFU | 30 days | 21 |
| Long-Term Effects of a Web-Based Low-FODMAP Diet Versus Probiotic Treatment for Irritable Bowel Syndrome, Including Shotgun Analyses of Microbiota: Randomized, Double-Crossover Clinical Trial 2021 · probiotic treatment (VSL#3) · Adults aged 18 years or older with IBS-diarrhea or IBS-mixed type | 900 billion CFU | 26 days | 21 |
| Do synbiotics really enhance beneficial synbiotics effect on defecation symptoms in healthy adults?: Randomized, double-blind, placebo-controlled trial 2022 · Probiotics · Healthy adults aged 20–60 years, men and women, with bowel movements 2–3 times per week and a tendency to constipation | 10 billion CFU | 2 weeks | 21 |
| Clinical, gut microbial and neural effects of a probiotic add-on therapy in depressed patients: a randomized controlled trial 2022 · probiotics · Adults aged 18 years or older with a current depressive episode and HAM-D score >7, receiving treatment as usual | 900 billion CFU | 31 days | 21 |
| Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis 2004 · VSL#3 · Adults with recurrent or refractory pouchitis whose remission had been induced with antibiotics | 6 g | 1 year | 20 |
| Decreased gum bleeding and reduced gingivitis by the probiotic Lactobacillus reuteri 2006 · LR-1 · Patients with moderate to severe gingivitis | 0.2 billion CFU | 2 weeks | 20 |
| Randomised clinical trial: efficacy of Lactobacillus paracasei-enriched artichokes in the treatment of patients with functional constipation--a double-blind, controlled, crossover study 2012 · Probiotic-enriched artichokes · Adults with functional constipation; 3 men and 17 women, mean age 38.8 years | 20 billion CFU | 15 days | 20 |
| Safety and immunomodulatory effects of three probiotic strains isolated from the feces of breast-fed infants in healthy adults: SETOPROB study 2013 · L. paracasei CNCM I-4034 · Healthy men and women aged 18–50 years | 9 billion CFU | 30 days | 20 |
| Safety and immunomodulatory effects of three probiotic strains isolated from the feces of breast-fed infants in healthy adults: SETOPROB study 2013 · B. breve CNCM I-4035 · Healthy men and women aged 18–50 years | 9 billion CFU | 30 days | 20 |
| Safety and immunomodulatory effects of three probiotic strains isolated from the feces of breast-fed infants in healthy adults: SETOPROB study 2013 · L. rhamnosus CNCM I-4036 · Healthy men and women aged 18–50 years | 9 billion CFU | 30 days | 20 |
| The early administration of Lactobacillus reuteri DSM 17938 controls regurgitation episodes in full-term breastfed infants 2014 · Lactobacillus reuteri DSM 17938 · Full-term breastfed infants, starting before the third day of life | 0.1 billion CFU | 4 weeks | 20 |
| Effect of probiotics on postoperative quality of gastric bypass surgeries: a prospective randomized trial 2016 · probiotics group A · Patients with severe obesity who had undergone gastric bypass and experienced postoperative symptomatic GI episodes; ages and sex not reported | 2 g | 2 weeks | 20 |
| Nonmotor gastrointestinal disorders in older patients with Parkinson's disease: is there hope? 2016 · Second group (treated with probiotics) · Older adults (mean age 69.80 years; men and women) with Parkinson’s disease and mild-to-moderate gastrointestinal symptoms | 120 mg | 90 days | 20 |
| Effects of Bifidobacterium probiotic on the treatment of chronic periodontitis: A randomized clinical trial 2018 · Test (SRP + Probiotic therapy) · Adults over 30 years with generalized chronic periodontitis | 2 billion CFU | 30 days | 20 |
| Clostridium butyricum MIYAIRI 588 as Adjunctive Therapy for Treatment-Resistant Major Depressive Disorder: A Prospective Open-Label Trial 2018 · CBM588 adjunctive treatment · Adults with treatment-resistant major depressive disorder receiving antidepressants | 60 mg | 8 weeks | 20 |
| Bifidobacterium longum 1714™ Strain Modulates Brain Activity of Healthy Volunteers During Social Stress 2019 · probiotic group · Healthy men and women aged 18–50 years | 1 billion CFU | 4 weeks | 20 |
| Lactobacillus reuteri DSM 17938 and Magnesium Oxide in Children with Functional Chronic Constipation: A Double-Blind and Randomized Clinical Trial 2020 · Group A · Children aged over 6 months and under 6 years with functional constipation | 0.2 billion CFU | 4 weeks | 20 |
| Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT Compliant] 2021 · Test-G · Men and women aged 18–65 years with irritable bowel syndrome diagnosed by Rome IV criteria | 6 billion CFU | 80 days | 20 |
| Bifidobacterium breve CCFM1025 attenuates major depression disorder via regulating gut microbiome and tryptophan metabolism: A randomized clinical trial 2022 · CCFM1025 · Patients diagnosed with major depressive disorder (MDD); age and sex not reported. | 10 billion CFU | 4 weeks | 20 |
| Bifidobacterium breve CCFM1025 Improves Sleep Quality via Regulating the Activity of the HPA Axis: A Randomized Clinical Trial 2023 · CCFM1025-treated group · Adults aged 18–65 with insomnia, defined by PSQI score >7 | 1 billion CFU | 4 weeks | 20 |
| Effect of combined probiotics and doxycycline therapy on the gut-skin axis in rosacea 2024 · probiotic group · Adults with rosacea; ages 42.40 ± 12.96 years on average; 12 women and 8 men | 2 g | 90 days | 20 |
| Therapeutic Value of Lactobacillus gasseri 345A in Chronic Constipation 2025 · Lactobacillus gasseri 345A · Women aged 18–59 with functional constipation | 7.2 billion CFU | 4 weeks | 20 |
| Multi-species probiotic supplement enhances vagal nerve function - results of a randomized controlled trial in patients with depression and healthy controls 2025 · Probiotic group — patients with major depression · Adults aged 18–65 with major depression | 30 billion CFU | 90 days | 20 |
| Lactobacillus reuteri accelerates gastric emptying and improves regurgitation in infants 2011 · Lactobacillus reuteri DSM 17938 · Infants with regurgitation and functional gastroesophageal reflux | 0.1 billion CFU | 30 days | 19 |
| Daily Intake of Heat-killed Lactobacillus plantarum L-137 Decreases the Probing Depth in Patients Undergoing Supportive Periodontal Therapy 2016 · HK L-137 group · Patients undergoing supportive periodontal therapy | 10 mg | 12 weeks | 19 |
| Use of the Probiotic Limosilactobacillus reuteri as an Adjunct to Subgingival Instrumentation in the Treatment of Periodontitis Patients With Diabetes: A Randomised Clinical Trial 2026 · test group · Adults with type 1 or type 2 diabetes and untreated stage II or III periodontitis; mean age about 63 years; men and women | 0.4 billion CFU | 90 days | 19 |
| Lactobacillus casei rhamnosus Lcr35 in children with chronic constipation 2007 · Lcr35 · Children under 10 years old with chronic constipation | 0.8 billion CFU | 4 weeks | 18 |
| Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection 2011 · Group A, S. boulardii · Children with gastrointestinal symptoms lasting more than 2 weeks and confirmed Blastocystis hominis infection | 500 mg | 10 days | 18 |
| Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study 2016 · Active · Men and women aged 18–55 with diarrhea-predominant irritable bowel syndrome | 2 billion CFU | 90 days | 18 |
| Rapid enteric testing to permit targeted antimicrobial therapy, with and without Lactobacillus reuteri probiotics, for paediatric acute diarrhoeal disease in Botswana: A pilot, randomized, factorial, controlled trial 2017 · Rapid testing and Lactobacillus reuteri · Children aged 2–60 months hospitalized with acute diarrhoeal disease, without severe acute malnutrition | 0.5 billion CFU | 60 days | 18 |
| Effect of the administration of a probiotic with a combination of Lactobacillus and Bifidobacterium strains on antibiotic-associated diarrhea 2019 · Pearls IC group · Adults over 18 of both sexes prescribed amoxicillin-clavulanic acid | 1 billion CFU | 30 days | 18 |
| Effect of Lactobacillus plantarum TWK10 on Exercise Physiological Adaptation, Performance, and Body Composition in Healthy Humans 2019 · 1× TWK10 (low dose) · Healthy, non-athletic men and women aged 20–30 years | 30 billion CFU | 6 weeks | 18 |
| Effect of Lactobacillus plantarum TWK10 on Exercise Physiological Adaptation, Performance, and Body Composition in Healthy Humans 2019 · 3× TWK10 (high dose) · Healthy, non-athletic men and women aged 20–30 years | 90 billion CFU | 6 weeks | 18 |
| Effect of prebiotic and probiotic supplementation on reduced pain in patients with fibromyalgia syndrome: a double-blind, placebo-controlled randomized clinical trial 2024 · probiotics group · Adult women with fibromyalgia syndrome; mean age not specified | 40 billion CFU | 8 weeks | 18 |
| Effects of probiotics on gastrointestinal symptoms, anthropometric measurements, and breastfeeding duration in infants with colic: a randomized control trial 2024 · probiotic group (A) · Mothers of breastfed term infants under 60 days old diagnosed with infantile colic; mothers averaged 25.58 years of age. | 80 mL | 15 days | 18 |
| Metabolome-associated psychological comorbidities improvement in irritable bowel syndrome patients receiving a probiotic 2024 · BL NCC3001 · Adults with IBS with diarrhea or mixed stool pattern and mild-to-moderate anxiety and/or depression | 10 billion CFU | 6 weeks | 18 |
| The impact of Limosilactobacillus reuteri in combination with non-surgical periodontal therapy on periodontal clinical parameters and salivary and subgingival microbiota composition in individuals with stage III-IV periodontitis: a randomized controlled trial 2025 · Test group · Adults aged 18–60 with stage III–IV periodontitis | 0.2 billion CFU | 3 weeks | 18 |
| 12-week preoperative probiotic supplementation versus placebo: effects on inflammation, endotoxemia, adipokines, and gastrointestinal peptides in patients six months after bariatric surgery - a double-blind, randomized, placebo-controlled clinical trial 2025 · probiotic group · Adults over 18 with obesity who qualified for bariatric surgery | 2 billion CFU | 12 weeks | 18 |
| Tolerance and safety of the potentially probiotic strain Lactobacillus rhamnosus PRSF-L477: a randomised, double-blind placebo-controlled trial in healthy volunteers 2010 · Lactobacillus rhamnosus PRSF-L477 group · Healthy volunteers; age and sex not specified | 100 billion CFU | 3 weeks | 17 |
| Probiotic Supplements Beneficially Affect Tryptophan-Kynurenine Metabolism and Reduce the Incidence of Upper Respiratory Tract Infections in Trained Athletes: A Randomized, Double-Blinded, Placebo-Controlled Trial 2016 · probiotics (PRO) · Healthy trained athletes aged 20–35 years, men and women | 10 billion CFU | 12 weeks | 17 |
| Altered Salivary Microbiota Following Bifidobacterium animalis Subsp. Lactis BL-11 Supplementation Are Associated with Anthropometric Growth and Social Behavior Severity in Individuals with Prader-Willi Syndrome 2022 · Probiotic group · Children with genetically confirmed Prader-Willi syndrome; mean age 60.66 months; male and female | 60 billion CFU | 12 weeks | 17 |
| A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial 2010 · L. plantarum MF1298 · Adults aged 18–75 with irritable bowel syndrome meeting Rome II criteria | 10 billion CFU | 3 weeks | 16 |
| Rapid enteric testing to permit targeted antimicrobial therapy, with and without Lactobacillus reuteri probiotics, for paediatric acute diarrhoeal disease in Botswana: A pilot, randomized, factorial, controlled trial 2017 · Standard care and Lactobacillus reuteri · Children aged 2–60 months hospitalized with acute diarrhoeal disease, without severe acute malnutrition | 0.5 billion CFU | 60 days | 16 |
| A Pilot Randomized Controlled Trial to Explore Cognitive and Emotional Effects of Probiotics in Fibromyalgia 2018 · Probiotic group · Adults with fibromyalgia; mean age 55.00 years; 15 women and 1 man among completers | 0.012 billion CFU | 8 weeks | 16 |
| Clinical efficacy of halophilic lactic acid bacterium Tetragenococcus halophilus Th221 from soy sauce moromi for perennial allergic rhinitis 2009 · high dose · People with perennial allergic rhinitis; age and sex not stated | 60 mg | 8 weeks | 15 |
| Clinical efficacy of halophilic lactic acid bacterium Tetragenococcus halophilus Th221 from soy sauce moromi for perennial allergic rhinitis 2009 · low dose · People with perennial allergic rhinitis; age and sex not stated | 20.4 mg | 8 weeks | 15 |
| Clinical and microbiological effects of Lactobacillus reuteri probiotics in the treatment of chronic periodontitis: a randomized placebo-controlled study 2013 · SRP + P (probiotic lozenge) · Adults aged at least 35 years with previously untreated moderate to severe generalized adult periodontitis; men and women | 0.2 billion CFU | 12 weeks | 15 |
| Probiotics drive gut microbiome triggering emotional brain signatures 2018 · Probiotic – PRP group · Healthy volunteers aged 20–40 years, both sexes | 3 g | 4 weeks | 15 |
| Are Lactobacillus salivarius G60 and inulin more efficacious to treat patients with oral halitosis and tongue coating than the probiotic alone and placebo? A randomized clinical trial 2020 · LS · Patients aged 35 ± 15 years with oral halitosis and tongue coating; 66% female | 2 billion CFU | 10 days | 15 |
| Bifidobacterium animalis subsp lactis HN019 presents antimicrobial potential against periodontopathogens and modulates the immunological response of oral mucosa in periodontitis patients 2020 · Test group · Adults over 30 years with generalized chronic periodontitis | 2 billion CFU | 30 days | 15 |
| Beneficial effect of Lactobacillus plantarum IS-10506 supplementation in adults with atopic dermatitis: a randomized controlled trial 2022 · intervention · Adults with mild or moderate atopic dermatitis | 20 billion CFU | 8 weeks | 15 |
| Effect of systemic antibiotic and probiotic therapies as adjuvant treatments of subgingival instrumentation for periodontitis: a randomized controlled clinical study 2022 · Debridement + probiotic (GProb) · Adults aged 35–50 with Stage II or III, Grade B periodontitis and good systemic health | 0.4 billion CFU | 3 weeks | 15 |
| Results of a phase Ib study of SB-121, an investigational probiotic formulation, a randomized controlled trial in participants with autism spectrum disorder 2023 · SB-121 · Males aged 15–27 years with autism spectrum disorder | 20 billion CFU | 4 weeks | 15 |
| Effect of Lacticaseibacillus rhamnosus IDCC 3201 on irritable bowel syndrome with constipation: a randomized, double-blind, and placebo-controlled trial 2024 · RH 3201 group · Adults with moderate irritable bowel syndrome with constipation (IBS-C); ages in this arm averaged 36.4 ± 13.6 years | 10 billion CFU | 8 weeks | 15 |
| Levilactobacillus brevis CD2 as a multifaceted probiotic to preserve oral health: results of a double-blind, randomized, placebo-controlled trial in healthy adults 2025 · L. brevis CD2 group · Adults aged 20–75 with at least localized gingivitis and no stated systemic or chronic disease | 4 billion CFU | 4 weeks | 15 |
| Impact of Probiotic Supplementation and High-Intensity Interval Training on Primary Dysmenorrhea: A Double-Blind, Randomized Controlled Trial Investigating Inflammation and Hormonal Modulation 2025 · DysmenPro · Females aged 18–40 with primary dysmenorrhea | 15 billion CFU | 10 weeks | 15 |
| [PROBIOTICS, NUTRITIONAL STATUS AND RESISTANCE TO RESPIRATORY INFECTIONS IN INFANTS] 2015 · main group · Children in their first year of life living in a specialised psychoneurologic orphanage; sex not specified | 1.5 billion CFU | 90 days | 14 |
| The Effect of Continuous Intake of Lactobacillus gasseri OLL2716 on Mild to Moderate Delayed Gastric Emptying: A Randomized Controlled Study 2021 · LG21 strain group · Japanese adults aged 20–64 with mild to moderate delayed gastric emptying and recent stomach upset | 1 billion CFU | 12 weeks | 14 |
| Impact of Probiotic Supplementation and High-Intensity Interval Training on Primary Dysmenorrhea: A Double-Blind, Randomized Controlled Trial Investigating Inflammation and Hormonal Modulation 2025 · DysmenExPro · Females aged 18–40 with primary dysmenorrhea | 15 billion CFU | 10 weeks | 14 |
| Feasibility, safety and tolerability of estrogen and/or probiotics for improving vaginal health in Canadian African, Caribbean, and Black women: A pilot phase 1 clinical trial 2025 · Group 3 (Estring and oral probiotic; ER+oP) · Premenopausal African, Caribbean, and Black women aged 18–49 in good general health | 2 billion CFU | 30 days | 13 |
| Yogurt containing probiotic Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 helps resolve moderate diarrhea and increases CD4 count in HIV/AIDS patients 2008 · Probiotic yogurt group · Adult women aged 18–44 with HIV/AIDS, moderate diarrhea and CD4 counts over 200; not receiving antiretrovirals or dietary supplements | 100 mL | 15 days | 12 |
| Lactobacillus plantarum IS-10506 supplementation reduced SCORAD in children with atopic dermatitis 2017 · intervention group · Children with mild or moderate atopic dermatitis; age and sex not specified | 10 billion CFU | 12 weeks | 12 |
| Four weeks of probiotic supplementation reduces GI symptoms during a marathon race 2019 · PRO (probiotic group) · Experienced marathon runners aged 22–50, 20 male and 4 female overall, with no stated gastrointestinal medical history; the probiotic arm included men and women. | 25 billion CFU | 4 weeks | 12 |
| A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of Lactiplantibacillus plantarum CJLP243 in Patients with Functional Diarrhea and High Fecal Calprotectin Levels 2022 · Probiotic group · Adults with functional diarrhea meeting Rome IV criteria and fecal calprotectin levels of at least 11.5 mg/kg; age range and sex not specified | 10 billion CFU | 60 days | 12 |
| Effects of probiotic supplementation with high-intensity interval training on cardiorespiratory endurance and metabolism in Middle-Aged Obese Women 2024 · probiotic group (P) · Women aged 35–55 years with obesity defined as body fat greater than 35%, without exercise habits | 60 billion CFU | 8 weeks | 12 |
| Effects of probiotic supplementation with high-intensity interval training on cardiorespiratory endurance and metabolism in Middle-Aged Obese Women 2024 · HIIT with probiotic group (HP) · Women aged 35–55 years with obesity defined as body fat greater than 35%, without exercise habits; also participated in HIIT | 60 billion CFU | 8 weeks | 12 |
| Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis 2003 · BFM group · People with ulcerative colitis; age and sex not reported | 100 mL | 1 year | 11 |
| Effects of Probiotic (Bacillus subtilis) Supplementation During Offseason Resistance Training in Female Division I Athletes 2020 · probiotic (DE111) group · Female Division I athletes, mean age 19.6 years, participating in offseason resistance training | 5 billion CFU | 10 weeks | 11 |
| The effect of probiotic supplementation on performance, inflammatory markers and gastro-intestinal symptoms in elite road cyclists 2021 · Experimental (E) group · Male elite road cyclists aged 19–40 years, without stated illness or medical condition | 15 billion CFU | 90 days | 11 |
| The effects of probiotics on feeding tolerance, bowel habits, and gastrointestinal motility in preterm newborns 2008 · Lactobacillus reuteri ATCC 55730 · Formula-fed preterm newborns | 0.1 billion CFU | 30 days | 10 |
| Effects of probiotic and prebiotic on gastrointestinal motility in newborns 2009 · probiotic-added formula · Preterm newborns | 0.1 billion CFU | 30 days | 10 |
| Effects of probiotics supplementation on gastrointestinal permeability, inflammation and exercise performance in the heat 2014 · probiotics capsule · male runners exercising in the heat | 45 billion CFU | 4 weeks | 10 |
| Early postoperative administration of probiotics versus placebo in elderly patients undergoing elective colorectal surgery: a double-blind randomized controlled trial 2013 · Group A (antibiotic + probiotic; VSL#3) · Adults aged over 70 years undergoing elective laparoscopic colonic resection | 900 billion CFU | 4 weeks | 10 |
| Effects of Daily Probiotics Supplementation on Anxiety Induced Physiological Parameters among Competitive Football Players 2020 · probiotic group · Male competitive football players aged 18–21, without stated psychological or other excluded conditions | 30 billion CFU | 8 weeks | 10 |
| Synergistic Effects of Probiotic and Omega-3 Supplementation with Ultra-Short Race Pace Training on Sprint Swimming Performance 2025 · Probiotics + USRPT (PRO + USRPT) · Male competitive sprint swimmers with at least five years of competitive experience and no stated disease or medical condition | 450 billion CFU | 8 weeks | 10 |
| Synbiotic Supplementation with Probiotics and Omega-3 Fatty Acids Enhances Upper-Body Muscle Strength in Elite Swimmers: Evidence for Gut-Muscle Axis Modulation During Race-Pace Training 2025 · PRO + USRPT · Male elite sprint freestyle swimmers with at least 5 years of competitive experience | 450 billion CFU | 8 weeks | 10 |
| Eight Weeks of Bifidobacterium lactis BL-99 Supplementation Improves Lipid Metabolism and Sports Performance through Short-Chain Fatty Acids in Cross-Country Skiers: A Preliminary Study 2023 · E group (experiment) · Male national-level cross-country skiing athletes, average age 19.4 years, without the listed cerebrovascular, metabolic, cardiovascular, liver or kidney conditions | 4 billion CFU | 8 weeks | 8 |
| Effect of Multi-Strain Probiotic Supplementation on URTI Symptoms and Cytokine Production by Monocytes after a Marathon Race: A Randomized, Double-Blind, Placebo Study 2021 · probiotic group · Male marathon runners who trained aerobically at least three times a week; mean age about 40 years | 5 billion CFU | 30 days | 7 |
| Protective Effects of Probiotics on Runners' Mood: Immunometabolic Mechanisms Post-Exercise 2024 · Probiotic group · Male runners aged 30–45 years, physically active and able to run a marathon, without stated chronic disease | 2 g | 30 days | 7 |
| Saccharomyces boulardii in maintenance treatment of Crohn's disease 2000 · mesalamine plus Saccharomyces boulardii · Patients with Crohn's disease in clinical remission (CDAI < 150) | 1 g | 26 weeks | — |
| Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation 2003 · LcS probiotic beverage group · Patients with chronic constipation; age and sex not specified | 65 mL | 4 weeks | — |
| Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis 2004 · bifidobacteria-fermented milk · Adults with mild to moderate active ulcerative colitis | 100 mL | 12 weeks | — |
| Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome 2004 · SCM-III · Adults with irritable bowel syndrome | 30 mL | 12 weeks | — |
| Effects of Saccharomyces boulardii in children with acute diarrhoea 2005 · S. boulardii group · Children with acute diarrhoea | 250 mg | 5 days | — |
| Effects of probiotics on atopic dermatitis: a randomised controlled trial 2005 · probiotic group · Children aged 6–18 months with moderate or severe atopic dermatitis | 2 billion CFU | 8 weeks | — |
| Lactobacillus paracasei strain ST11 has no effect on rotavirus but ameliorates the outcome of nonrotavirus diarrhea in children from Bangladesh 2005 · ST11 · Male infants and young children aged 4 to 24 months presenting with diarrhea of less than 2 days' duration | 10 billion CFU | 5 days | — |
| The efficacy and safety of heat-killed Lactobacillus paracasei for treatment of perennial allergic rhinitis induced by house-dust mite 2005 · Group A · Patients with perennial allergic rhinitis induced by house-dust mite; age and sex not specified | 10 billion CFU | 30 days | — |
| The efficacy and safety of heat-killed Lactobacillus paracasei for treatment of perennial allergic rhinitis induced by house-dust mite 2005 · Group B · Patients with perennial allergic rhinitis induced by house-dust mite; age and sex not specified | 10 billion CFU | 30 days | — |
| Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacterpylori eradication 2005 · treatment group · Adults with peptic ulcer disease or non-ulcer dyspepsia receiving Helicobacter pylori eradication antibiotics | 1 g | 2 weeks | — |
| Treatment of acute infectious diarrhoea in infants and children with a mixture of three Lactobacillus rhamnosus strains--a randomized, double-blind, placebo-controlled trial 2006 · Lakcid L · Children aged 2 months to 6 years with infectious diarrhoea | 24 billion CFU | 5 days | — |
| The effect of a multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking the antibiotic amoxycillin 2008 · multispecies probiotic group · Healthy volunteers taking amoxycillin; ages and sex not specified | 10 g | 2 weeks | — |
| Improvement of periodontal condition by probiotics with Lactobacillus salivarius WB21: a randomized, double-blind, placebo-controlled study 2008 · WB21-containing tablets with xylitol · Volunteers without severe periodontitis; age and sex not reported | 2.01 billion CFU | 8 weeks | — |
| Nitazoxanide vs. probiotics for the treatment of acute rotavirus diarrhea in children: a randomized, single-blind, controlled trial in Bolivian children 2009 · probiotics · Children aged 28 days to 24 months with rotavirus diarrhea | 2 g | 5 days | — |
| Improvement of constipation and liver function by plant-derived lactic acid bacteria: a double-blind, randomized trial 2010 · type A · Healthy adults with complaints about intestinal health, including constipation and diarrhea | 100 g | 6 weeks | — |
| Improvement of constipation and liver function by plant-derived lactic acid bacteria: a double-blind, randomized trial 2010 · type B · Healthy adults with complaints about intestinal health, including constipation and diarrhea | 100 g | 6 weeks | — |
| Improvement of constipation and liver function by plant-derived lactic acid bacteria: a double-blind, randomized trial 2010 · type C · Healthy adults with complaints about intestinal health, including constipation and diarrhea | 100 g | 6 weeks | — |
| Lactobacillus reuteri in children with functional abdominal pain (FAP) 2014 · L. reuteri · Children aged 6–16 years with functional abdominal pain | 0.2 billion CFU | 4 weeks | — |
| Efficacy and safety of Saccharomyces boulardii in acute childhood diarrhea: a double blind randomised controlled trial 2012 · Saccharomyces boulardii group · Children aged 3–59 months admitted with acute-onset diarrhea of less than 48 hours | 500 mg | 5 days | — |
| [Efficacy of probiotics on ulcerative colitis and its mechanism] 2013 · Golden Bifid group · Patients with mild to moderate ulcerative colitis; age and sex not reported | 4 g | 2 years | — |
| [Efficacy of probiotics on ulcerative colitis and its mechanism] 2013 · Changmei group · Patients with mild to moderate ulcerative colitis; age and sex not reported | 3 g | 2 years | — |
| Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease--a double-blind, randomised, placebo-controlled study 2013 · Group L · Patients with symptomatic uncomplicated diverticular disease | 24 billion CFU | 1 year | — |
| Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease--a double-blind, randomised, placebo-controlled study 2013 · Group LM · Patients with symptomatic uncomplicated diverticular disease | 24 billion CFU | 1 year | — |
| Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis 2014 · probiotic group · patients with rheumatoid arthritis; age and sex not specified | 0.1 billion CFU | 8 weeks | — |
| Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of Bifidobacterium longum CECT 7347 in children with newly diagnosed coeliac disease 2014 · Bifidobacterium longum CECT 7347 group · Children with newly diagnosed coeliac disease | 1 billion CFU | 90 days | — |
| Clinical Evidence of Effects of Lactobacillus plantarum HY7714 on Skin Aging: A Randomized, Double Blind, Placebo-Controlled Study 2015 · probiotic group · Volunteers aged 41–59 with dry skin and wrinkles | 10 billion CFU | 12 weeks | — |
| Efficacy of probiotic supplementation on quality of life and pulmonary symptoms due to sulfur mustard exposure: a randomized double-blind placebo-controlled trial 2017 · probiotic · Subjects with chronic pulmonary complications following sulfur mustard exposure | 2 billion CFU | 6 weeks | — |
| The effects of the DDS-1 strain of lactobacillus on symptomatic relief for lactose intolerance - a randomized, double-blind, placebo-controlled, crossover clinical trial 2016 · DDS-1 active product · Adults aged 18–75 with lactose-intolerance symptoms after a lactose challenge; otherwise healthy volunteers | 10 billion CFU | 4 weeks | — |
| Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults-Randomized Controlled Trial 2016 · B420 · Adults aged 18–65 with overweight or obesity (BMI 28.0–34.9) | 10 billion CFU | 26 weeks | — |
| Yogurt Containing Lactobacillus gasseri Mitigates Aspirin-Induced Small Bowel Injuries: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial 2017 · LG group · Patients taking aspirin for more than 1 month; age and sex not specified | 224 mL | 6 weeks | — |
| Probiotics (Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2) improve rhinoconjunctivitis-specific quality of life in individuals with seasonal allergies: a double-blind, placebo-controlled, randomized trial 2017 · probiotic · Adults (mean age 27 years) who self-identified as having seasonal allergies | 3 billion CFU | 8 weeks | — |
| The positive benefit of Lactobacillus paracasei NCC2461 ST11 in healthy volunteers with moderate to severe dandruff 2017 · ST11 · Healthy males aged 18 to 60 years with moderate to severe dandruff | 1 billion CFU | 8 weeks | — |
| Probiotic Supplementation in Preterm: Feeding Intolerance and Hospital Cost 2017 · L. reuteri DSM 17938 supplementation group · Preterm, formula-fed newborns born before 37 weeks’ gestation | 0.1 billion CFU | 30 days | — |
| Crying Time and RORγ/FOXP3 Expression in Lactobacillus reuteri DSM17938-Treated Infants with Colic: A Randomized Trial 2018 · Lactobacillus reuteri DSM 17938 group · Infants with infantile colic | 0.1 billion CFU | 30 days | — |
| The effects of combined probiotic ingestion and circuit training on muscular strength and power and cytokine responses in young males 2018 · circuit training with probiotics (CTP) · healthy sedentary young males | 60 billion CFU | 12 weeks | — |
| Effect of Oral Administration of a Mixture of Probiotic Strains on SCORAD Index and Use of Topical Steroids in Young Patients With Moderate Atopic Dermatitis: A Randomized Clinical Trial 2018 · probiotic group · Children aged 4 to 17 years with moderate atopic dermatitis | 1 billion CFU | 12 weeks | — |
| Effects of using symbiotics in the clinical nutritional evolution of patients with chronic pancreatitis: Study prospective, randomized, controlled, double blind 2017 · intervention group · Patients with chronic pancreatitis; age range and sex not reported | 12 g | 90 days | — |
| Evidences of a New Psychobiotic Formulation on Body Composition and Anxiety 2017 · psychobiotics oral suspension group (POSG) · Adults aged 21–72 years, men and women, with BMI 18.5–39.9 kg/m² and no metabolic complications | 3 g | 3 weeks | — |
| Evidences of a New Psychobiotic Formulation on Body Composition and Anxiety 2017 · combined treatment group (CTG) · Adults aged 21–72 years, men and women, with BMI 18.5–39.9 kg/m² and no metabolic complications | 3 g | 3 weeks | — |
| Lactobacillus gasseri BNR17 Supplementation Reduces the Visceral Fat Accumulation and Waist Circumference in Obese Adults: A Randomized, Double-Blind, Placebo-Controlled Trial 2018 · low-dose BNR (BNR-L) · Adults aged 20–75 years with obesity-range BMI of 25–35 kg/m² | 1 billion CFU | 12 weeks | — |
| Lactobacillus gasseri BNR17 Supplementation Reduces the Visceral Fat Accumulation and Waist Circumference in Obese Adults: A Randomized, Double-Blind, Placebo-Controlled Trial 2018 · high-dose BNR (BNR-H) · Adults aged 20–75 years with obesity-range BMI of 25–35 kg/m² | 10 billion CFU | 12 weeks | — |
| Regulatory T cells and Toll-like receptor 2 and 4 mRNA expression in infants with colic treated with Lactobacillus reuteri DSM17938 2018 · L. reuteri DSM17938 · Infants younger than 60 days with colic | 0.1 billion CFU | 4 weeks | — |
| Bacillus coagulans Unique IS2 in Constipation: A Double-Blind, Placebo-Controlled Study 2020 · B. coagulans Unique IS2 group · Adults with functional constipation; age range and sex not reported | 2 billion CFU | 4 weeks | — |
| Effect of synbiotic and probiotic supplementation on serum brain-derived neurotrophic factor level, depression and anxiety symptoms in hemodialysis patients: a randomized, double-blinded, clinical trial 2021 · probiotics · Hemodialysis patients; age and sex not specified | 5 g | 12 weeks | — |
| Efficacy of a multispecies probiotic as adjunctive therapy in generalized anxiety disorder: a double blind, randomized, placebo-controlled trial 2021 · Probiotics + sertraline (PS) group · Drug-free patients with generalized anxiety disorder diagnosed using DSM-V criteria; age and sex not reported | 18 billion CFU | 8 weeks | — |
| Effects of Diet Based on IgG Elimination Combined with Probiotics on Migraine Plus Irritable Bowel Syndrome 2019 · probiotics · Adults aged 18–65 with migraine and uncomplicated irritable bowel syndrome | 4.5 g | 14 weeks | — |
| Effects of Diet Based on IgG Elimination Combined with Probiotics on Migraine Plus Irritable Bowel Syndrome 2019 · elimination diet combined with probiotics · Adults aged 18–65 with migraine and uncomplicated irritable bowel syndrome | 4.5 g | 14 weeks | — |
| Bacillus coagulans GBI-30, 6068 decreases upper respiratory and gastrointestinal tract symptoms in healthy Mexican scholar-aged children by modulating immune-related proteins 2019 · GanedenBC 30 probiotic group · Healthy children aged 6–8 years | 1 billion CFU | 90 days | — |
| Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome 2020 · Saccharomyces cerevisiae CNCM I-3856 group · Newly diagnosed subjects with irritable bowel syndrome, including IBS-D, IBS-C, and IBS-M; age and sex not reported | 4 billion CFU | 8 weeks | — |
| A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial 2020 · probiotics · Adults with irritable bowel syndrome | 10 billion CFU | 8 weeks | — |
| Lactobacillus reuteri DSM 17938 is effective in the treatment of functional abdominal pain in children: Results of the double-blind randomized study 2020 · Lactobacillus reuteri DSM 17938 group · Children aged 4–18 years with functional abdominal pain | 0.1 billion CFU | 12 weeks | — |
| PHAGE-2 Study: Supplemental Bacteriophages Extend Bifidobacterium animalis subsp. lactis BL04 Benefits on Gut Health and Microbiota in Healthy Adults 2020 · B. lactis BL04 · Healthy adults; age range and sex not specified | 1 billion CFU | 4 weeks | — |
| Efficacy of Bifidobacterium breve CECT7263 for infantile colic treatment: an open-label, parallel, randomised, controlled trial 2021 · Bb group · Infants diagnosed with infantile colic according to Rome III criteria | 0.2 billion CFU | 4 weeks | — |
| Effects of probiotic and alpha-lipoic acid supplements, separately or in combination on the anthropometric indicators and maintenance of weight in overweight individuals 2021 · Probiotic group · Overweight individuals | 500 mg | 24 weeks | — |
| The effects of co-administration of probiotics and prebiotics on chronic inflammation, and depression symptoms in patients with coronary artery diseases: a randomized clinical trial 2022 · LGG · Patients with coronary artery disease; age and sex not specified | 1.9 billion CFU | 8 weeks | — |
| Probiotics reduce self-reported symptoms of upper respiratory tract infection in overweight and obese adults: should we be considering probiotics during viral pandemics? 2021 · Lab4P probiotic group · Adults aged 30–65 with BMI 25–34.9 kg/m² who were overweight or obese | 50 billion CFU | 26 weeks | — |
| Effects of Probiotics on Anxiety, Stress, Mood and Fitness of Badminton Players 2021 · probiotic group (PG) · Healthy badminton players aged 18 to 30, male and female not specified | 30 billion CFU | 6 weeks | — |
| Effects of Fermented Milk Containing Lacticaseibacillus paracasei Strain Shirota on Constipation in Patients with Depression: A Randomized, Double-Blind, Placebo-Controlled Trial 2021 · LcS group · Adults aged 18–60 with depression and constipation | 10 billion CFU | 9 weeks | — |
| Efficacy of Bifidobacterium animalis subsp. lactis, BB-12(®) on infant colic - a randomised, double-blinded, placebo-controlled study 2021 · BB-12 · Breastfed, full-term infants less than 3 months old with infant colic | 1 billion CFU | 3 weeks | — |
| The effect of probiotics on mood and sleep quality in postmenopausal women: A triple-blind randomized controlled trial 2022 · Intervention group · Postmenopausal women aged 45–55 years | 100 g | 6 weeks | — |
| Effect of probiotics combined with metformin on improvement of menstrual and metabolic patterns in women with polycystic ovary syndrome: a randomized clinical trial 2022 · probiotics group · non-obese women with PCOS | 4 g | 12 weeks | — |
| Effect of probiotics combined with metformin on improvement of menstrual and metabolic patterns in women with polycystic ovary syndrome: a randomized clinical trial 2022 · combination group · non-obese women with PCOS | 4 g | 12 weeks | — |
| Does Multi-Strain Probiotic Supplementation Impact the Effort Capacity of Competitive Road Cyclists? 2022 · probiotic group (P) · Male competitive road cyclists aged 18–26 years, in good health and with at least 5 years of competitive cycling experience | 100 billion CFU | 120 days | — |
| Effect of short-term, high-dose probiotic supplementation on cognition, related brain functions and BDNF in patients with depression: a secondary analysis of a randomized controlled trial 2023 · probiotics group · Adults aged 18 years or older with major depressive disorder and a depressive episode, receiving inpatient treatment as usual | 900 billion CFU | 31 days | — |
| Evaluation of Bacillus clausii CSI08, Bacillus megaterium MIT411 and a Bacillus cocktail on gastrointestinal health: a randomised, double-blind, placebo-controlled pilot study 2023 · Bacillus clausii CSI08 · Study participants; age, sex, and health status not specified | 1 billion CFU | 45 days | — |
| Evaluation of Bacillus clausii CSI08, Bacillus megaterium MIT411 and a Bacillus cocktail on gastrointestinal health: a randomised, double-blind, placebo-controlled pilot study 2023 · Bacillus megaterium MIT411 · Study participants; age, sex, and health status not specified | 1 billion CFU | 45 days | — |
| Evaluation of Bacillus clausii CSI08, Bacillus megaterium MIT411 and a Bacillus cocktail on gastrointestinal health: a randomised, double-blind, placebo-controlled pilot study 2023 · Probiotic cocktail · Study participants; age, sex, and health status not specified | 2 billion CFU | 45 days | — |
| Effect of probiotics on nutritional status, biochemical parameters, and disease severity in cirrhotic patients referred for liver transplantation-A randomised double blind, placebo-controlled trial 2023 · probiotics · Patients with cirrhosis referred for liver transplantation | 113 billion CFU | 6 weeks | — |
| A double-blind, randomized, placebo-controlled study assessing the impact of probiotic supplementation on the symptoms of irritable bowel syndrome in females 2024 · Lab4 probiotic · Females with Rome IV-diagnosed irritable bowel syndrome; age range not reported | 25 billion CFU | 8 weeks | — |
| Effectiveness of phototherapy with and without probiotics for the treatment of indirect hyperbilirubinaemia in preterm neonates: a randomised controlled trial 2024 · Group B · Preterm neonates with indirect hyperbilirubinaemia | 250 mg | — | — |
| Effect of Maternal Probiotics on Infantile Colic Symptoms and Maternal Quality of Life and Maternal Attachment: A Single-Blind, Randomized Controlled Study 2025 · Experimental group · Mothers of babies with infantile colic; maternal age and other conditions not reported | 0.5 billion CFU | 15 days | — |
| Lactiplantibacillus plantarum Lp815 decreases anxiety in people with mild to moderate anxiety: a direct-to-consumer, randomised, double-blind, placebo-controlled study 2025 · 1 billion CFU · Adults with mild to moderate anxiety | 1 billion CFU | 6 weeks | — |
| Lactiplantibacillus plantarum Lp815 decreases anxiety in people with mild to moderate anxiety: a direct-to-consumer, randomised, double-blind, placebo-controlled study 2025 · 5 billion CFU · Adults with mild to moderate anxiety | 5 billion CFU | 6 weeks | — |
| Weizmannia coagulans BC99 alleviates pediatric allergic rhinitis via the gut microbiota-SCFAs- immunomodulatory axis: A randomized, double-blind, placebo-controlled trial 2026 · W. coagulans BC99 · Children with allergic rhinitis; age range and sex not specified | 2 billion CFU | 8 weeks | — |
| Probiotics in the prevention of eczema: a randomised controlled trial 2014 · Probiotic arm · Pregnant women aged 16 years or older with a normal singleton pregnancy and their infants; infants with and without increased risk of atopy | 10 billion CFU | 26 weeks | 220 |
| Efficacy of a Probiotic Consisting of Lacticaseibacillus rhamnosus PDV 1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911, and Bifidobacterium longum subsp. longum PDV 2301 in the Treatment of Hospitalized Patients with COVID-19: a Randomized Controlled Trial 2023 · PRO group · Adults aged 18–75 hospitalized with COVID-19 | 12 billion CFU | 2 weeks | 99 |
| Effect of an Immune-Boosting, Antioxidant and Anti-Inflammatory Food Supplement in Hospitalized COVID-19 Patients: A Prospective Randomized Pilot Study 2023 · intervention group · Adults aged 18 years or older hospitalized with PCR-confirmed COVID-19 who required more than 48 hours of admission | 1 billion CFU | — | 78 |
| Preventive effects of combined live Bifidobacterium, Lactobacillus, Enterococcus, and Bacillus cereus tablets on radiation pneumonitis-associated with cyberknife treatment for pulmonary malignancies 2025 · Experimental group · Adults aged 35–80 with primary lung cancer or secondary metastatic pulmonary malignancy receiving CyberKnife treatment | 0.0135 billion CFU | — | 65 |
| Randomised clinical trial: a Lactobacillus GG and micronutrient-containing mixture is effective in reducing nosocomial infections in children, vs. placebo 2016 · treatment group · Children aged 6 months to 5 years hospitalised for any condition | 6 billion CFU | 15 days | 45 |
| Do Probiotics During In-Hospital Antibiotic Treatment Prevent Colonization of Gut Microbiota With Multi-Drug-Resistant Bacteria? A Randomized Placebo-Controlled Trial Comparing Saccharomyces to a Mixture of Lactobacillus, Bifidobacterium, and Saccharomyces 2020 · Probiotic mixture · Adults aged 48–96 hospitalized with infectious diseases and treated with antibiotics; mostly older adults with comorbidities | 28 billion CFU | 30 days | 40 |
| Effect of a Nutritional Support System to Increase Survival and Reduce Mortality in Patients with COVID-19 in Stage III and Comorbidities: A Blinded Randomized Controlled Clinical Trial 2022 · Intervention Group (IG) · Hospitalized men and women aged 30–75 years with stage III COVID-19, oxygen saturation below 90%, and comorbidities including type 2 diabetes, systemic arterial hypertension, or BMI 25–40 | 500 mg | 3 weeks | 40 |
| Perioperative synbiotics decrease postoperative complications in periampullary neoplasms: a randomized, double-blind clinical trial 2015 · group S (synbiotics) · Adults undergoing surgery for periampullary neoplasms; age and sex not specified | 8 billion CFU | 2 weeks | 23 |
| Maternal fish oil and/or probiotics intervention: Allergic diseases in children up to two years old 2023 · fish oil + probiotics · Women in early pregnancy | 20 billion CFU | — | — |
| A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial 2024 · SIM01 · Adults with post-acute COVID-19 syndrome (PACS), with at least one PACS symptom persisting for 4 weeks or more after confirmed SARS-CoV-2 infection | 20 billion CFU | 26 weeks | 232 |
| Treatment with a Probiotic Mixture Containing Bifidobacterium animalis Subsp. Lactis BB12 and Enterococcus faecium L3 for the Prevention of Allergic Rhinitis Symptoms in Children: A Randomized Controlled Trial 2021 · Group A (probiotic treatment group) · Children and adolescents aged 6–17 years with allergic rhinitis | 4 billion CFU | 90 days | 150 |
| Improved gastrointestinal tolerance and iron status via probiotic use in iron deficiency anaemia patients initiating oral iron replacement: a randomised controlled trial 2024 · IRT-Pro group · Adults over 18 with newly diagnosed iron deficiency anaemia; 97.8% female | 10 billion CFU | 30 days | 138 |
| Randomized trial of probiotics and calcium on diarrhea and respiratory tract infections in Indonesian children 2012 · RC with Lactobacillus reuteri DSM17938 (reuteri) · Healthy children aged 1 to 6 years in low-socioeconomic communities of Jakarta, Indonesia | 0.51 billion CFU | 26 weeks | 124 |
| Probiotics Lactobacillus reuteri DSM 17938 and Lactobacillus casei CRL 431 modestly increase growth, but not iron and zinc status, among Indonesian children aged 1-6 years 2013 · reuteri · Healthy Indonesian children aged 1–6 years in low-socioeconomic urban communities of Jakarta | 0.5 billion CFU | 26 weeks | 124 |
| Randomized trial of probiotics and calcium on diarrhea and respiratory tract infections in Indonesian children 2012 · RC with Lactobacillus casei CRL431 (casei) · Healthy children aged 1 to 6 years in low-socioeconomic communities of Jakarta, Indonesia | 0.51 billion CFU | 26 weeks | 120 |
| Probiotics Lactobacillus reuteri DSM 17938 and Lactobacillus casei CRL 431 modestly increase growth, but not iron and zinc status, among Indonesian children aged 1-6 years 2013 · casei · Healthy Indonesian children aged 1–6 years in low-socioeconomic urban communities of Jakarta | 0.5 billion CFU | 26 weeks | 120 |
| Effect of Lactobacillus rhamnosus LGG® and Bifidobacterium animalis ssp. lactis BB-12® on health-related quality of life in college students affected by upper respiratory infections 2013 · probiotic-containing powder · Apparently healthy college students living in campus residence halls; outcomes assessed in students who developed an upper respiratory infection | 2 billion CFU | 12 weeks | 114 |
| The effect of a multispecies synbiotic mixture on the duration of diarrhea and length of hospital stay in children with acute diarrhea in Turkey: single blinded randomized study 2013 · synbiotic group · hospitalized children with acute watery diarrhea | 2.5 billion CFU | 5 days | 113 |
| Effectiveness of a Balanced Nine-Strain Synbiotic in Primary-Care Irritable Bowel Syndrome Patients-A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial 2024 · multi-strain synbiotic group · Female and male patients aged 18–65 years with moderate to severe irritable bowel syndrome | 4.5 billion CFU | 12 weeks | 101 |
| Effects of probiotic yogurt on relative respiratory tract infections, urine, saliva biomarkers, and fecal bacterial load in Ugandan children: a randomized controlled trial 2025 · probiotic yoghurt group · Children aged 3–6 years attending a school in Southwest Uganda | 110 billion CFU | 8 weeks | 101 |
| Effect of a Multi-Strain Probiotic on the Incidence and Severity of Necrotizing Enterocolitis and Feeding Intolerances in Preterm Neonates 2022 · probiotic (intervention) group · Male and female preterm neonates born at <37 weeks’ gestation with birth weights of 750–1500 g | 0.67 billion CFU | 4 weeks | 100 |
| Beneficial Effects of Limosilactobacillus reuteri PBS072 and Bifidobacterium breve BB077 on Mood Imbalance, Self-Confidence, and Breastfeeding in Women during the First Trimester Postpartum 2023 · active treatment · Women aged 18–50 in the immediate postpartum period; healthy pregnant women at enrolment | 4 billion CFU | 90 days | 95 |
| Role of Lactobacillus rhamnosus (FloraActive™) 19070-2 and Lactobacillus reuteri (FloraActive™) 12246 in Infant Colic: A Randomized Dietary Study 2018 · probiotic group · Exclusively breastfed infants aged 4–12 weeks with infant colic | 0.25 billion CFU | 4 weeks | 86 |
| Probiotics with vitamin C for the prevention of upper respiratory tract symptoms in children aged 3-10 years: randomised controlled trial 2021 · active group · Healthy school children aged 3–10 years | 12.5 billion CFU | 26 weeks | 86 |
| Fish Oil And/Or Probiotics Intervention in Overweight/Obese Pregnant Women and Overweight Risk in 24-Month-Old Children 2023 · Probiotics + fish oil · Pregnant women with overweight or obesity, enrolled before 18 gestational weeks; no chronic diseases stated | 10 billion CFU | — | 82 |
| Effectiveness of Sterilized Symbiotic Drink Containing Lactobacillus helveticus Comparable to Probiotic Alone in Patients with Constipation-Predominant Irritable Bowel Syndrome 2020 · Group A (symbiotic group) · Adults with constipation-predominant irritable bowel syndrome; age range not reported; both sexes | 350 mL | 7 days | 79 |
| Consumption of Dairy Yogurt Containing Lactobacillus paracasei ssp. paracasei, Bifidobacterium animalis ssp. lactis and Heat-Treated Lactobacillus plantarum Improves Immune Function Including Natural Killer Cell Activity 2017 · test group (dairy yogurt group) · Adults aged over 60 years, nondiabetic and without the listed exclusion conditions | 2.4 billion CFU | 12 weeks | 73 |
| Effect of maternal supplement beverage with and without probiotics during pregnancy and lactation on maternal and infant health: a randomized controlled trial in the Philippines 2018 · Supplement plus probiotics · Healthy pregnant women aged 24–28 weeks’ gestation; age range not otherwise specified; willing to exclusively breastfeed for at least 2 months postpartum | 2.8 billion CFU | 180 days | 70 |
| Daily consumption of a synbiotic yogurt decreases energy intake but does not improve gastrointestinal transit time: a double-blind, randomized, crossover study in healthy adults 2013 · synbiotic yogurt · Healthy males and females aged 18–65 years, BMI 18–35 kg/m²; short or long gastrointestinal transit time at baseline | 2 billion CFU | 15 days | 65 |
| Adjunctive probiotic therapy sustains symptom relief in gastroesophageal reflux disease through gut microbiome-metabolome remodeling 2026 · probiotic group · Adults aged 18–65 with gastroesophageal reflux disease | 80 billion CFU | 12 weeks | 64 |
| Probiotics and Fever Duration in Children With Upper Respiratory Tract Infections: A Randomized Clinical Trial 2025 · Probiotic group · Children aged 28 days to 4 years with fever and an upper respiratory tract infection | 3 billion CFU | 2 weeks | 63 |
| Effect of Continuous Ingestion of Bifidobacteria and Inulin on Reducing Body Fat: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Comparison Study 2023 · active drink intake group · Japanese men and women aged 20–65 with BMI 23 to less than 30 | 10 billion CFU | 12 weeks | 60 |
| The effects of LactoCare synbiotic administration on chemotherapy-induced nausea, vomiting, diarrhea, and constipation in children with ALL: A double-blind randomized clinical trial 2023 · LactoCare-treatment group · Children with acute lymphoblastic leukemia receiving maintenance chemotherapy | 10 billion CFU | 7 days | 58 |
| A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Saccharomyces boulardii in Infants and Children With Acute Diarrhea 2020 · S. boulardii CNCM I-3799 · Infants and children aged 3–36 months with acute diarrhea | 10 billion CFU | 5 days | 57 |
| A Randomized, Double-Blind, Placebo-Controlled Trial: The Efficacy of Multispecies Probiotic Supplementation in Alleviating Symptoms of Irritable Bowel Syndrome Associated with Constipation 2016 · F1 · Adults aged 18–65, male and female, with irritable bowel syndrome with constipation (IBS-C) | 10 billion CFU | 60 days | 53 |
| Probiotics combined with prebiotics alleviated seasonal allergic rhinitis by altering the composition and metabolic function of intestinal microbiota: a prospective, randomized, double-blind, placebo-controlled clinical trial 2024 · test group (probiotics and prebiotics) · Adults aged 18–65 with seasonal allergic rhinitis lasting more than 1 year and TNSS greater than 4 | 8 g | 90 days | 53 |
| Effect of MED-02 Containing Two Probiotic Strains, Limosilactobacillus fermentum MG4231 and MG4244, on Body Fat Reduction in Overweight or Obese Subjects: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study 2022 · MED-02 group · Men and women aged 19–65 years who were overweight or obese (BMI 25.0–31.9 kg/m²), without diabetes | 5 billion CFU | 12 weeks | 50 |
| Effects of dietary fibers or probiotics on functional constipation symptoms and roles of gut microbiota: a double-blinded randomized placebo trial 2023 · Group D · Adults aged 18–70 with functional constipation | 19.2 billion CFU | 4 weeks | 50 |
| Effects of Bifidobacterium longum BB536 and Bifidobacterium breve MCC1274 on Body Composition in Normal and Overweight Adults in Randomized Placebo-Controlled Study 2024 · probiotics group · Adults aged 29–64 with BMI greater than 23 and less than 30; healthy, normal-weight or overweight | 15 billion CFU | 16 weeks | 50 |
| Effect of a Combination of Lactiplantibacillus plantarum KC3 and Leonurus japonicus Extracts in Respiratory Discomfort: A Randomized, Double-Blind, Placebo-Controlled Trial 2024 · CKDB-315 group · Adults aged 19–75 with persistent respiratory discomfort symptoms for at least 12 weeks | 180 mg | 12 weeks | 50 |
| Efficacy and Safety of CKDB-322, a Combination of Lactiplantibacillus plantarum Q180 and Phaeodactylum tricornutum, for Reducing Body Fat and Abdominal Adiposity in Overweight Adults 2026 · CKDB-322 group · Men and women aged 19–65 years with overweight (BMI 25.0–29.9 kg/m²) | 1 billion CFU | 12 weeks | 50 |
| Oral Administration of S-Adenosylmethionine (SAMe) and Lactobacillus Plantarum HEAL9 Improves the Mild-To-Moderate Symptoms of Depression: A Randomized, Double-Blind, Placebo-Controlled Study 2020 · SAMe plus L. plantarum HEAL9 · Adults aged 18–60 with subthreshold or mild-to-moderate depression | 1 billion CFU | 6 weeks | 46 |
| Lactobacillus GG (LGG) and smectite versus LGG alone for acute gastroenteritis: a double-blind, randomized controlled trial 2013 · LGG/smectite · Children aged 4–60 months with acute gastroenteritis | 6 billion CFU | — | 44 |
| Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial 2019 · h-k Ba8145 · Adults older than 18 with abdominal obesity (waist circumference ≥102 cm in men or ≥88 cm in women) | 100 mg | 90 days | 44 |
| Functional response to a microbial synbiotic in the gastrointestinal system of children: a randomized clinical trial 2023 · Active synbiotic arm · Children aged 3–17, male and female, with variable weekly bowel movement frequency; some had low-frequency bowel movements or constipation | 10 billion CFU | 12 weeks | 43 |
| The promising effects of a multi-species synbiotic preparation on metabolic profile in elderly patients with type 2 diabetes and high cardiovascular risk: a randomized, triple-blind, placebo-controlled trial 2025 · Synbiotic group · Men and women aged 65 years or older with type 2 diabetes and high cardiovascular risk | 2 billion CFU | 120 days | 43 |
| Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial 2019 · Ba8145 · Adults older than 18 with abdominal obesity (waist circumference ≥102 cm in men or ≥88 cm in women) | 100 mg | 90 days | 42 |
| Effect of Continuous Ingestion of Bifidobacteria and Dietary Fiber on Improvement in Cognitive Function: A Randomized, Double-Blind, Placebo-Controlled Trial 2023 · active drink intake group · Japanese men and women aged 50–80 years who were healthy and had mild cognitive decline associated with aging | 10 billion CFU | 12 weeks | 40 |
| PROBIOTIC SUPPLEMENTATION ATTENUATES BINGE EATING AND FOOD ADDICTION 1 YEAR AFTER ROUX-EN-Y GASTRIC BYPASS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL 2022 · probiotic group · Adults aged 18–59 with severe obesity undergoing Roux-en-Y gastric bypass | 20 billion CFU | 90 days | 38 |
| Bifidobacterium animalis subsp. lactis Probio-M8 enhances chondroitin efficacy for knee osteoarthritis in postmenopausal women via the gut-joint axis 2025 · probiotic group · Postmenopausal women aged 50–70 with clinically diagnosed knee osteoarthritis | 50 billion CFU | 90 days | 38 |
| Effect of the Multi-Strain Probiotic SYN-53 in the Management of Allergic Rhinoconjunctivitis 2025 · SYN-53 · Adults aged 18–65 with clinically relevant grass-pollen sensitization and allergic rhinoconjunctivitis | 150 billion CFU | 9 weeks | 37 |
| Effects of Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 on Overweight and the Gut Microbiota in Humans: Randomized, Double-Blinded, Placebo-Controlled Clinical Trial 2022 · probiotics group · Otherwise healthy Korean men and women aged over 19 to 65 years with overweight or obesity (BMI ≥23.0 and <35.0 kg/m²) | 10 billion CFU | 12 weeks | 36 |
| Effect of a Multispecies Synbiotic Supplementation on Body Composition, Antioxidant Status, and Gut Microbiomes in Overweight and Obese Subjects: A Randomized, Double-Blind, Placebo-Controlled Study 2023 · synbiotic group · Adults aged 18–45 with BMI 23–30 kg/m², classified as overweight or obese | 37 billion CFU | 12 weeks | 36 |
| Effects of probiotic and vitamin D co-supplementation on clinical symptoms, mental health, and inflammation in adult patients with migraine headache: a randomized, triple-blinded, placebo-controlled trial 2024 · probiotic and vitamin D supplementation group · Adults aged 18–55 with migraine with or without aura and more than 2 migraine attacks per month | 450 billion CFU | 12 weeks | 36 |
| Weizmannia coagulans BC99 Improves Strength Performance by Enhancing Protein Digestion and Regulating Skeletal Muscle Quality in College Students of Physical Education Major 2024 · probiotic group · Male college students studying physical education; no specific diagnosed condition reported | 48 billion CFU | 12 weeks | 36 |
| Effects of probiotic and vitamin D co-supplementation on migraine index, quality of life, and oxidative stress in adults with migraine headache: a randomized triple-blinded clinical trial 2025 · multispecies probiotic plus vitamin D · Adults aged 18 to 55 years with migraine headache diagnosed according to ICHD-3 | 450 billion CFU | 12 weeks | 36 |
| Randomized, double-blind, placebo-controlled study of oral lactobacilli to improve the vaginal flora of postmenopausal women 2008 · intervention group · Postmenopausal women with Nugent scores between 4 and 6 | 5 billion CFU | 2 weeks | 35 |
| Safety and acceptability of Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 in Bangladeshi infants: a phase I randomized clinical trial 2016 · Daily · Infants aged 4–12 weeks at enrollment, healthy, recruited from lower socioeconomic status communities in Dhaka, Bangladesh | 1.1 billion CFU | 30 days | 35 |
| The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome-A Randomized Double-Blind, Placebo-Controlled Study 2020 · synbiotic group · Female and male adults aged 18–60 with moderate or severe diarrhea-predominant irritable bowel syndrome (IBS-D) | 10 billion CFU | 8 weeks | 35 |
| Co-administration of probiotic and vitamin D significantly improves cognitive function in schizophrenic patients: A double-blinded randomized controlled trial 2024 · Probiotic group · Adults aged 18–65 with schizophrenia | 2 billion CFU | 12 weeks | 35 |
| Probiotics and vitamin C for the prevention of respiratory tract infections in children attending preschool: a randomised controlled pilot study 2015 · active group · Healthy preschool children aged 3–6 years in Slovakia | 12.5 billion CFU | 26 weeks | 34 |
| Can probiotic yogurt prevent diarrhoea in children on antibiotics? A double-blind, randomised, placebo-controlled study 2015 · Probiotic group · Children aged 1–12 years prescribed broad-spectrum oral antibiotics | 19.4 billion CFU | 6 days | 34 |
| The effects of probiotics plus dietary fiber on antipsychotic-induced weight gain: a randomized clinical trial 2022 · Probiotics plus dietary fiber · Adults aged 18–45 with schizophrenia or bipolar disorder, receiving atypical antipsychotics and with more than 10% weight gain | 1.68 g | 12 weeks | 34 |
| The effects of synbiotics supplementation on reducing chemotherapy-induced side effects in women with breast cancer: a randomized placebo-controlled double-blind clinical trial 2023 · Synbiotics · Women aged 18 years or older with breast cancer, no metastasis, undergoing neoadjuvant or adjuvant chemotherapy | 2 billion CFU | 8 weeks | 34 |
| Effects and Persistence of Bifidobacterium animalis subsp. lactis BL-99 and Fructooligosaccharides on Older Adults with Functional Constipation: A Randomized, Double-Blind, Placebo-Controlled Trial 2025 · synbiotic group · Adults aged 60 years or older with functional constipation by Rome IV criteria and no significant comorbidities | 20 billion CFU | 4 weeks | 34 |
| Randomized controlled trial evaluating synbiotic supplementation as an adjuvant therapy in the treatment of Parkinson's disease 2025 · synbiotic group · Adults aged 45–65, both sexes, newly diagnosed with Parkinson's disease, stages 1–4 | 20 billion CFU | 90 days | 33 |
| A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis 2009 · synbiotic group · Adults with ulcerative colitis | 2 billion CFU | 4 weeks | 32 |
| Lactobacillus reuteri influences regrowth of mutans streptococci after full-mouth disinfection: a double-blind, randomised controlled trial 2013 · test group · Healthy subjects with moderate to high counts of mutans streptococci; ages and sex not reported | 0.4 billion CFU | 6 weeks | 32 |
| Effect of probiotic Lactobacillus strains in young children hospitalized with acute diarrhea 2002 · probiotic treatment group · Hospitalized children with acute diarrhea | 40 billion CFU | 5 days | 30 |
| A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms 2009 · Gas Defense · Adults aged 20–68 with self-reported post-meal intestinal gas symptoms and no gastrointestinal diagnosis | 2 billion CFU | 29 days | 30 |
| Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients 2019 · Vitamin D plus probiotic group · Adults aged 25–65 with chronic schizophrenia | 8 billion CFU | 12 weeks | 30 |
| The Effects of Probiotic and Selenium Co-supplementation on Clinical and Metabolic Scales in Chronic Schizophrenia: a Randomized, Double-blind, Placebo-Controlled Trial 2021 · Probiotic plus selenium · People with chronic schizophrenia | 8 billion CFU | 12 weeks | 30 |
| Probiotics Plus Dietary Fiber Supplements Attenuate Olanzapine-Induced Weight Gain in Drug-Naïve First-Episode Schizophrenia Patients: Two Randomized Clinical Trials 2022 · Olanzapine and probiotics plus dietary fiber (Study 2) · Adults aged 18–50 with drug-naïve first-episode schizophrenia | 1.68 g | 12 weeks | 30 |
| Evaluation of the efficacy of supplementary probiotic capsules with topical clobetasol propionate 0.05% versus topical clobetasol propionate 0.05% in the treatment of oral lichen planus (a randomized clinical trial) 2025 · Group P (probiotics group) · Adults aged 20–75 with symptomatic atrophic or erosive oral lichen planus | 400 mg | 4 weeks | 30 |
| Probiotics, soluble fiber, and L-Glutamine (GLN) reduce nelfinavir (NFV)- or lopinavir/ritonavir (LPV/r)-related diarrhea 2004 · Supplement group · HIV-positive men with diarrhea receiving nelfinavir- or lopinavir/ritonavir-containing antiretroviral therapy | 1.2 g | 12 weeks | 28 |
| Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis 2016 · synbiotic group · Adults aged 25–74 with biopsy-confirmed nonalcoholic steatohepatitis (NASH); both sexes | 0.2 billion CFU | 90 days | 27 |
| The effects of probiotic and selenium co-supplementation on mental health parameters and metabolic profiles in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial 2019 · Probiotic and selenium co-supplementation · Adults with type 2 diabetes and coronary heart disease | 8 billion CFU | 12 weeks | 27 |
| Probiotic and selenium co-supplementation, and the effects on clinical, metabolic and genetic status in Alzheimer's disease: A randomized, double-blind, controlled trial 2019 · selenium plus probiotic · Patients with Alzheimer's disease; age range and sex not reported | 2 billion CFU | 12 weeks | 27 |
| Multi-strain probiotics (Hexbio) containing MCP BCMC strains improved constipation and gut motility in Parkinson's disease: A randomised controlled trial 2020 · Probiotic · Adults with idiopathic Parkinson’s disease, Hoehn and Yahr stages 1–4, and functional constipation; median age approximately 69 years; men and women | 60 billion CFU | 8 weeks | 27 |
| Effects of synbiotic supplementation on the components of metabolic syndrome in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial 2024 · Synbiotic + antipsychotic group · Adults aged 18–65 with schizophrenia, BMI ≥23 and at least two metabolic-syndrome criteria, taking antipsychotic drugs | 2 billion CFU | 8 weeks | 27 |
| Effect of yogurt containing polydextrose, Lactobacillus acidophilus NCFM and Bifidobacterium lactis HN019: a randomized, double-blind, controlled study in chronic constipation 2014 · Treatment Group (TG) · Adults aged 18–45 years, both sexes, with chronic constipation | 2 billion CFU | 2 weeks | 26 |
| Regular consumption of Lactobacillus reuteri-containing lozenges reduces pregnancy gingivitis: an RCT 2016 · Test (L. reuteri) Group · Healthy pregnant women aged 24–40 with gingival inflammation, at the beginning of the third trimester of pregnancy | 0.4 billion CFU | 6 weeks | 24 |
| Evaluating probiotic efficacy on weight loss in adults with overweight through a double-blind, placebo-controlled randomized trial 2023 · Initial single dose probiotics followed by triple dose probiotics · Adults aged 18–45 with overweight who continued after the initial 3-month phase | 0.0416 billion CFU | 26 weeks | 24 |
| Lactobacillus acidophilus and Bifidobacterium bifidum stored at ambient temperature are effective in the treatment of acute diarrhoea 2010 · Probiotics at 4°C · Children aged 2 months to 7 years with acute diarrhoea | 6 billion CFU | 5 days | 23 |
| Effects of probiotic and synbiotic supplementation on ponderal and linear growth in severely malnourished young infants in a randomized clinical trial 2023 · Synbiotic · Infants aged 2–6 months with severe acute malnutrition, recovering from acute illness; both sexes | 8 billion CFU | 4 weeks | 23 |
| Ameliorating effects of L-carnitine and synbiotic co-supplementation on anthropometric measures and cardiometabolic traits in women with obesity: a randomized controlled clinical trial 2023 · L-carnitine + synbiotic · Women aged 19–49 with obesity (BMI 30–35 kg/m²), without the listed comorbidities | 0.1 billion CFU | 8 weeks | 23 |
| Lactobacillus acidophilus and Bifidobacterium bifidum stored at ambient temperature are effective in the treatment of acute diarrhoea 2010 · Probiotics at room temperature · Children aged 2 months to 7 years with acute diarrhoea | 6 billion CFU | 5 days | 22 |
| Do synbiotics really enhance beneficial synbiotics effect on defecation symptoms in healthy adults?: Randomized, double-blind, placebo-controlled trial 2022 · Synbiotics · Healthy adults aged 20–60 years, men and women, with bowel movements 2–3 times per week and a tendency to constipation | 10 billion CFU | 2 weeks | 22 |
| Effect of Intake of Bifidobacteria and Dietary Fiber on Resting Energy Expenditure: A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Comparison Study 2024 · active group · Japanese men and women aged 25–61 years with BMI 25–30 kg/m² and low resting energy metabolism | 10 billion CFU | 4 weeks | 22 |
| The effect of a new developed synbiotic yogurt consumption on metabolic syndrome components in adults with metabolic syndrome: a randomized controlled clinical trial 2024 · intervention group · Adults aged 30–50 with metabolic syndrome and BMI 25–35 kg/m² | 0.2 billion CFU | 12 weeks | 22 |
| Evaluating probiotic efficacy on weight loss in adults with overweight through a double-blind, placebo-controlled randomized trial 2023 · Initial double dose probiotics followed by triple dose probiotics · Adults aged 18–45 with overweight who continued after the initial 3-month phase | 0.052 billion CFU | 26 weeks | 21 |
| Safety and immunomodulatory effects of three probiotic strains isolated from the feces of breast-fed infants in healthy adults: SETOPROB study 2013 · Mixture of B. breve CNCM I-4035 and L. rhamnosus CNCM I-4036 · Healthy men and women aged 18–50 years | 18 billion CFU | 30 days | 20 |
| Bifidobacterium mixture (B longum BB536, B infantis M-63, B breve M-16V) treatment in children with seasonal allergic rhinitis and intermittent asthma 2017 · Group B (actively-treated) · Children aged 4–17 with seasonal allergic rhinitis due to Parietaria pollen and well-controlled intermittent asthma | 5 billion CFU | 8 weeks | 20 |
| A dual-strain Lactobacilli reuteri probiotic improves the treatment of residual pockets: A randomized controlled clinical trial 2020 · Probiotic group · Adults aged 34–83 with residual periodontal pockets after treatment for moderate to severe chronic periodontitis | 0.4 billion CFU | 12 weeks | 20 |
| Gut Microbiota Modulation of Moderate Undernutrition in Infants through Gummy Lactobacillus plantarum Dad-13 Consumption: A Randomized Double-Blind Controlled Trial 2022 · probiotics · Infants with moderate undernutrition, Z-score between −2 and −3 standard deviations; sex and exact age range not reported. | 3 g | 50 days | 20 |
| A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Multi-Strain Synbiotic in Patients with Functional Diarrhea and High Fecal Calprotectin Levels: A Pilot Study 2022 · synbiotic group · Adults with functional diarrhea and fecal calprotectin levels of at least 11.5 mg/kg; mean age 49.8 years | 0.1 billion CFU | 8 weeks | 20 |
| Lactobacillus reuteri DSM 17938 and Magnesium Oxide in Children with Functional Chronic Constipation: A Double-Blind and Randomized Clinical Trial 2020 · Group B · Children aged over 6 months and under 6 years with functional constipation | 0.2 billion CFU | 4 weeks | 19 |
| Probiotic and Oxytocin Combination Therapy in Patients with Autism Spectrum Disorder: A Randomized, Double-Blinded, Placebo-Controlled Pilot Trial 2021 · Probiotics group (probiotic + oxytocin combination in stage 2) · Participants aged 3–20 years with autism spectrum disorder; mixed sex | 60 billion CFU | 28 weeks | 18 |
| Effects of adjunctive light-activated disinfection and probiotics on clinical and microbiological parameters in periodontal treatment: a randomized, controlled, clinical pilot study 2021 · Group 3 (SD + LAD + probiotics) · Systemically healthy adults, mean age 58.3 years, with stage II or III, grade B periodontitis | 125 mg | 90 days | 16 |
| Are Lactobacillus salivarius G60 and inulin more efficacious to treat patients with oral halitosis and tongue coating than the probiotic alone and placebo? A randomized clinical trial 2020 · LS + inulin · Patients aged 35 ± 15 years with oral halitosis and tongue coating; 66% female | 2 billion CFU | 10 days | 15 |
| Comparison of the Effects of Prebiotics and Synbiotics Supplementation on the Immune Function of Male University Football Players 2023 · synbiotic group (SG) · Male university football players; age not reported; healthy student-athletes undergoing high-intensity training | 14 billion CFU | 6 weeks | 15 |
| Comparison of cheese with and without Propionibacterium freudenreichii subsp. shermanii LMGT 2951 on off-season muscle strength and VO(2) max development in Nordic skiers: a randomized clinical trial 2025 · Jarlsberg group — female participants · Female cross-country and biathlon skiers aged 17–27 | 7.5 billion CFU | 24 weeks | 15 |
| Comparison of cheese with and without Propionibacterium freudenreichii subsp. shermanii LMGT 2951 on off-season muscle strength and VO(2) max development in Nordic skiers: a randomized clinical trial 2025 · Jarlsberg group — male participants · Male cross-country and biathlon skiers aged 18–30 | 9 billion CFU | 24 weeks | 14 |
| Probiotic Supplementation Can Alter Inflammation Parameters and Self-Reported Sleep After a Marathon: A Randomized, Double-Blind, Placebo-Controlled Study 2025 · Probiotic · Men who were experienced marathon runners and trained at least five times per week; no age range stated | 40 billion CFU | 30 days | 14 |
| Alteration of the Gut-Lung Axis After Severe COVID-19 Infection and Modulation Through Probiotics: A Randomized, Controlled Pilot Study 2024 · probiotic group · Adults aged 18 or older who had experienced severe COVID-19 infection within the previous 12 months | 10 billion CFU | 26 weeks | 13 |
| Consumption of fermented milk product with probiotic modulates brain activity 2013 · FMPP · Healthy women aged 18–55 years | 27.4 billion CFU | 4 weeks | 12 |
| Effects of 60-Day Saccharomyces boulardii and Superoxide Dismutase Supplementation on Body Composition, Hunger Sensation, Pro/Antioxidant Ratio, Inflammation and Hormonal Lipo-Metabolic Biomarkers in Obese Adults: A Double-Blind, Placebo-Controlled Trial 2021 · intervention group · Obese men and women aged 30–65 years with BMI 30–35 kg/m² | 500 mg | 60 days | 12 |
| Augmenting Cognitive Function in the Elderly with Mild Cognitive Impairment Using Probiotic Lacticaseibacillus rhamnosus CBT-LR5: A 12-Week Randomized, Double-Blind, Parallel-Group Non-Comparative Study 2025 · MH-Pro low-dose group · Men and women aged 60 or older with mild cognitive impairment | 10 billion CFU | 12 weeks | 10 |
| Augmenting Cognitive Function in the Elderly with Mild Cognitive Impairment Using Probiotic Lacticaseibacillus rhamnosus CBT-LR5: A 12-Week Randomized, Double-Blind, Parallel-Group Non-Comparative Study 2025 · MH-Pro high-dose group · Men and women aged 60 or older with mild cognitive impairment | 10 billion CFU | 12 weeks | 10 |
| Synbiotic Supplementation with Probiotics and Omega-3 Fatty Acids Enhances Upper-Body Muscle Strength in Elite Swimmers: Evidence for Gut-Muscle Axis Modulation During Race-Pace Training 2025 · PRO + OMEGA + USRPT · Male elite sprint freestyle swimmers with at least 5 years of competitive experience | 450 billion CFU | 8 weeks | 10 |
| Effect of probiotic Lactobacillus strains on acute diarrhea in a cohort of nonhospitalized children attending day-care centers 2002 · Lactobacillus strains group · Children with mild acute diarrhea recruited from local day-care centers; ages and sex not stated | 40 billion CFU | 5 days | — |
| Prebiotics and synbiotics: two promising approaches for the treatment of atopic dermatitis in children above 2 years 2006 · Synbiotic group · Children aged 2 years and over with moderate or severe atopic dermatitis and a SCORAD score of at least 15 | 3.6 billion CFU | 90 days | — |
| Short-term effect of chewing gums containing probiotic Lactobacillus reuteri on the levels of inflammatory mediators in gingival crevicular fluid 2009 · Group A/P · Healthy adults with moderate levels of gingival inflammation | 0.2 billion CFU | 2 weeks | — |
| Short-term effect of chewing gums containing probiotic Lactobacillus reuteri on the levels of inflammatory mediators in gingival crevicular fluid 2009 · Group A/A · Healthy adults with moderate levels of gingival inflammation | 0.2 billion CFU | 2 weeks | — |
| Probiotic supplement reduces atopic dermatitis in preschool children: a randomized, double-blind, placebo-controlled, clinical trial 2010 · probiotic group · Children aged 1–3 years with moderate-to-severe atopic dermatitis | 10 billion CFU | 8 weeks | — |
| Beneficial effects of a synbiotic supplement on self-perceived gastrointestinal well-being and immunoinflammatory status of healthy adults 2011 · synbiotic product · Healthy adults aged 25–45 years; 20 women and 16 men overall | 2.4 billion CFU | 6 weeks | — |
| Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study 2011 · synbiotics treatment group · Patients with mild to moderate ulcerative colitis | 3 g | 1 year | — |
| [Efficacy of probiotics on ulcerative colitis and its mechanism] 2013 · combination group · Patients with mild to moderate ulcerative colitis; age and sex not reported | 7 g | 2 years | — |
| Lactobacillus GG for treatment of acute childhood diarrhoea: an open labelled, randomized controlled trial 2014 · intervention group · Children aged 6 months to 5 years with acute diarrhoea | 10 billion CFU | 5 days | — |
| Synbiotic in the management of infantile colic: a randomised controlled trial 2014 · synbiotic group · Breastfed infants aged 15–120 days with infantile colic | 1 billion CFU | 30 days | — |
| Efficacy of synbiotics to reduce acute radiation proctitis symptoms and improve quality of life: a randomized, double-blind, placebo-controlled pilot trial 2014 · synbiotic · Patients with prostate cancer receiving 3-dimensional conformal radiation therapy; age and sex not specified | 0.1 billion CFU | 4 weeks | — |
| Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults-Randomized Controlled Trial 2016 · LU + B420 · Adults aged 18–65 with overweight or obesity (BMI 28.0–34.9) | 10 billion CFU | 26 weeks | — |
| Strain-specific probiotic (microbial cell preparation) and omega-3 fatty acid in modulating quality of life and inflammatory markers in colorectal cancer patients: a randomized controlled trial 2018 · MCP and omega-3 fatty acid group · Colorectal cancer patients on chemotherapy | 60 billion CFU | 8 weeks | — |
| Efficacy of Synbiotics to Reduce Symptoms and Rectal Inflammatory Response in Acute Radiation Proctitis: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial 2020 · synbiotic · Patients with prostate cancer receiving radiotherapy | 0.1 billion CFU | 7 weeks | — |
| Effect of synbiotic and probiotic supplementation on serum brain-derived neurotrophic factor level, depression and anxiety symptoms in hemodialysis patients: a randomized, double-blinded, clinical trial 2021 · synbiotic · Hemodialysis patients; age and sex not specified | 5 g | 12 weeks | — |
| Effect of multi-strain probiotic (UB0316) in weight management in overweight/obese adults: a 12-week double blind, randomised, placebo-controlled study 2019 · UB0316 (probiotic) · Adults aged 30–65 years with overweight or obesity (BMI 25–32 kg/m²) | 10 billion CFU | 12 weeks | — |
| PHAGE-2 Study: Supplemental Bacteriophages Extend Bifidobacterium animalis subsp. lactis BL04 Benefits on Gut Health and Microbiota in Healthy Adults 2020 · B. lactis BL04 + PreforPro · Healthy adults; age range and sex not specified | 1 billion CFU | 4 weeks | — |
| Efficacy of Bifidobacterium breve CECT7263 for infantile colic treatment: an open-label, parallel, randomised, controlled trial 2021 · Bb+Lf group · Infants diagnosed with infantile colic according to Rome III criteria | 0.2 billion CFU | 4 weeks | — |
| Effects of probiotic and alpha-lipoic acid supplements, separately or in combination on the anthropometric indicators and maintenance of weight in overweight individuals 2021 · ALA and probiotic group · Overweight individuals | 500 mg | 24 weeks | — |
| The effects of co-administration of probiotics and prebiotics on chronic inflammation, and depression symptoms in patients with coronary artery diseases: a randomized clinical trial 2022 · Co-supplemented · Patients with coronary artery disease; age and sex not specified | 1.9 billion CFU | 8 weeks | — |
| Effect of synbiotic supplementation on migraine characteristics and inflammatory biomarkers in women with migraine: Results of a randomized controlled trial 2021 · synbiotic · Women with migraine | 2 billion CFU | 12 weeks | — |
| Comparative Evaluation of 3 Commercial Mouthwash Formulations on Clinical Parameters of Chronic Gingivitis 2022 · Group 3 (PRO-Dental probiotic mouthwash) · Adults aged 20–40 years with mild to moderate chronic plaque-induced gingivitis | 0.1 billion CFU | 2 weeks | — |
| Effectiveness of a Novel Food Composed of Leucine, Omega-3 Fatty Acids and Probiotic Lactobacillus paracasei PS23 for the Treatment of Sarcopenia in Elderly Subjects: A 2-Month Randomized Double-Blind Placebo-Controlled Trial 2022 · intervention group (OLEP) · men and women aged 55 years or older with sarcopenia | 30 billion CFU | 60 days | — |
| Efficacy of a food supplement based on S-adenosyl methionine and probiotic strains in subjects with subthreshold depression and mild-to-moderate depression: A monocentric, randomized, cross-over, double-blind, placebo-controlled clinical trial 2022 · Food supplement · People with subthreshold depression or mild-to-moderate depression | 3 billion CFU | 90 days | — |
| Effects of Synbiotic Supplementation on Metabolic Syndrome Traits and Gut Microbial Profile among Overweight and Obese Hong Kong Chinese Individuals: A Randomized Trial 2023 · synbiotic supplementation group (SG) · Overweight and obese Hong Kong Chinese individuals aged 20–65 years | 20 billion CFU | 8 weeks | — |
| Effects of Synbiotic Supplementation on Metabolic Syndrome Traits and Gut Microbial Profile among Overweight and Obese Hong Kong Chinese Individuals: A Randomized Trial 2023 · dietary intervention with synbiotic supplementation group (DSG) · Overweight and obese Hong Kong Chinese individuals aged 20–65 years | 20 billion CFU | 8 weeks | — |
| Effect of Probiotic Drinks Containing 2,3-Dihydro-3,5-dihydroxy-6-methyl-4H-pyran-4-one on Cognitive Function of Middle-Aged and Older Individuals 2025 · intervention group · Healthy middle-aged and older Japanese individuals aware of memory decline | 65 mL | 12 weeks | — |
| Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study) 2020 · Prob · Men and women aged 20 to under 70 with newly diagnosed, drug-naive type 2 diabetes | 4 g | 12 weeks | 102 |
| Metformin with Versus without Concomitant Probiotic Therapy in Newly Diagnosed Patients with Type 2 Diabetes or Prediabetes: A Comparative Analysis in Relation to Glycemic Control, Gastrointestinal Side Effects, and Treatment Compliance 2022 · MET-PRO group · Adults aged 31–80 with newly diagnosed type 2 diabetes or prediabetes | 4.6 mg | 30 days | 72 |
| Distinct Microbial Taxa Are Associated with LDL-Cholesterol Reduction after 12 Weeks of Lactobacillus plantarum Intake in Mild Hypercholesterolemia: Results of a Randomized Controlled Study 2025 · Lacto group · Women and men aged 30–75 years with mild hypercholesterolemia (LDL-C 160–220 mg/dl) | 1.2 billion CFU | 12 weeks | 43 |
| Lactofermented Annurca Apple Puree as a Functional Food Indicated for the Control of Plasma Lipid and Oxidative Amine Levels: Results from a Randomised Clinical Trial 2019 · LAB group · Adults aged 18–70 with elevated serum lipid and glucose values at study entry | 0.3 billion CFU | 8 weeks | 30 |
| Effects of Bifidobacterium animalis subsp. lactis BB-12(®) on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial 2017 · POST · Healthy adults aged 18–40 years, women and men, with BMI 20–35 kg/m² and delayed transit time | 3.16 billion CFU | 4 weeks | 26 |
| Effects of Bifidobacterium animalis subsp. lactis BB-12(®) on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial 2017 · CAP · Healthy adults aged 18–40 years, women and men, with BMI 20–35 kg/m² and delayed transit time | 3.16 billion CFU | 4 weeks | 26 |
| Effects of Bifidobacterium animalis subsp. lactis BB-12(®) on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial 2017 · PRE · Healthy adults aged 18–40 years, women and men, with BMI 20–35 kg/m² and delayed transit time | 3.16 billion CFU | 4 weeks | 25 |
| Multispecies Probiotic Supplementation Favorably Affects Vascular Function and Reduces Arterial Stiffness in Obese Postmenopausal Women-A 12-Week Placebo-Controlled and Randomized Clinical Study 2018 · low dose of the probiotic (LD) group · Women aged 45–70 years who were postmenopausal and had obesity | 4 g | 12 weeks | 24 |
| Bacillus subtilis DE111 intake may improve blood lipids and endothelial function in healthy adults 2020 · B. lactis BL04 · Healthy male and female adults aged 18–65 years | 1 billion CFU | 4 weeks | 23 |
| The beneficial effects of Lactobacillus reuteri ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial 2018 · live L. reuteri ADR-1 · Adults aged 25–70 with type 2 diabetes mellitus and HbA1c of 7% to 10% | 4 billion CFU | 26 weeks | 22 |
| Bacillus subtilis DE111 intake may improve blood lipids and endothelial function in healthy adults 2020 · B. subtilis DE111 · Healthy male and female adults aged 18–65 years | 1 billion CFU | 4 weeks | 22 |
| Effect of powdered fermented milk with Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension 2005 · test group, high-normal blood pressure group · Subjects with high-normal blood pressure | 12 g | 4 weeks | — |
| Effect of powdered fermented milk with Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension 2005 · test group, mild hypertension group · Subjects with mild hypertension | 12 g | 4 weeks | — |
| Lactobacillus reuteri reduces bone loss in older women with low bone mineral density: a randomized, placebo-controlled, double-blind, clinical trial 2018 · Lactobacillus reuteri 6475 group · Women aged 75–80 years with low bone mineral density | 10 billion CFU | 1 year | — |
| Effects of multi-strain probiotics supplementation on body adiposity and metabolic profile in individuals with hypertension and overweight following an energy-restricted diet: A randomized clinical trial 2025 · group with supplementation of 8 probiotic strains in capsules · Adults aged 40–65 years, both sexes, with hypertension and BMI ≥25 | 30 billion CFU | 12 weeks | — |
| A Four-Probiotics Regimen Combined with A Standard Helicobacter pylori-Eradication Treatment Reduces Side Effects and Increases Eradication Rates 2022 · group A (probiotic regimen) · Adults older than 18 years with Helicobacter pylori infection, including patients with chronic gastritis or peptic ulcer disease | 11 billion CFU | 15 days | 371 |
| Comprehensive nursing care for advanced digestive malignancy patients during chemotherapy based on probiotic intervention: a randomized controlled study on improvement of gastrointestinal function and prevention of complications 2025 · Observation group · Adults aged 18–75 with stage IV gastric, colorectal, or esophageal cancer receiving chemotherapy | 0.005 billion CFU | 8 weeks | 150 |
| Psychobiotics Ameliorate Depression and Anxiety Status in Surgical Oncology Patients: Results from the ProDeCa Study 2025 · psychobiotic group · Adults aged 18–85 on chemotherapy for gastrointestinal cancer after surgery | 176 billion CFU | 30 days | 132 |
| A young child formula with Limosilactobacillus reuteri and GOS modulates gut microbiome and enhances bone and muscle development: a randomized trial 2025 · experimental young child formula (EYCF) · Healthy Filipino boys and girls aged 24–36 months | 0.1 billion CFU | 26 weeks | 91 |
| Beyond Analgesia: Psychobiotics as an Adjunctive Approach to Pain Management in Gastrointestinal Oncology-A Post Hoc Analysis from the ProDeCa Study 2025 · Non-depressed psychobiotics group · Adults aged 18 years or older with gastrointestinal cancer after tumor resection, receiving postoperative chemotherapy and classified as non-depressed | 176 billion CFU | 4 weeks | 84 |
| Psychobiotics Regulate the Anxiety Symptoms in Carriers of Allele A of IL-1β Gene: A Randomized, Placebo-Controlled Clinical Trial 2020 · psychobiotic oral suspension group (POSG) · Male and female volunteers aged 18–62; participants included carriers and noncarriers of the IL-1β rs16944 allele A | 135 billion CFU | 12 weeks | 65 |
| Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms: A Randomized, Double-Blind, Placebo-controlled, Multicenter Trial 2019 · probiotics · Adults aged 18 years or older with celiac disease and persistent IBS-type symptoms despite long-term strict gluten-free diet | 40 billion CFU | 6 weeks | 54 |
| A Randomized, Double-Blind, Placebo-Controlled Trial: The Efficacy of Multispecies Probiotic Supplementation in Alleviating Symptoms of Irritable Bowel Syndrome Associated with Constipation 2016 · F2 · Adults aged 18–65, male and female, with irritable bowel syndrome with constipation (IBS-C) | 15 billion CFU | 60 days | 52 |
| Beyond Analgesia: Psychobiotics as an Adjunctive Approach to Pain Management in Gastrointestinal Oncology-A Post Hoc Analysis from the ProDeCa Study 2025 · Depressed psychobiotics group · Adults aged 18 years or older with gastrointestinal cancer after tumor resection, receiving postoperative chemotherapy and classified as depressed | 176 billion CFU | 4 weeks | 48 |
| Clinical Efficacy of Probiotics for Relieving Cold Symptoms in Healthy Individuals: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial 2025 · Probiotic group · Healthy adults aged 18–44, both genders | 3 billion CFU | 12 weeks | 40 |
| A Phase II Randomized Clinical Trial and Mechanistic Studies Using Improved Probiotics to Prevent Oral Mucositis Induced by Concurrent Radiotherapy and Chemotherapy in Nasopharyngeal Carcinoma 2021 · probiotic cocktail group · men and women aged 18–70 with locally advanced nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy | 8 billion CFU | 7 weeks | 39 |
| Exploring the impact of probiotics on adult ADHD management through a double-blind RCT 2024 · probiotic · College students aged 19–30 with ADHD, not taking ADHD medication; women and men | 80 billion CFU | 90 days | 30 |
| Synbiotic as an ameliorating factor in the health-related quality of life in women with polycystic ovary syndrome. A randomized, triple-blind, placebo-controlled trial 2024 · synbiotic group · Women aged 18–45 with newly diagnosed polycystic ovary syndrome (PCOS) | 20 billion CFU | 12 weeks | 28 |
| Effectiveness of Multistrain Probiotic Formulation on Common Infectious Disease Symptoms and Gut Microbiota Modulation in Flu-Vaccinated Healthy Elderly Subjects 2022 · probiotics group · Influenza-vaccinated healthy adults aged 60–80 years, both sexes | 4 billion CFU | 4 weeks | 25 |
| Effect of Probiotics Supplementation on REM Sleep Behavior Disorder and Motor Symptoms in Parkinson's Disease: A Pilot Study 2025 · Probiotics group · Adults aged 40–80 with idiopathic Parkinson’s disease, modified Hoehn and Yahr stages 1–3 | 7.56 billion CFU | 12 weeks | 25 |
| Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial 2010 · Bacillus coagulans GBI-30, 6086 group · Adults aged 36–82 with rheumatoid arthritis | 2 billion CFU | 60 days | 23 |
| Probiotic Mixture Containing Lactobacillus helveticus, Bifidobacterium longum and Lactiplantibacillus plantarum Affects Brain Responses to an Arithmetic Stress Task in Healthy Subjects: A Randomised Clinical Trial and Proof-of-Concept Study 2022 · probiotic intervention · Healthy adults aged 18–65 years | 2.87 billion CFU | 4 weeks | 22 |
| Clinical Efficacy of Probiotics for Allergic Rhinitis: Results of an Exploratory Randomized Controlled Trial 2024 · Probiotic group · Adults aged 18–60 with persistent or seasonal allergic rhinitis, both sexes | 4 billion CFU | 8 weeks | 21 |
| Effects of a Synbiotic Formula on Functional Bowel Disorders and Gut Microbiota Profile during Long-Term Home Enteral Nutrition (LTHEN): A Pilot Study 2020 · intervention group (IG) · Bedridden adults with neurological disorders receiving long-term home enteral nutrition; average age 75.2 years | 1.01 billion CFU | 120 days | 11 |
| Synergistic Effects of Probiotic and Omega-3 Supplementation with Ultra-Short Race Pace Training on Sprint Swimming Performance 2025 · Probiotics + Omega-3 + USRPT (PRO + OMEGA + USRPT) · Male competitive sprint swimmers with at least five years of competitive experience and no stated disease or medical condition | 450 billion CFU | 8 weeks | 10 |
| Effect of Multi-strain Probiotic Formulation on Students Facing Examination Stress: a Double-Blind, Placebo-Controlled Study 2021 · multi-strain probiotic · Students aged 18–24 facing examination stress | 20 billion CFU | 4 weeks | — |
| Differential Health Effects on Inflammatory, Immunological and Stress Parameters in Professional Soccer Players and Sedentary Individuals after Consuming a Synbiotic. A Triple-Blinded, Randomized, Placebo-Controlled Pilot Study 2021 · Sedentary participants administered with the synbiotic · Sedentary male students with low physical activity (≤150 min/week) | 1 billion CFU | 30 days | — |
| Differential Health Effects on Inflammatory, Immunological and Stress Parameters in Professional Soccer Players and Sedentary Individuals after Consuming a Synbiotic. A Triple-Blinded, Randomized, Placebo-Controlled Pilot Study 2021 · Professional soccer players administered with the synbiotic · Male professional soccer players competing in the Spanish Second Division B | 1 billion CFU | 30 days | — |
| Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study) 2020 · Prob + BBR · Men and women aged 20 to under 70 with newly diagnosed, drug-naive type 2 diabetes | 4 g | 12 weeks | 106 |
| The effects of synbiotic supplementation on blood pressure and other maternal outcomes in pregnant mothers with mild preeclampsia: a triple-blinded randomized controlled trial 2024 · synbiotic group · Pregnant women aged 24 years or older with mild preeclampsia | 1 billion CFU | — | 64 |
| Efficacy of UB0316, a multi-strain probiotic formulation in patients with type 2 diabetes mellitus: A double blind, randomized, placebo controlled study 2019 · UB0316 · Adults aged 18–65 years, either sex, with type 2 diabetes, HbA1c 7–9%, and stable metformin therapy | 30 billion CFU | 12 weeks | 40 |
| The efficacy of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome: A randomized, double-blinded, placebo-controlled study 2025 · Probiotics group · Adults aged 18–60 with three or more metabolic-syndrome risk factors | 2 billion CFU | 12 weeks | 31 |
| Bacillus subtilis DE111 intake may improve blood lipids and endothelial function in healthy adults 2020 · B. lactis BL04 + PreforPro · Healthy male and female adults aged 18–65 years | 1 billion CFU | 4 weeks | 22 |
| A Combination of Lactoplantibacillus plantarum Strains CECT7527, CECT7528, and CECT7529 Plus Monacolin K Reduces Blood Cholesterol: Results from a Randomized, Double-Blind, Placebo-Controlled Study 2021 · active group · Men and women aged 18–70 with total cholesterol ≥200 mg/dL who were statin-naïve or had recently stopped statin treatment because of intolerance | 1 billion CFU | 12 weeks | 21 |
| Efficacy of novel activated bamboo charcoal in reducing uremic toxins and enhancing kidney function in chronic kidney disease patients: a pilot randomized controlled trial 2025 · ABC with probiotics group · Adults with stage 3 chronic kidney disease; mean age 68.8 years, 58.3% male | 800 mg | 90 days | 12 |
| A randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy of the synbiotic medical food, SBD111, for the clinical dietary management of bone loss in menopausal women 2025 · SBD111 · Healthy postmenopausal women 1–6 years after menopause, aged about 55 years; some had osteopenia or BMI ≥30 | 95 billion CFU | 1 year | 144 |
| The Effect of Probiotic Supplements on Metabolic Parameters of People with Type 2 Diabetes in Greece-A Randomized, Double-Blind, Placebo-Controlled Study 2023 · probiotic group · Adults with type 2 diabetes, aged over 18 years, with HbA1c above 6% | 5.5 billion CFU | 26 weeks | 68 |
| Adjuvant probiotic Bifidobacterium animalis subsp. lactis CP-9 improve phototherapeutic treatment outcomes in neonatal jaundice among full-term newborns: A randomized double-blind clinical study 2022 · probiotic group · Newborns older than 35 weeks’ gestation with neonatal jaundice and serum bilirubin above 15 mg/dL on day four after birth; includes full-term and 35–37-week newborns | 10 billion CFU | 2 days | 43 |
| Effects of probiotic administration on immune responses of children and adolescents with type 1 diabetes to a quadrivalent inactivated influenza vaccine 2020 · Probiotic group · Children and adolescents aged 3–18 years with type 1 diabetes | 10 billion CFU | 180 days | 34 |
| Lacticaseibacillus rhamnosus GG in a chewable colonizes the nose and facilitates local immune benefits in allergic rhinoconjunctivitis patients 2025 · Probiotic · Adults older than 18 with seasonal allergic rhinitis | 10 billion CFU | 8 weeks | 33 |
| Influence of probiotic and conventional yoghurt on the status of vitamins B1, B2 and B6 in young healthy women 2008 · Probiotic yoghurt · Healthy young women | 100 g | 4 weeks | 17 |
| Survival of Lactobacillus reuteri DSM 17938 and Lactobacillus rhamnosus GG in the human gastrointestinal tract with daily consumption of a low-fat probiotic spread 2009 · Lactobacillus rhamnosus GG group · Healthy human volunteers | 5 billion CFU | 3 weeks | 16 |
| Heat-Killed Lactococcus lactis subsp. cremoris H61 Altered the Iron Status of Young Women: A Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Comparative Study 2022 · H61 group · Healthy women aged 18–25; participants were physically active members of collegiate athletic clubs. | 60 mg | 4 weeks | 14 |
| Survival of Lactobacillus reuteri DSM 17938 and Lactobacillus rhamnosus GG in the human gastrointestinal tract with daily consumption of a low-fat probiotic spread 2009 · Lactobacillus reuteri DSM 17938 group · Healthy human volunteers | 1 billion CFU | 3 weeks | 13 |
| Dose-response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults 2006 · 10(8) CFU/day group · Healthy adults aged 18–40 years | 0.1 billion CFU | 3 weeks | — |
| Dose-response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults 2006 · 10(9) CFU/day group · Healthy adults aged 18–40 years | 1 billion CFU | 3 weeks | — |
| Dose-response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults 2006 · 10(10) CFU/day group · Healthy adults aged 18–40 years | 10 billion CFU | 3 weeks | — |
| Dose-response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults 2006 · 10(11) CFU/day group · Healthy adults aged 18–40 years | 100 billion CFU | 3 weeks | — |
| Lactobacillus paracasei A survives gastrointestinal passage and affects the fecal microbiota of healthy infants 2006 · Fermented milk containing strain A · Healthy children aged 12–24 months | 100 g | 4 weeks | — |
| Quantification of folic acid in human feces after administration of Bifidobacterium probiotic strains 2008 · Bifidobacterium adolescentis DSM 18350 group · Healthy volunteers | 5 billion CFU | — | — |
| Quantification of folic acid in human feces after administration of Bifidobacterium probiotic strains 2008 · Bifidobacterium adolescentis DSM 18352 group · Healthy volunteers | 5 billion CFU | — | — |
| Quantification of folic acid in human feces after administration of Bifidobacterium probiotic strains 2008 · Bifidobacterium pseudocatenulatum DSM 18353 group · Healthy volunteers | 5 billion CFU | — | — |
| Effects of Lactobacillus coryniformis K8 CECT5711 on the immune response to influenza vaccination and the assessment of common respiratory symptoms in elderly subjects: a randomized controlled trial 2019 · probiotic group · Nursing-home residents older than 65 years | 3 billion CFU | 2 weeks | — |
| Effect of the Food Matrix on the Survival to the Gastrointestinal Transit of Lacticaseibacillus rhamnosus CRL1505: A Randomized, Controlled, Crossover Study 2025 · Freeze-dried cells (FDC) · Healthy adults of both sexes, aged 22–57 years | 1 billion CFU | 7 days | — |
| Effect of the Food Matrix on the Survival to the Gastrointestinal Transit of Lacticaseibacillus rhamnosus CRL1505: A Randomized, Controlled, Crossover Study 2025 · Oat-fermented drink (OFD) · Healthy adults of both sexes, aged 22–57 years | 1 billion CFU | 7 days | — |
| Effect of the Food Matrix on the Survival to the Gastrointestinal Transit of Lacticaseibacillus rhamnosus CRL1505: A Randomized, Controlled, Crossover Study 2025 · Milk-fermented drink (MFD) · Healthy adults of both sexes, aged 22–57 years | 1 billion CFU | 7 days | — |
| Effect of Lactobacillus paracasei subsp. paracasei, L. casei 431 on immune response to influenza vaccination and upper respiratory tract infections in healthy adult volunteers: a randomized, double-blind, placebo-controlled, parallel-group study 2015 · L. casei 431 group · Healthy adults aged 18–60 years | 1 billion CFU | 6 weeks | 553 |
| Baseline gut microbiome as a predictive biomarker of response to probiotic adjuvant treatment in gout management 2024 · probiotic group · patients with gout; age range and sex not reported | 30 billion CFU | 60 days | 120 |
| Ingested probiotics reduce nasal colonization with pathogenic bacteria (Staphylococcus aureus, Streptococcus pneumoniae, and beta-hemolytic streptococci) 2003 · Probiotic fermented milk drink · Volunteers; age, sex, and health condition not specified | 65 mL | 3 weeks | 108 |
| Neonatal administration of Lactiplantibacillus plantarum ATCC 202195 with or without fructooligosaccharide in Bangladesh: a placebo-controlled randomized trial 2025 · LP1 · Newborn infants aged 0–4 days at enrollment, generally healthy, born in two public hospitals in Dhaka, Bangladesh | 1 billion CFU | 1 day | 105 |
| Neonatal administration of Lactiplantibacillus plantarum ATCC 202195 with or without fructooligosaccharide in Bangladesh: a placebo-controlled randomized trial 2025 · LP7 · Newborn infants aged 0–4 days at enrollment, generally healthy, born in two public hospitals in Dhaka, Bangladesh | 1 billion CFU | 7 days | 104 |
| Effects of Loigolactobacillus coryniformis K8 CECT 5711 on the Immune Response of Elderly Subjects to COVID-19 Vaccination: A Randomized Controlled Trial 2022 · probiotic group · Nursing-home residents older than 60 years who had received the first dose of a COVID-19 vaccination schedule | 3 billion CFU | 90 days | 99 |
| Effect of probiotic on innate inflammatory response and viral shedding in experimental rhinovirus infection - a randomised controlled trial 2017 · probiotic group · Healthy adult volunteers susceptible to rhinovirus type 39 | 2 billion CFU | 33 days | 95 |
| Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study 2022 · Prob · Adults aged 20–70 years, both sexes, with newly diagnosed type 2 diabetes | 4 g | 12 weeks | 92 |
| Effect of Probiotic-Assisted Eradication of cagA+/vacA s1m1 Helicobacter pylori on Intestinal Flora 2022 · Group B · Adults aged 60–70 with cagA+/vacA s1m1 Helicobacter pylori infection and chronic nonatrophic gastritis | 1 g | 2 weeks | 90 |
| Impact of Probiotic Lacticaseibacillus paracasei Strain Shirota (LcS) on Aflatoxin Exposure among Healthy Malaysian Adults: A Randomized, Double-Blind, Placebo-Controlled Intervention Study 2025 · probiotic group · Healthy Malaysian adults aged 20–60 of Chinese, Malay, or Indian ethnicity with elevated urinary AFM1 and serum AFB1-albumin concentrations | 60 billion CFU | 12 weeks | 87 |
| The Roles of Probiotics in the Gut Microbiota Composition and Metabolic Outcomes in Asymptomatic Post-Gestational Diabetes Women: A Randomized Controlled Trial 2022 · probiotics group · Women aged 18–45 with a recent history of gestational diabetes, selected for postpartum glucose intolerance, overweight, or obesity; asymptomatic of hyperglycemia | 60 billion CFU | 12 weeks | 83 |
| Effect of Bifidobacterium breve M-16V supplementation on fecal bifidobacteria in preterm neonates--a randomised double blind placebo controlled trial 2014 · Probiotic · Preterm very-low-birth-weight neonates born at up to 32 weeks and 6 days, birth weight under 1500 g, ready to commence enteral feeds or fed for less than 12 hours | 3 billion CFU | — | 79 |
| Human supplementation with Pediococcus acidilactici GR-1 decreases heavy metals levels through modifying the gut microbiota and metabolome 2022 · Probiotic yogurt group · Adults aged 20–56, male and female occupational workers exposed to metals in a metallurgical enterprise | 10 billion CFU | 12 weeks | 76 |
| Effect of a Short-Time Probiotic Supplementation on the Abundance of the Main Constituents of the Gut Microbiota of Term Newborns Delivered by Cesarean Section-A Randomized, Prospective, Controlled Clinical Trial 2020 · intervention group · Healthy term newborns born at 38–40 weeks by cesarean section | 0.002 billion CFU | 6 days | 71 |
| Cardiometabolic benefits of Lacticaseibacillus paracasei 8700:2: A randomized double-blind placebo-controlled trial 2023 · L. paracasei · Adults with metabolic syndrome; mean age 45.97 years, 73.1% men | 10 billion CFU | 12 weeks | 66 |
| Effect of probiotic yoghurt on plasma glucose in overweight and obese pregnant women: a randomized controlled clinical trial 2020 · probiotic yoghurt group · Overweight or obese pregnant women with no diabetes in pregnancy, with pre- or early-pregnancy BMI ≥ 25 and fasting plasma glucose < 92 mg/dl at 22 weeks of gestation | 100 g | — | 65 |
| Randomized control trial on the efficacy of Limosilactobacillus reuteri ATCC PTA 4659 in reducing inflammatory markers in acute uncomplicated diverticulitis 2022 · probiotic group · Adults aged 18–80 with acute uncomplicated diverticulitis (AUD; Hinchey grade 0) | 1 billion CFU | 10 days | 61 |
| Effects of probiotics (cultured Lactobacillus subtilis/Streptococcus faecium) in the treatment of alcoholic hepatitis: randomized-controlled multicenter study 2015 · probiotics · Hospitalized patients with alcoholic hepatitis; age and sex not reported | 1.5 g | 7 days | 60 |
| Clinical Effects of Lactobacillus reuteri on Gingival Inflammation and Alveolar Bone Loss in Periodontitis 2025 · test group · Adults aged 22–47 with periodontitis or gingivitis | 1 billion CFU | 8 weeks | 60 |
| Early Probiotic Supplementation of Healthy Term Infants with Bifidobacterium longum subsp. infantis M-63 Is Safe and Leads to the Development of Bifidobacterium-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial 2023 · M-63 group · Healthy full-term infants born at ≥37 and <42 weeks’ gestation, enrolled within 7 days after birth | 1 billion CFU | 90 days | 57 |
| Effects of fermented soymilk with Lacticaseibacillus paracasei YIT 9029 on gut microbiota and defecation habits: a randomised, double-blind, placebo-controlled study 2024 · FSM group · Healthy Japanese adults with a low faecal Bifidobacterium count | 100 mL | 4 weeks | 57 |
| Randomized study of Lacticaseibacillus fermented milk in Indonesian elderly houses: Impact on gut microbiota and gut environment 2025 · Probiotic group · Residents and staff of Indonesian elderly houses; median age about 65 years; physically and mentally healthy, without a stated diagnosed condition | 6.5 billion CFU | 24 weeks | 56 |
| Probiotic for pathogen-specific Staphylococcus aureus decolonisation in Thailand: a phase 2, double-blind, randomised, placebo-controlled trial 2023 · treatment group · Adults aged 18 years or older who were healthy and colonized with Staphylococcus aureus | 250 mg | 30 days | 55 |
| Novel targets in rectal cancer by considering lncRNA-miRNA-mRNA network in response to Lactobacillus acidophilus consumption: a randomized clinical trial 2022 · probiotic group · Adults aged 30–70 with non-metastatic stage II or III rectal cancer | 3 billion CFU | 13 weeks | 53 |
| Lactobacillus paracasei subsp. paracasei LC01 positively modulates intestinal microflora in healthy young adults 2013 · LC01 probiotic stage · Healthy young adults | 10 billion CFU | 4 weeks | 52 |
| Efficacy and Safety of MED-01 Probiotics on Vaginal Health: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial 2023 · MED-01-intake group · Women aged 19–50 with Nugent scores of 4–6 | 5 billion CFU | 12 weeks | 50 |
| The Potential Immunomodulatory Effect of Bifidobacterium longum subsp. longum BB536 on Healthy Adults through Plasmacytoid Dendritic Cell Activation in the Peripheral Blood 2023 · BB536 group · Japanese healthy adults aged 20 to under 65 years | 10 billion CFU | 4 weeks | 50 |
| A Double-Blind, Randomized Placebo-Controlled Trial of Probiotic Lactobacillus casei Shirota in Stable Cirrhotic Patients 2020 · LcS group · Adults aged 18–78 with stable cirrhosis of any cause | 19.5 billion CFU | 26 weeks | 46 |
| Effects of supplementation with two probiotic strains (Lactobacillus helveticus and Bifidobacterium longum) on hormonal status, oxidative stress, and clinical symptoms in women with polycystic ovary syndrome: a randomized clinical trial 2025 · Probiotic group · Women with polycystic ovary syndrome (PCOS); age range not stated | 3 billion CFU | 8 weeks | 45 |
| Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis 2016 · probiotic group · Adults aged 18–80 with liver cirrhosis of any aetiology | 6 g | 26 weeks | 44 |
| Probiotics and Antibiotic-Induced Microbial Aberrations in Children: A Secondary Analysis of a Randomized Clinical Trial 2024 · probiotic group · Children aged 3 months to 18 years receiving broad-spectrum antibiotics | 10 billion CFU | 17 days | 44 |
| Probiotic reduces vaginal HPV abundance, improves immunity and quality of life in HPV-positive women: a randomised, placebo-controlled and double-blind study 2025 · probiotic group · Women with HPV infection; mean age 41.70 years | 1 billion CFU | 12 weeks | 44 |
| Bifidobacterium animalis subsp. lactis TISTR 2591 Improves Glycemic Control and Immune Response in Adults with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Crossover Clinical Trial 2025 · BA-2591 probiotic phase (both crossover sequences) · Adults aged 35–65 years with type 2 diabetes diagnosed within six months, receiving metformin monotherapy | 1.05 g | 6 weeks | 44 |
| Effects of a live versus heat-inactivated probiotic Bifidobacterium spp in preterm infants: a randomised clinical trial 2025 · HP group · Very preterm infants born at less than 32 weeks’ gestation | 3 billion CFU | 3 weeks | 43 |
| Effects of a live versus heat-inactivated probiotic Bifidobacterium spp in preterm infants: a randomised clinical trial 2025 · P group · Very preterm infants born at less than 32 weeks’ gestation | 3 billion CFU | 3 weeks | 43 |
| Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study 2021 · probiotic group · Adults aged 18–75 with type 2 diabetes and diabetic nephropathy | 3.2 billion CFU | 12 weeks | 42 |
| Bifidobacterium animalis subsp. lactis BB-12 Protects against Antibiotic-Induced Functional and Compositional Changes in Human Fecal Microbiome 2021 · BB-12 group · Generally healthy adults aged 18–65 years | 10 billion CFU | 2 weeks | 42 |
| Impact of Streptococcus salivarius K12 on Nasopharyngeal and Saliva Microbiome: A Randomized Controlled Trial 2021 · S. salivarius K12 tablet group · Children aged 1–6 years attending daycare; mean age 4.8 years in the tablet group; no specified diagnosed condition | 1 billion CFU | 30 days | 41 |
| Effects of Lactobacillus plantarum and Lactobacillus paracasei on the Peripheral Immune Response in Children with Celiac Disease Autoimmunity: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial 2019 · probiotic-treated group · Children at genetic risk for celiac disease, on a gluten-containing diet, with celiac disease autoimmunity and no previous celiac disease diagnosis | 10 billion CFU | 26 weeks | 40 |
| Impact of Streptococcus salivarius K12 on Nasopharyngeal and Saliva Microbiome: A Randomized Controlled Trial 2021 · S. salivarius K12 powder group · Children aged 1–6 years attending daycare; mean age 3.6 years in the powder group; no specified diagnosed condition | 5 billion CFU | 30 days | 40 |
| Effect of probiotics on vaginal Ureaplasma parvum in women suffering from unexplained infertility 2021 · probiotic treatment group · Women with primary or secondary infertility | 2 g | 4 weeks | 40 |
| Probiotics Enhance Bone Density and Reduce Inflammation Postalveolar Surgery 2025 · experimental group · Adults aged 21–64 undergoing non-molar tooth extraction for caries or periodontitis, without systemic diseases affecting bone metabolism | 10 billion CFU | 8 weeks | 40 |
| Effects of a multi-strain probiotic supplement for 12 weeks in circulating endotoxin levels and cardiometabolic profiles of medication naïve T2DM patients: a randomized clinical trial 2017 · probiotic group · Adults aged 30–60 with newly diagnosed type 2 diabetes mellitus, medication naïve | 4 g | 12 weeks | 39 |
| Three probiotic strains exert different effects on plasma bile acid profiles in healthy obese adults: randomised, double-blind placebo-controlled crossover study 2019 · Bacillus subtilis R0179 · Healthy obese adults, mean age 53±8 years, with high waist circumference | 2.5 billion CFU | 6 weeks | 39 |
| Three probiotic strains exert different effects on plasma bile acid profiles in healthy obese adults: randomised, double-blind placebo-controlled crossover study 2019 · Lactobacillus plantarum HA-119 · Healthy obese adults, mean age 53±8 years, with high waist circumference | 5 billion CFU | 6 weeks | 38 |
| Effects of a Four-Strain Probiotic on Gut Microbiota, Inflammation, and Symptoms in Parkinson's Disease: A Randomized Clinical Trial 2025 · active · Adults aged 18 years or older with Parkinson's disease and functional constipation | 70 mL | 12 weeks | 38 |
| Effect of daily consumption of probiotic yoghurt on insulin resistance in pregnant women: a randomized controlled trial 2013 · probiotic group · Primigravida pregnant women with singleton pregnancies in the third trimester | 0.01 billion CFU | 9 weeks | 37 |
| Three probiotic strains exert different effects on plasma bile acid profiles in healthy obese adults: randomised, double-blind placebo-controlled crossover study 2019 · Bifidobacterium animalis subsp. lactis B94 · Healthy obese adults, mean age 53±8 years, with high waist circumference | 5 billion CFU | 6 weeks | 37 |
| Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease 2014 · intervention group · Adults aged 23 to 63 with nonalcoholic fatty liver disease; 33 males and 39 females across the study | 300 g | 8 weeks | 36 |
| Effects of maternal allergy and supplementation with ω-3 fatty acid and probiotic on human milk oligosaccharides 2025 · PL (placebo + L. reuteri) · Pregnant women with a family history of allergies who intended to breastfeed for the first 3 months; maternal age median about 32 years | 2 billion CFU | 20 weeks | 36 |
| Supplementation with Lactobacillus rhamnosus or Bifidobacterium lactis probiotics in pregnancy increases cord blood interferon-gamma and breast milk transforming growth factor-beta and immunoglobin A detection 2008 · Bifidobacterium lactis HN019 · Pregnant and lactating women; age and condition not reported | 9 billion CFU | 26 weeks | 35 |
| [Effects of probiotics on intestinal bacterial colonization in premature infants] 2010 · probiotics treatment group · premature infants | 500 mg | — | 35 |
| Effects of Lactobacillus plantarum Q180 on Postprandial Lipid Levels and Intestinal Environment: A Double-Blind, Randomized, Placebo-Controlled, Parallel Trial 2020 · LPQ180 group · Men and women over 20 years of age with blood triglyceride levels below 200 mg/dL | 4 billion CFU | 12 weeks | 35 |
| The Improvement Effects of Weizmannia coagulans BC99 on Liver Function and Gut Microbiota of Long-Term Alcohol Drinkers: A Randomized Double-Blind Clinical Trial 2025 · probiotic group · Adults aged 18–65 with long-term alcohol consumption of at least 20 g/day for more than 1 year; people with hepatitis, cirrhosis, hypertension, or diabetes were excluded. | 10 billion CFU | 60 days | 35 |
| Supplementation with Lactobacillus rhamnosus or Bifidobacterium lactis probiotics in pregnancy increases cord blood interferon-gamma and breast milk transforming growth factor-beta and immunoglobin A detection 2008 · Lactobacillus rhamnosus HN001 · Pregnant and lactating women; age and condition not reported | 6 billion CFU | 26 weeks | 34 |
| Effect of Lactobacillus brevis CD2 containing lozenges and plaque pH and cariogenic bacteria in diabetic children: a randomised clinical trial 2021 · probiotic group · Children aged 4–14 years with type 1 diabetes diagnosed at least 2 years previously | 4 billion CFU | 60 days | 34 |
| A combination of calcium phosphate and probiotics beneficially influences intestinal lactobacilli and cholesterol metabolism in humans 2012 · LPC37 alone · Healthy, moderately hypercholesterolemic men and women | 10 billion CFU | 4 weeks | 32 |
| A comparative evaluation of probiotic formulations in prevention of dental caries: A clinical study 2021 · study group · Children aged 6–12 years with DMFT and/or deft ≥2 | 200 g | 3 weeks | 31 |
| The effect of probiotics on faecal microbiota and genotoxic activity of faecal water in patients with atopic dermatitis: a randomized, placebo-controlled study 2012 · probiotic period · 15 healthy adults and 15 adults with atopic dermatitis | 200 mL | 8 weeks | 30 |
| Cholesterol-lowering efficacy of Lactobacillus plantarum CECT 7527, 7528 and 7529 in hypercholesterolaemic adults 2013 · L. plantarum group · Adults aged 18–65 years with hypercholesterolaemia | 1.2 billion CFU | 12 weeks | 30 |
| The effect of multistrain probiotic supplementation in two doses on iron metabolism in obese postmenopausal women: a randomized trial 2019 · LD group · Obese postmenopausal women | 2.5 billion CFU | 12 weeks | 30 |
| The effect of multistrain probiotic supplementation in two doses on iron metabolism in obese postmenopausal women: a randomized trial 2019 · HD group · Obese postmenopausal women | 10 billion CFU | 12 weeks | 30 |
| Targeting the Intestinal Microbiota to Prevent Type 2 Diabetes and Enhance the Effect of Metformin on Glycaemia: A Randomised Controlled Pilot Study 2020 · multi-strain probiotic group · Adults aged 18 years or older with BMI ≥25 kg/m² and prediabetes or type 2 diabetes diagnosed within the previous 12 months; treated by diet alone or diet plus metformin | 200 billion CFU | 12 weeks | 30 |
| Kinetics of Intestinal Presence of Spores Following Oral Administration of Bacillus clausii Formulations: Three Single-Centre, Crossover, Randomised, Open-Label Studies 2021 · E6 OD (powder without suspension; 2016 EGKINETIC6OP) · Healthy men and women aged 18–45 years | 6 billion CFU | — | 30 |
| Kinetics of Intestinal Presence of Spores Following Oral Administration of Bacillus clausii Formulations: Three Single-Centre, Crossover, Randomised, Open-Label Studies 2021 · ES6 OD (powder for suspension; 2016 EGKINETIC6OP) · Healthy men and women aged 18–45 years | 6 billion CFU | — | 30 |
| Probiotic supplementation in neonates with congenital gastrointestinal surgical conditions: a pilot randomised controlled trial 2022 · Probiotic · Neonates born at 35 or more weeks’ gestation with congenital gastrointestinal surgical conditions | 1 billion CFU | 19 days | 30 |
| Effectiveness of three mouth rinsing agents against mutans Streptococcus and Lactobacillus species - A comparative study 2023 · Group 3 – probiotic group · Children aged 6–15 years with fewer than four carious teeth and poor oral hygiene | 20 mL | 2 weeks | 30 |
| Synergistic immunomodulatory effect of synbiotics pre- and postoperative resection of pancreatic ductal adenocarcinoma: a randomized controlled study 2024 · Probiotics · Adults with pancreatic ductal adenocarcinoma undergoing pancreatoduodenectomy; age and sex not restricted | 25 billion CFU | 6 weeks | 30 |
| Effect of Lacticaseibacillus casei LC2W Supplementation on Glucose Metabolism and Gut Microbiota in Subjects at High Risk of Metabolic Syndrome: A Randomized, Double-blinded, Placebo-controlled Clinical Trial 2025 · L. casei LC2W group · Men and women aged 45–65 years with impaired fasting blood glucose (6.1–6.9 mmol/L), at high risk of metabolic syndrome and not receiving glucose-lowering treatment | 600 billion CFU | 26 weeks | 30 |
| Is there a value for probiotic supplements in gestational diabetes mellitus? A randomized clinical trial 2015 · Probiotic · Nulliparous pregnant women aged 18–45 with newly diagnosed gestational diabetes at 24–28 weeks of gestation | 4 billion CFU | 8 weeks | 29 |
| Does Streptococcus Salivarius Strain M18 Assumption Make Black Stains Disappear in Children? 2020 · Group A (treated group) · Children aged 4–10 years with extrinsic black teeth stains | 1 billion CFU | 90 days | 29 |
| Probiotics, Anticipation Stress, and the Acute Immune Response to Night Shift 2020 · DDS-1 · Adults aged 18–65 undertaking rotating day and night shift work, without stated gastrointestinal or metabolic conditions or current illness | 10 billion CFU | 4 weeks | 29 |
| Probiotics, Anticipation Stress, and the Acute Immune Response to Night Shift 2020 · UABla-12 · Adults aged 18–65 undertaking rotating day and night shift work, without stated gastrointestinal or metabolic conditions or current illness | 10 billion CFU | 4 weeks | 29 |
| Effect of fermented soy milk on the intestinal bacterial ecosystem 2005 · fermented soy milk · healthy adults | 500 mL | 2 weeks | 28 |
| Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut 2013 · B. infantis 35624, chronic fatigue syndrome patients · Women aged 18–65 with chronic fatigue syndrome | 10 billion CFU | 8 weeks | 28 |
| Interleukin-6 Gene Expression Changes after a 4-Week Intake of a Multispecies Probiotic in Major Depressive Disorder-Preliminary Results of the PROVIT Study 2020 · intervention group · Adults aged 18–75 with major depressive disorder; inpatient psychiatric treatment | 7.5 billion CFU | 4 weeks | 28 |
| The Efficacy of Lactobacillus-Containing Probiotic Supplementation in Hemodialysis Patients: A Randomized, Double-Blind, Placebo-Controlled Trial 2021 · probiotic group · Patients aged 39–75 years with end-stage renal disease receiving hemodialysis | 100 billion CFU | 26 weeks | 28 |
| The Consumption of Synbiotic Bread Containing Lactobacillus sporogenes and Inulin Affects Nitric Oxide and Malondialdehyde in Patients with Type 2 Diabetes Mellitus: Randomized, Double-Blind, Placebo-Controlled Trial 2016 · Group B (probiotic bread) · Patients with type 2 diabetes mellitus, aged 35–70 years; sex not specified | 0.3 billion CFU | 8 weeks | 27 |
| A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer 2019 · Probiotic group (AGE 1) · Adults aged 18 years and above with colorectal cancer who underwent colorectal resection | 60 billion CFU | 26 weeks | 27 |
| Probiotics-induced changes in gut microbial composition and its effects on cognitive performance after stress: exploratory analyses 2021 · probiotics group · Healthy women aged 18–40 years | 5 billion CFU | 4 weeks | 27 |
| Adjuvant Probiotics of Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 Attenuate Glycemic Levels and Inflammatory Cytokines in Patients With Type 1 Diabetes Mellitus 2022 · probiotic group · Patients with type 1 diabetes mellitus, age of onset 6–18 years; mean age 14.1 years | 10 billion CFU | 180 days | 27 |
| Adjunctive Probio-X Treatment Enhances the Therapeutic Effect of a Conventional Drug in Managing Type 2 Diabetes Mellitus by Promoting Short-Chain Fatty Acid-Producing Bacteria and Bile Acid Pathways 2023 · probiotic group · Adults aged 20–65 with clinically diagnosed type 2 diabetes mellitus | 30 billion CFU | 90 days | 27 |
| Probiotic-induced enrichment of Adlercreutzia equolifaciens increases gut microbiome wellness index and maps to lower host blood glucose levels 2025 · composite probiotics group · Chinese adults over 40, male and female, described as healthy without major diseases and selected for at least one biochemical indicator outside the stated range | 10 billion CFU | 60 days | 27 |
| Probiotic-induced enrichment of Adlercreutzia equolifaciens increases gut microbiome wellness index and maps to lower host blood glucose levels 2025 · LCZ single-strain probiotic intervention · Chinese adults over 40, male and female, described as healthy without major diseases | 10 billion CFU | 60 days | 27 |
| Lactobacillus acidophilus 74-2 and Bifidobacterium animalis subsp lactis DGCC 420 modulate unspecific cellular immune response in healthy adults 2008 · probiotic yoghurt supplement · Healthy adults; mean age 25 years; men and women, with sex distribution not reported | 300 g | 5 weeks | 26 |
| [Effects of probiotics on blood glucose levels and clinical outcomes in patients with severe craniocerebral trauma] 2013 · experimental group · Patients with severe craniocerebral trauma admitted to an intensive care unit | 10.5 g | 3 weeks | 26 |
| Beneficial effects of Bifidobacterium lactis on lipid profile and cytokines in patients with metabolic syndrome: A randomized trial. Effects of probiotics on metabolic syndrome 2016 · probiotic group · Patients with metabolic syndrome; age range and sex not reported | 27.2 billion CFU | 45 days | 26 |
| Early probiotic supplementation with B. infantis in breastfed infants leads to persistent colonization at 1 year 2022 · EVC treatment · Healthy, full-term, breastfed infants, supplemented from 7 days of age | 18 billion CFU | 3 weeks | 26 |
| Oral administration of Lactobacillus casei DG® after ileostomy closure in restorative proctocolectomy: a randomized placebo-controlled trial (microbiota and immune microenvironment in pouchitis -MEP1) 2024 · L. casei DG® group · Adults with ulcerative colitis who underwent restorative proctocolectomy with ileal pouch-anal anastomosis; age and sex were not restricted | 24 billion CFU | 8 weeks | 26 |
| The Probiotic Effects of Lactobacillus brevis CD2 on Caries Related Variables of Dental Plaque Biofilm 2025 · L. brevis CD2 lozenge period · Healthy adults; age range not stated; both sexes; no diagnosed condition stated | 600 mg | 4 weeks | 26 |
| Oral intake of Lactobacillus fermentum CECT5716 enhances the effects of influenza vaccination 2007 · probiotic group · Adults, mean age 33.0 ± 7.7 years, 31 male and 19 female volunteers; no condition stated | 10 billion CFU | 4 weeks | 25 |
| Effect of Probiotic Yogurt and Xylitol-Containing Chewing Gums on Salivary S Mutans Count 2017 · Probiotic yogurt group · Female students with more than 10^5 colony-forming units of S. mutans per milliliter of saliva | 200 g | 3 weeks | 25 |
| Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: A randomized controlled trial 2019 · treatment group · Patients with inflammatory bowel disease (ulcerative colitis or Crohn's disease) | 400 mL | 4 weeks | 25 |
| Examining the Gastrointestinal and Immunomodulatory Effects of the Novel Probiotic Bacillus subtilis DE111 2021 · Bacillus subtilis strain DE111 spores (DE111 group) · Healthy male and female adults aged 20–65 years with BMI 20–34.9 kg/m² | 1 billion CFU | 4 weeks | 25 |
| Changes in Hormonal Profile and Body Mass Index in Women with Polycystic Ovary Syndrome After Probiotic Intake: A 12-Week Placebo-Controlled and Randomized Clinical Study 2025 · probiotic group · Women aged 19–42 with polycystic ovary syndrome (PCOS) | 1 billion CFU | 12 weeks | 25 |
| Effects of oral Lactobacillus GG on enteric microflora in low-birth-weight neonates 2003 · Infants weighing less than 1500 g, treated · Preterm infants with birth weight less than 1500 g | 2 billion CFU | 3 weeks | 24 |
| Administration of Bifidobacterium breve Decreases the Production of TNF-α in Children with Celiac Disease 2015 · B. breve BR03 and B632 group · Children with celiac disease on a gluten-free diet; age and sex not stated | 2 billion CFU | 90 days | 24 |
| Dose-Dependent Effects of Multispecies Probiotic Supplementation on the Lipopolysaccharide (LPS) Level and Cardiometabolic Profile in Obese Postmenopausal Women: A 12-Week Randomized Clinical Trial 2018 · low-dose probiotic (LD) group · Women aged 45–70 years with obesity who were postmenopausal for at least one year | 2.5 billion CFU | 12 weeks | 24 |
| Effect of oral consumption of capsules containing Lactobacillus paracasei LPC-S01 on the vaginal microbiota of healthy adult women: a randomized, placebo-controlled, double-blind crossover study 2020 · probiotic phase · Healthy women aged 18–45 years of reproductive age | 24 billion CFU | 4 weeks | 24 |
| Treatment With Multi-Species Probiotics Changes the Functions, Not the Composition of Gut Microbiota in Postmenopausal Women With Obesity: A Randomized, Double-Blind, Placebo-Controlled Study 2022 · Low probiotic dose group (LPD) · Women aged 45–70 years who were postmenopausal and had obesity | 2.5 billion CFU | 12 weeks | 24 |
| Study of the effect of Lactobacillus crispatus FSCDJY67L3 on Helicobacter Pylori eradication: a double-blind randomized controlled clinical trial 2023 · L. crispatus FSCDJY67L3 group · Men and women aged 18–65 with confirmed H. pylori infection and no reported symptoms other than the infection | 10 billion CFU | 30 days | 24 |
| Effect of Daily Lactococcus cremoris spp. Consumption Immobilized on Oat Flakes on Blood and Urine Biomarkers: A Randomized Placebo-Controlled Clinical Trial 2025 · probiotic group · Otherwise healthy adults aged 18–65 years, men and women, with fasting plasma glucose below 100 mg/dL and cholesterol below 220 mg/dL | 2 billion CFU | 12 weeks | 24 |
| Effects of oral Lactobacillus GG on enteric microflora in low-birth-weight neonates 2003 · Infants weighing 1500 to 1999 g, treated · Preterm infants with birth weight 1500 to 1999 g | 2 billion CFU | 8 days | 23 |
| An in vivo assessment of the cholesterol-lowering efficacy of Lactobacillus plantarum ECGC 13110402 in normal to mildly hypercholesterolaemic adults 2017 · active · Adults aged 30–65, men and women, healthy with normal to mildly elevated cholesterol | 4 billion CFU | 12 weeks | 23 |
| Dose-Dependent Effects of Multispecies Probiotic Supplementation on the Lipopolysaccharide (LPS) Level and Cardiometabolic Profile in Obese Postmenopausal Women: A 12-Week Randomized Clinical Trial 2018 · high-dose probiotic (HD) group · Women aged 45–70 years with obesity who were postmenopausal for at least one year | 10 billion CFU | 12 weeks | 23 |
| Changes in peripheral immune populations during pregnancy and modulation by probiotics and ω-3 fatty acids 2020 · placebo + L. reuteri · Pregnant women included at gestational week 20, with at least one parent or sibling with allergic disease history or symptoms | 2 billion CFU | 132 days | 23 |
| Treatment With Multi-Species Probiotics Changes the Functions, Not the Composition of Gut Microbiota in Postmenopausal Women With Obesity: A Randomized, Double-Blind, Placebo-Controlled Study 2022 · High probiotic dose group (HPD) · Women aged 45–70 years who were postmenopausal and had obesity | 10 billion CFU | 12 weeks | 23 |
| Comparative study of Kefir yogurt-drink and sodium fluoride mouth rinse on salivary mutans streptococci 2014 · Kefir drink · Healthy adults aged 22–32 years without active caries lesions | 100 mL | 2 weeks | 22 |
| Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial 2017 · Saccharomyces boulardii probiotic group · Adults with chronic HIV infection, aged 47.5 years median; men and women with suppressed viral load on stable antiretroviral therapy, including immunologic responders and non-responders | 339 mg | 12 weeks | 22 |
| Kinetics of Intestinal Presence of Spores Following Oral Administration of Bacillus clausii Formulations: Three Single-Centre, Crossover, Randomised, Open-Label Studies 2021 · E4 OD (vial; 2012 EGKINETIC4) · Healthy men and women aged 18–45 years | 4 billion CFU | — | 22 |
| Kinetics of Intestinal Presence of Spores Following Oral Administration of Bacillus clausii Formulations: Three Single-Centre, Crossover, Randomised, Open-Label Studies 2021 · E2 BID (vial; 2012 EGKINETIC4) · Healthy men and women aged 18–45 years | 4 billion CFU | — | 22 |
| Kinetics of Intestinal Presence of Spores Following Oral Administration of Bacillus clausii Formulations: Three Single-Centre, Crossover, Randomised, Open-Label Studies 2021 · ES6 OD (powder for suspension; 2012 EGKINETIC6) · Healthy men and women aged 18–45 years | 6 billion CFU | — | 22 |
| Kinetics of Intestinal Presence of Spores Following Oral Administration of Bacillus clausii Formulations: Three Single-Centre, Crossover, Randomised, Open-Label Studies 2021 · EC2 TID (capsule; 2012 EGKINETIC6) · Healthy men and women aged 18–45 years | 6 billion CFU | — | 22 |
| Effect of probiotic supplementation along with calorie restriction on metabolic endotoxemia, and inflammation markers in coronary artery disease patients: a double blind placebo controlled randomized clinical trial 2021 · probiotic group · Adults with coronary artery disease and BMI 25–35 kg/m² | 1.6 billion CFU | 90 days | 22 |
| Multi-Strain Probiotic Mixture Affects Brain Morphology and Resting State Brain Function in Healthy Subjects: An RCT 2022 · probiotic intervention · Healthy adults; mean age 24.2 years; 6 male and 16 female | 3 billion CFU | 4 weeks | 22 |
| Probiotic-Reduced Inflammaging in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial 2025 · LpHEAL9 · Men and women aged 70 years or older with moderately elevated CRP (2–10 mg/L), otherwise healthy | 10 billion CFU | 4 weeks | 22 |
| Effect of Lacticaseibacillus rhamnosus L8020 on the abundance of periodontal pathogens in individuals with intellectual disability: a randomized clinical trial 2023 · L8020 (test group) · Outpatients with intellectual disability and gingivitis; age and sex not reported | 80 g | 12 weeks | 21 |
| Impact on human intestinal microflora of an Enterococcus faecium probiotic and vancomycin 2000 · E. faecium supplement only · Healthy Danish and Swedish volunteers; age and sex not reported | 150 mL | 10 days | 20 |
| Impact on human intestinal microflora of an Enterococcus faecium probiotic and vancomycin 2000 · E. faecium supplement plus vancomycin · Healthy Danish and Swedish volunteers; age and sex not reported | 150 mL | 10 days | 20 |
| Impact of consumption of different levels of Bifidobacterium lactis HN019 on the intestinal microflora of elderly human subjects 2007 · low dose group · Volunteers over 60 years old | 0.065 billion CFU | 4 weeks | 20 |
| Impact of consumption of different levels of Bifidobacterium lactis HN019 on the intestinal microflora of elderly human subjects 2007 · medium dose group · Volunteers over 60 years old | 1 billion CFU | 4 weeks | 20 |
| Impact of consumption of different levels of Bifidobacterium lactis HN019 on the intestinal microflora of elderly human subjects 2007 · high dose group · Volunteers over 60 years old | 5 billion CFU | 4 weeks | 20 |
| The Effects of Lactobacillus casei on Glycemic Response, Serum Sirtuin1 and Fetuin-A Levels in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial 2019 · probiotic group · Adults aged 30–50 years with type 2 diabetes mellitus | 0.1 billion CFU | 8 weeks | 20 |
| Recovery of Saccharomyces cerevisiae CNCM I-3856 in Vaginal Samples of Healthy Women after Oral Administration 2020 · 500 mg Probiotic group · Healthy women; age range and sex-specific eligibility details are not provided in the reported text. | 2.5 billion CFU | 4 weeks | 20 |
| Recovery of Saccharomyces cerevisiae CNCM I-3856 in Vaginal Samples of Healthy Women after Oral Administration 2020 · 1000 mg Probiotic group · Healthy women; age range and sex-specific eligibility details are not provided in the reported text. | 5 billion CFU | 4 weeks | 20 |
| Lactobacillus plantarum HAC01 Supplementation Improves Glycemic Control in Prediabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial 2021 · Lactobacillus plantarum HAC01 group · Adults aged 19–70 with isolated impaired glucose tolerance (prediabetes) | 4 billion CFU | 8 weeks | 20 |
| Efficacy of Probiotic Supplements on Brain-Derived Neurotrophic Factor, Inflammatory Biomarkers, Oxidative Stress and Cognitive Function in Patients with Alzheimer's Dementia: A 12-Week Randomized, Double-Blind Active-Controlled Study 2023 · Treatment group · Adults aged 50–90 with mild to moderate Alzheimer’s dementia | 10 billion CFU | 12 weeks | 20 |
| Efficacy of Probiotic Supplements on Brain-Derived Neurotrophic Factor, Inflammatory Biomarkers, Oxidative Stress and Cognitive Function in Patients with Alzheimer's Dementia: A 12-Week Randomized, Double-Blind Active-Controlled Study 2023 · Active control group · Adults aged 50–90 with mild to moderate Alzheimer’s dementia | 0.05 billion CFU | 12 weeks | 20 |
| Effects of Probiotics on Inflammatory Biomarkers and Its Associations With Cardiac Autonomic Function in Women With Arterial Hypertension: A Secondary Analysis of a Randomized Clinical Trial 2025 · probiotics · Women with arterial hypertension | 1 billion CFU | 8 weeks | 20 |
| Strain specific effects of probiotic supplementation on serum amino acid profiles in Alzheimer's disease: a randomized, double blind, placebo controlled trial 2025 · Lactobacillus rhamnosus HA-114 · Adults aged 50–90 years with mild to moderate Alzheimer’s disease | 2 billion CFU | 12 weeks | 20 |
| Strain specific effects of probiotic supplementation on serum amino acid profiles in Alzheimer's disease: a randomized, double blind, placebo controlled trial 2025 · Bifidobacterium longum R0175 · Adults aged 50–90 years with mild to moderate Alzheimer’s disease | 2 billion CFU | 12 weeks | 20 |
| A mixture of Lactobacillus plantarum CECT 7315 and CECT 7316 enhances systemic immunity in elderly subjects. A dose-response, double-blind, placebo-controlled, randomized pilot trial 2011 · high probiotic dose · Institutionalized elderly subjects; age and sex not specified | 5 billion CFU | 12 weeks | 19 |
| Dietary modulation of the gut microbiota--a randomised controlled trial in obese postmenopausal women 2015 · Lactobacillus paracasei F19 · Women aged 40–70 years, postmenopausal for at least 1 year, with obesity (BMI 30–45 kg/m²) | 94 billion CFU | 6 weeks | 19 |
| A Symbiotic Meal Containing Extruded Sorghum and Probiotic (Bifidobacterium longum) Ameliorated Intestinal Health Markers in Individuals with Chronic Kidney Disease: A Secondary Analysis of a Subsample from a Previous Randomized and Controlled Clinical Trial 2024 · symbiotic group (SG) · Adults aged 18 years or older, both sexes, with chronic kidney disease receiving hemodialysis | 0.8 billion CFU | 7 weeks | 19 |
| Examining immune-inflammatory mechanisms of probiotic supplementation in depression: secondary findings from a randomized clinical trial 2024 · probiotics group · Adults aged 18–65 with a current mild depressive episode, receiving treatment as usual; inpatients | 900 billion CFU | 4 weeks | 19 |
| Multispecies probiotic affects fecal short-chain fatty acids in postmenopausal women with obesity: A post hoc analysis of a randomized, double-blind, placebo-controlled study 2023 · lower probiotic dose (LPD) · Postmenopausal women with obesity | 2.5 billion CFU | — | 18 |
| Multispecies probiotic affects fecal short-chain fatty acids in postmenopausal women with obesity: A post hoc analysis of a randomized, double-blind, placebo-controlled study 2023 · higher probiotic dose (HPD) · Postmenopausal women with obesity | 10 billion CFU | — | 18 |
| Probiotics combined with atorvastatin administration in the treatment of hyperlipidemia: A randomized, double-blind, placebo-controlled clinical trial 2024 · probiotic + atorvastatin group (probiotic group) · Adults aged 55.57 ± 10.04 years with hyperlipidemia; both sexes | 2 g | 90 days | 18 |
| A probiotics-containing biscuit modulates the intestinal microbiota in the elderly 2013 · probiotic biscuit (Ep) · Men and women aged 71–88 years in good physical health, living independently; elderly volunteers | 1 billion CFU | 30 days | 17 |
| The preterm gut microbiota and administration routes of different probiotics: a randomized controlled trial 2023 · M-LGG · Mothers of preterm neonates born at 25–35 weeks’ gestation | 1 billion CFU | — | 17 |
| A multistrain probiotic increases the serum glutamine/glutamate ratio in patients with cirrhosis: a metabolomic analysis 2023 · Probiotic group · Adults with cirrhosis and cognitive dysfunction and/or falls during the previous year; mean age 64.5 years, 65.6% women | 900 billion CFU | 12 weeks | 17 |
| Live microbials to boost Anti-SARS-CoV-2 immunity clinical trial (Live BASIC trial): a triple-blind randomized controlled trial 2026 · Standard-Dose · Generally healthy, unvaccinated adults aged 18–60 with documented SARS-CoV-2 infection at least 4 months before enrollment | 43 billion CFU | 3 weeks | 17 |
| Live microbials to boost Anti-SARS-CoV-2 immunity clinical trial (Live BASIC trial): a triple-blind randomized controlled trial 2026 · High-Dose · Generally healthy, unvaccinated adults aged 18–60 with documented SARS-CoV-2 infection at least 4 months before enrollment | 75 billion CFU | 3 weeks | 17 |
| Effects of a nutritional intervention with yogurt on lymphocyte subsets and cytokine production capacity in anorexia nervosa patients 2006 · AN-y · Patients with anorexia nervosa undergoing refeeding; age and sex not reported | 375 g | 10 weeks | 16 |
| Effects of a nutritional intervention with yogurt on lymphocyte subsets and cytokine production capacity in anorexia nervosa patients 2006 · HA-y · Healthy adolescents; age and sex not reported | 375 g | 10 weeks | 16 |
| Effect of probiotics on gut microbiome in patients with administration of surgical antibiotic prophylaxis: A randomized controlled study 2020 · probiotics group · Patients who underwent spinal surgery and received surgical antibiotic prophylaxis | 3 g | 5 days | 16 |
| The Metabolic Effects of Pre-probiotic Supplementation After Roux-en-Y Gastric Bypass (RYGB) Surgery: a Prospective, Randomized Controlled Study 2021 · Probiotic group (ProBG) · Adults who had undergone Roux-en-Y gastric bypass; age and sex not stated | 200 g | 26 weeks | 16 |
| Postbiotic Supplementation Increases Amino Acid Absorption from Plant-Based Meal: A Placebo-Controlled, Randomized, Double-Blind, Crossover Study 2025 · PRO (probiotic) · Normal-weight recreationally active males, mean age 23.1 years, without the listed diagnosed disorders | 10 billion CFU | 2 weeks | 16 |
| Five-Day Treatment with B. licheniformis Along with Classical Vancomycin Treatment Was Effective in Preserving Gut Microbiota in Patients with Clostridioides difficile Infection 2025 · study group · Adults aged 18 years or older with mild to moderate Clostridioides difficile infection | 750 mg | 5 days | 16 |
| Lactobacillus gasseri CECT 30648 shows probiotic characteristics and colonizes the vagina of healthy women after oral administration 2025 · Lg · Healthy premenopausal women aged 18–45 years | 1 billion CFU | 18 days | 16 |
| Effect of probiotic (VSL#3) and omega-3 on lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight adults: a randomized, controlled trial 2014 · VSL#3 capsules · Adults aged 40–60 of both sexes with BMI >25, apparently healthy and overweight | 113 billion CFU | 6 weeks | 15 |
| Influence of 4-week multi-strain probiotic administration on resting-state functional connectivity in healthy volunteers 2019 · probiotics (PRP) group · Healthy adults aged 20–40 years; 23 women among 45 participants overall | 3 g | 4 weeks | 15 |
| Probiotic Lactobacillus fermentum TSF331, Lactobacillus reuteri TSR332, and Lactobacillus plantarum TSP05 improved liver function and uric acid management-A pilot study 2024 · 3 Mix · Adults aged 18 or older with elevated AST, ALT, and uric acid levels and potential risk of MAFLD | 20.1 billion CFU | 60 days | 15 |
| Cholesterol-lowering effect of probiotic yogurt in comparison with ordinary yogurt in mildly to moderately hypercholesterolemic subjects 2009 · probiotic yogurt · Adults with mildly to moderately hypercholesterolemia; age and sex not stated | 300 g | 6 weeks | 14 |
| Probiotic Lactobacillus fermentum TSF331, Lactobacillus reuteri TSR332, and Lactobacillus plantarum TSP05 improved liver function and uric acid management-A pilot study 2024 · TSF331 · Adults aged 18 or older with elevated AST, ALT, and uric acid levels and potential risk of MAFLD | 20.1 billion CFU | 60 days | 14 |
| Probiotic Lactobacillus fermentum TSF331, Lactobacillus reuteri TSR332, and Lactobacillus plantarum TSP05 improved liver function and uric acid management-A pilot study 2024 · TSR332 · Adults aged 18 or older with elevated AST, ALT, and uric acid levels and potential risk of MAFLD | 20.1 billion CFU | 60 days | 14 |
| Dietary supplementation of probiotic Bacillus polyfermenticus, Bispan strain, modulates natural killer cell and T cell subset populations and immunoglobulin G levels in human subjects 2006 · experimental group · men aged 20–35 years, with no condition specified | 0.31 billion CFU | 8 weeks | 13 |
| A mixture of Lactobacillus plantarum CECT 7315 and CECT 7316 enhances systemic immunity in elderly subjects. A dose-response, double-blind, placebo-controlled, randomized pilot trial 2011 · low probiotic dose · Institutionalized elderly subjects; age and sex not specified | 0.5 billion CFU | 12 weeks | 13 |
| Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut 2013 · B. infantis 35624, ulcerative colitis patients · Men and women aged 18–75 with mild to moderate active ulcerative colitis | 10 billion CFU | 6 weeks | 13 |
| Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers 2017 · Group 1 Sb · Healthy adults aged 18–65, male or female, in good general health | 1 g | 2 weeks | 13 |
| Modulation of the peripheral blood transcriptome by the ingestion of probiotic yoghurt and acidified milk in healthy, young men 2018 · probiotic yoghurt · Healthy young men, mean age 24.6 years | 400 g | 2 weeks | 13 |
| The preterm gut microbiota and administration routes of different probiotics: a randomized controlled trial 2023 · C-LGG · Preterm neonates born at 25–35 weeks’ gestation, younger than 3 days at recruitment and admitted to the NICU | 1 billion CFU | — | 13 |
| Probiotic Lactobacillus fermentum TSF331, Lactobacillus reuteri TSR332, and Lactobacillus plantarum TSP05 improved liver function and uric acid management-A pilot study 2024 · TSP05 · Adults aged 18 or older with elevated AST, ALT, and uric acid levels and potential risk of MAFLD | 20.1 billion CFU | 60 days | 13 |
| Screening of probiotic activities of forty-seven strains of Lactobacillus spp. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans 1999 · Selected Lactobacillus strains · 12 healthy volunteers | 20 billion CFU | 18 days | 12 |
| Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut 2013 · B. infantis 35624, psoriasis patients · Men and women aged 18–60 with mild to moderate chronic plaque psoriasis | 10 billion CFU | 8 weeks | 12 |
| Effect of probiotic L. plantarum IS-10506 and zinc supplementation on humoral immune response and zinc status of Indonesian pre-school children 2014 · probiotic · Indonesian children aged 12–24 months | 10 billion CFU | 90 days | 12 |
| Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers 2017 · Group 3 Sb + AC · Healthy adults aged 18–65, male or female, in good general health | 1 g | 2 weeks | 12 |
| Salivary IgA response to probiotic bacteria and mutans streptococci after the use of chewing gum containing Lactobacillus reuteri 2013 · test group · Participants; age and sex not reported, with no condition stated | 0.4 billion CFU | 12 weeks | 11 |
| The Efficacy of Short-Term Weight Loss Programs and Consumption of Natural Probiotic Bryndza Cheese on Gut Microbiota Composition in Women 2021 · WLPB group (weight loss program with Bryndza) · Healthy women aged 18–65 years with BMI 20–40 kg/m² | 30 g | 30 days | 11 |
| A probiotic lozenge administered medical device and its effect on salivary mutans streptococci and lactobacilli 2008 · Group A · Healthy young women aged 20 years with high Streptococcus mutans counts | 0.11 billion CFU | 10 days | 10 |
| Vaginal impact of the oral administration of total freeze-dried culture of LCR 35 in healthy women 2012 · Group 1 · Healthy premenopausal women aged 18–45 | 0.1 billion CFU | 4 weeks | 10 |
| Vaginal impact of the oral administration of total freeze-dried culture of LCR 35 in healthy women 2012 · Group 2 · Healthy premenopausal women aged 18–45 | 0.2 billion CFU | 4 weeks | 10 |
| Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut 2013 · B. infantis 35624, healthy volunteers · Healthy adults aged 18–65, men and women | 10 billion CFU | 8 weeks | 10 |
| Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG: a randomised clinical trial 2014 · LGG · Children aged 2–9 years with cystic fibrosis, clinically stable and without recent antibiotic use | 6 billion CFU | 4 weeks | 10 |
| Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain - a randomised clinical study 2014 · L-NCFM alone · Caucasian women aged 18–70 with active mild-to-moderate abdominal pain | 20 billion CFU | 4 weeks | 10 |
| Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain - a randomised clinical study 2014 · L-NCFM and B-LBi07 dual-probiotic blend · Caucasian women aged 18–70 with active mild-to-moderate abdominal pain | 20 billion CFU | 4 weeks | 10 |
| The effects of Lactobacillus plantarum on small intestinal barrier function and mucosal gene transcription; a randomized double-blind placebo controlled trial 2017 · L. plantarum WCFS1 · Healthy adults aged 19–48 years, women and men, without stated gastrointestinal disease | 52 billion CFU | 7 days | 10 |
| The effects of Lactobacillus plantarum on small intestinal barrier function and mucosal gene transcription; a randomized double-blind placebo controlled trial 2017 · L. plantarum CIP48 · Healthy adults aged 19–48 years, women and men, without stated gastrointestinal disease | 48 billion CFU | 7 days | 10 |
| The effects of Lactobacillus plantarum on small intestinal barrier function and mucosal gene transcription; a randomized double-blind placebo controlled trial 2017 · L. plantarum TIFN101 · Healthy adults aged 19–48 years, women and men, without stated gastrointestinal disease | 118 billion CFU | 7 days | 10 |
| Delayed gut microbiota development in high-risk for asthma infants is temporarily modifiable by Lactobacillus supplementation 2018 · high-risk LGG-supplemented (HRLGG) group · Newborn infants at high risk for asthma because at least one biological parent had asthma | 10 billion CFU | 26 weeks | 10 |
| Probiotics maintain the gut microbiome homeostasis during Indian Antarctic expedition by ship 2021 · Probiotic (PB) group · Healthy Indian men aged 27–45 participating in the 38th Indian Scientific Expedition to Antarctica by ship | 1 g | 24 days | 10 |
| A Pilot Study of the Effect of Lactobacillus casei Obtained from Long-Lived Elderly on Blood Biochemical, Oxidative, and Inflammatory Markers, and on Gut Microbiota in Young Volunteers 2021 · probiotic group · Healthy volunteers aged 20–35 years; sex not specified for the group | 2 g | 3 weeks | 10 |
| Antimicrobial efficacy of Xylitol, Probiotic and Chlorhexidine mouth rinses among children and elderly population at high risk for dental caries - A Randomized Controlled Trial 2022 · Group C — probiotic mouth rinse, children · Children aged 5–12 years at high risk for dental caries | 1.5 billion CFU | 2 weeks | 10 |
| Antimicrobial efficacy of Xylitol, Probiotic and Chlorhexidine mouth rinses among children and elderly population at high risk for dental caries - A Randomized Controlled Trial 2022 · Group C — probiotic mouth rinse, elderly · Adults over 60 years at high risk for dental caries | 1.5 billion CFU | 2 weeks | 10 |
| Use of Streptococcus salivarius K12 in supporting the mucosal immune function of active young subjects: A randomised double-blind study 2023 · S. salivarius K12 group · Healthy, physically active adults aged 20–25 years, without chronic disease | 5 billion CFU | 30 days | 10 |
| Lactobacillus acidophilus ameliorates cholestatic liver injury through inhibiting bile acid synthesis and promoting bile acid excretion 2024 · Treatment group (UDCA + L. acidophilus) · Adults over 18 years with diagnosed cholestatic liver disease | 0.015 billion CFU | 2 weeks | 10 |
| Randomized, placebo-controlled trial reveals the impact of dose and timing of Bifidobacterium infantis probiotic supplementation on breastfed infants' gut microbiome 2026 · 4.0 × 10⁹ CFU/day B. infantis EVC001 (low dose) · Exclusively breastfed healthy full-term infants aged 60–125 days at enrollment | 4 billion CFU | 4 weeks | 10 |
| Randomized, placebo-controlled trial reveals the impact of dose and timing of Bifidobacterium infantis probiotic supplementation on breastfed infants' gut microbiome 2026 · 8.0 × 10⁹ CFU/day B. infantis EVC001 (medium dose) · Exclusively breastfed healthy full-term infants aged 60–125 days at enrollment | 8 billion CFU | 4 weeks | 10 |
| Randomized, placebo-controlled trial reveals the impact of dose and timing of Bifidobacterium infantis probiotic supplementation on breastfed infants' gut microbiome 2026 · 1.8 × 10¹⁰ CFU/day B. infantis EVC001 (high dose) · Exclusively breastfed healthy full-term infants aged 60–125 days at enrollment | 18 billion CFU | 4 weeks | 10 |
| Dose-dependent effect of Lactobacillus rhamnosus on quantitative reduction of faecal rotavirus shedding in children 2009 · low-dose group · Children with acute rotaviral gastroenteritis | 0.2 billion CFU | 3 days | 9 |
| Dose-dependent effect of Lactobacillus rhamnosus on quantitative reduction of faecal rotavirus shedding in children 2009 · high-dose group · Children with acute rotaviral gastroenteritis | 0.6 billion CFU | 3 days | 8 |
| Probiotic supplementation prevents high-fat, overfeeding-induced insulin resistance in human subjects 2015 · probiotic supplemented group · Healthy, physically active young adult males and females with normal BMI and no cardiovascular or metabolic disease; exact age range not reported. | 130 mL | 4 weeks | 8 |
| UCC118 supplementation reduces exercise-induced gastrointestinal permeability and remodels the gut microbiome in healthy humans 2019 · UCC118 · Healthy trained endurance athletes aged 18–45 years | 0.2 billion CFU | 4 weeks | 7 |
| Administration of probiotics to healthy volunteers: effects on reactivity of intestinal mucosa and systemic leukocytes 2022 · Lactiplantibacillus plantarum 299 (Lp299) group · Healthy adult volunteers, women and men; median age 46 years (range 28–79), without gastrointestinal symptoms or known disease | 10 billion CFU | 6 weeks | 7 |
| Administration of probiotics to healthy volunteers: effects on reactivity of intestinal mucosa and systemic leukocytes 2022 · Bifidobacterium infantis CURE21 group · Healthy adult volunteers, women and men; median age 46 years (range 28–79), without gastrointestinal symptoms or known disease | 10 billion CFU | 6 weeks | 7 |
| Pyrosequencing analysis reveals changes in intestinal microbiota of healthy adults who received a daily dose of immunomodulatory probiotic strains 2015 · Lactobacillus rhamnosus CNCM I-4036 · Healthy adults; ages 20–29; both sexes | 9 billion CFU | 30 days | 5 |
| Pyrosequencing analysis reveals changes in intestinal microbiota of healthy adults who received a daily dose of immunomodulatory probiotic strains 2015 · Lactobacillus paracasei CNCM I-4034 · Healthy adults; ages 25–31; both sexes | 9 billion CFU | 30 days | 5 |
| Pyrosequencing analysis reveals changes in intestinal microbiota of healthy adults who received a daily dose of immunomodulatory probiotic strains 2015 · Bifidobacterium breve CNCM I-4035 · Healthy adults; ages 20–35; both sexes | 9 billion CFU | 30 days | 4 |
| Pyrosequencing analysis reveals changes in intestinal microbiota of healthy adults who received a daily dose of immunomodulatory probiotic strains 2015 · Bifidobacterium breve CNCM I-4035 and Lactobacillus rhamnosus CNCM I-4036 mixture · Healthy adults; ages 20–30; both sexes | 9 billion CFU | 30 days | 4 |
| Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019 2001 · typical dose · healthy elderly adults aged 63–84 years | 50 billion CFU | 3 weeks | — |
| Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019 2001 · low dose · healthy elderly adults aged 63–84 years | 5 billion CFU | 3 weeks | — |
| The effect of a probiotic drink with Lactobacillus plantarum 299v on the bacterial composition in faeces and mucosal biopsies of rectum and ascending colon 2006 · Lactobacillus plantarum 299v drink · Patients undergoing colonoscopic examination for polyps; age and sex not reported | 100 billion CFU | 2 weeks | — |
| Oral supplementation with Lactobacillus casei subspecies rhamnosus prevents enteric colonization by Candida species in preterm neonates: a randomized study 2006 · group A · Preterm neonates with very low birth weight (<1500 g) | 6 billion CFU | 6 weeks | — |
| Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial 2008 · Bifidobacterium lactis Bl-04 group · Healthy adults aged 18–62 years | 20 billion CFU | 3 weeks | — |
| Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial 2008 · Lactobacillus acidophilus La-14 group · Healthy adults aged 18–62 years | 20 billion CFU | 3 weeks | — |
| Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial 2008 · Probiotic strain group 3 (strain not identified in abstract) · Healthy adults aged 18–62 years | 20 billion CFU | 3 weeks | — |
| Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial 2008 · Probiotic strain group 4 (strain not identified in abstract) · Healthy adults aged 18–62 years | 20 billion CFU | 3 weeks | — |
| Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial 2008 · Probiotic strain group 5 (strain not identified in abstract) · Healthy adults aged 18–62 years | 20 billion CFU | 3 weeks | — |
| Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial 2008 · Probiotic strain group 6 (strain not identified in abstract) · Healthy adults aged 18–62 years | 20 billion CFU | 3 weeks | — |
| Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial 2008 · Probiotic strain group 7 (strain not identified in abstract) · Healthy adults aged 18–62 years | 20 billion CFU | 3 weeks | — |
| In school-aged children a combination of galacto-oligosaccharides and Lactobacillus GG increases bifidobacteria more than Lactobacillus GG on its own 2008 · LGG alone · Healthy school-aged children | 6.5 billion CFU | 3 weeks | — |
| Lactobacillus casei abundance is associated with profound shifts in the infant gut microbiome 2010 · daily probiotic (Lactobacillus casei subsp. rhamnosus, LGG) · Infants at high risk for asthma development, supplemented from birth to 6 months; sex and exact age range not reported. | 1 billion CFU | 26 weeks | — |
| The effects of probiotic and conventional yoghurt on lipid profile in women 2010 · Probiotic yoghurt group · Women aged 19–49 years; no specific health condition stated | 300 g | 6 weeks | — |
| Intestinal and immunological effects of daily oral administration of Lactobacillus salivarius CECT5713 to healthy adults 2010 · Probiotic group · Healthy adults | 0.2 billion CFU | 4 weeks | — |
| The effect of pre- and probiotics on the colonic ammonia metabolism in humans as measured by lactose-[¹⁵N₂]ureide 2010 · Lactobacillus acidophilus (LC1) yoghurt · Healthy adults aged 20–28 years | 375 g | 10 days | — |
| Persistence of probiotic strains in the gastrointestinal tract when administered as capsules, yoghurt, or cheese 2010 · Capsules · Volunteers; age, sex, and health condition not specified | 10 billion CFU | 2 weeks | — |
| Persistence of probiotic strains in the gastrointestinal tract when administered as capsules, yoghurt, or cheese 2010 · Yoghurt · Volunteers; age, sex, and health condition not specified | 10 billion CFU | 2 weeks | — |
| Persistence of probiotic strains in the gastrointestinal tract when administered as capsules, yoghurt, or cheese 2010 · Cheese · Volunteers; age, sex, and health condition not specified | 10 billion CFU | 2 weeks | — |
| Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease 2011 · probiotic Lactobacillus rhamnosus strain GG · Obese children, mean age 10.7 years, with persisting hypertransaminasemia and ultrasonographic bright liver | 12 billion CFU | 8 weeks | — |
| Evaluation of the immune benefits of two probiotic strains Bifidobacterium animalis ssp. lactis, BB-12® and Lactobacillus paracasei ssp. paracasei, L. casei 431® in an influenza vaccination model: a randomised, double-blind, placebo-controlled study 2012 · BB-12® group · Healthy adults; mean age 33.2 years; 56% female | 1 billion CFU | 6 weeks | — |
| Evaluation of the immune benefits of two probiotic strains Bifidobacterium animalis ssp. lactis, BB-12® and Lactobacillus paracasei ssp. paracasei, L. casei 431® in an influenza vaccination model: a randomised, double-blind, placebo-controlled study 2012 · L. casei 431® group · Healthy adults; mean age 33.2 years; 56% female | 1 billion CFU | 6 weeks | — |
| Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial 2011 · group I · Patients with nonalcoholic fatty liver disease diagnosed by liver biopsy | 0.5 billion CFU | 90 days | — |
| Oral supplementation with Lactobacillus delbrueckii subsp. bulgaricus 8481 enhances systemic immunity in elderly subjects 2013 · probiotics · Elderly volunteers; age range and sex not specified | 0.09 billion CFU | 26 weeks | — |
| Lactobacillus plantarum CECT7315 and CECT7316 stimulate immunoglobulin production after influenza vaccination in elderly 2012 · group A · Institutionalized adults aged 65–85 years | 5 billion CFU | 90 days | — |
| Lactobacillus plantarum CECT7315 and CECT7316 stimulate immunoglobulin production after influenza vaccination in elderly 2012 · group B · Institutionalized adults aged 65–85 years | 0.5 billion CFU | 90 days | — |
| [Effect of perioperative intestinal probiotics on intestinal flora and immune function in patients with colorectal cancer] 2012 · oral intestinal probiotics (Jinshuangqi Tablets) · Patients with colorectal cancer undergoing elective laparoscopic radical surgery; age and sex not reported. | 6 g | 7 days | — |
| Immunomodulatory effects of a probiotic drink containing Lactobacillus casei Shirota in healthy older volunteers 2013 · Probiotic drink containing Lactobacillus casei Shirota · Healthy older volunteers; age range and sex not specified; no diagnosed condition stated | 13 billion CFU | 4 weeks | — |
| Probiotics for rectal volume variation during radiation therapy for prostate cancer 2013 · L acidophilus group · Prostate cancer patients receiving tomotherapy as radical treatment | 0.2 billion CFU | — | — |
| Oxalobacter formigenes: Opening the door to probiotic therapy for the treatment of hyperoxaluria 2015 · O. formigenes preparation group · Patients with calcium oxalate stones | 1.4 billion CFU | 30 days | — |
| Heat-killed Lactobacillus gasseri can enhance immunity in the elderly in a double-blind, placebo-controlled clinical study 2015 · Heat-killed TMC0356 · Healthy adults aged 50–70 years | 1 billion CFU | 4 weeks | — |
| Bacillus coagulans GBI-30, 6086 Modulates Faecalibacterium prausnitzii in Older Men and Women 2015 · probiotic BC30 · men and women aged 65–80 years | 1 billion CFU | 4 weeks | — |
| Supplementation with two probiotic strains, Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032, reduces fasting triglycerides and enhances apolipoprotein A-V levels in non-diabetic subjects with hypertriglyceridemia 2015 · probiotic group · Non-diabetic subjects with hypertriglyceridemia | 2 g | 12 weeks | — |
| Lactobacillus fermentum CECT 5716 Reduces Staphylococcus Load in the Breastmilk of Lactating Mothers Suffering Breast Pain: A Randomized Controlled Trial 2015 · 3×10(9) CFU/day group · Lactating women suffering from breast pain | 3 billion CFU | 3 weeks | — |
| Lactobacillus fermentum CECT 5716 Reduces Staphylococcus Load in the Breastmilk of Lactating Mothers Suffering Breast Pain: A Randomized Controlled Trial 2015 · 6×10(9) CFU/day group · Lactating women suffering from breast pain | 6 billion CFU | 3 weeks | — |
| Lactobacillus fermentum CECT 5716 Reduces Staphylococcus Load in the Breastmilk of Lactating Mothers Suffering Breast Pain: A Randomized Controlled Trial 2015 · 9×10(9) CFU/day group · Lactating women suffering from breast pain | 9 billion CFU | 3 weeks | — |
| Effect of Probiotic Soy Milk on Serum Levels of Adiponectin, Inflammatory Mediators, Lipid Profile, and Fasting Blood Glucose Among Patients with Type II Diabetes Mellitus 2017 · intervention group · Patients aged 35–68 with type 2 diabetes mellitus | 200 mL | 8 weeks | — |
| Kidney Function Improvement by Soy Milk Containing Lactobacillus plantarum A7 in Type 2 Diabetic Patients With Nephropathy: a Double-Blinded Randomized Controlled Trial 2017 · Probiotic soy milk · Patients with type 2 diabetes and diabetic nephropathy | 200 mL | 8 weeks | — |
| Probiotic yogurt and acidified milk similarly reduce postprandial inflammation and both alter the gut microbiota of healthy, young men 2017 · probiotic yogurt · healthy young men | 400 g | 2 weeks | — |
| Probiotic Soy Milk Consumption and Renal Function Among Type 2 Diabetic Patients with Nephropathy: a Randomized Controlled Clinical Trial 2019 · intervention group · Adults with type 2 diabetic nephropathy; age and sex not specified | 200 mL | 8 weeks | — |
| The effects of combined probiotic ingestion and circuit training on muscular strength and power and cytokine responses in young males 2018 · probiotics (P) · healthy sedentary young males | 60 billion CFU | 12 weeks | — |
| Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics 2018 · IVS-1 · Women and men aged 18–65 years with obesity (BMI 30.0–40.0 kg/m²) | 1 billion CFU | 3 weeks | — |
| Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics 2018 · BB-12 · Women and men aged 18–65 years with obesity (BMI 30.0–40.0 kg/m²) | 1 billion CFU | 3 weeks | — |
| Nasal microbiota clusters associate with inflammatory response, viral load, and symptom severity in experimental rhinovirus challenge 2018 · Probiotic · Healthy young adults challenged with rhinovirus | 2 billion CFU | 32 days | — |
| Probiotic or synbiotic alters the gut microbiota and metabolism in a randomised controlled trial of weight management in overweight adults 2019 · Bifidobacterium animalis subsp. lactis 420™ (B420) · Overweight or obese adults | 10 billion CFU | 26 weeks | — |
| An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans 2019 · SYNB1020, highest dose · Healthy adult men and women | 1,500 billion CFU | 2 weeks | — |
| Effect of ingesting yogurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 on influenza virus-bound salivary IgA in elderly residents of nursing homes: a randomized controlled trial 2019 · 1073R-1-yogurt group · elderly residents of nursing homes | 100 g | 12 weeks | — |
| Gut microbiota is associated with adiposity markers and probiotics may impact specific genera 2020 · probiotic mixture · Overweight or obese women | 20 billion CFU | — | — |
| Effects of the Consumption of Probiotic Yogurt Containing Bifidobacterium lactis Bb12 on the Levels of Streptococcus mutans and Lactobacilli in Saliva of Students with Initial Stages of Dental Caries: A Double-Blind Randomized Controlled Trial 2020 · intervention group · Students aged 18–30 with initial stages of dental caries | 300 g | 2 weeks | — |
| The Effect of Lactofem Oral Probiotic Capsule on Lactobacilli Colonization and Some Vaginal Health Parameters 2020 · oral probiotic group · Women aged 18–55 years with Nugent scores of 4–6 and vaginal pH greater than 4.5 | 500 mg | 60 days | — |
| Effects of probiotic supplementation on serum trimethylamine-N-oxide level and gut microbiota composition in young males: a double-blinded randomized controlled trial 2021 · probiotic group · Healthy males aged 20–25 years | 132 billion CFU | 4 weeks | — |
| The effects of 6 mo of supplementation with probiotics and synbiotics on gut microbiota in the adults with prediabetes: A double blind randomized clinical trial 2020 · multispecies probiotic · Adults with prediabetes | 6 g | 26 weeks | — |
| Lactobacillus reuteri DSM 17938 and Agave Inulin in Children with Cerebral Palsy and Chronic Constipation: A Double-Blind Randomized Placebo Controlled Clinical Trial 2020 · Probiotic group · Children aged 14–60 months with cerebral palsy (gross motor function levels IV or V) and chronic constipation | 0.1 billion CFU | 4 weeks | — |
| Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader-Willi Syndrome: A Randomized Crossover Trial 2020 · BPL1 probiotic · Children and adolescents aged 2–19 years with genetically confirmed Prader–Willi syndrome | 10 billion CFU | 12 weeks | — |
| The Impacts of Fish Oil and/or Probiotic Intervention on Low-Grade Inflammation, IGFBP-1 and MMP-8 in Pregnancy: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial 2020 · probiotics + placebo · Overweight or obese pregnant women at increased risk for gestational diabetes | 10 billion CFU | — | — |
| Lactobacillus casei Alleviated the Abnormal Increase of Cholestasis-Related Liver Indices During Tuberculosis Treatment: A Post Hoc Analysis of Randomized Controlled Trial 2021 · low-dose group · Patients receiving tuberculosis treatment; age range and sex not specified | 10 billion CFU | — | — |
| Lactobacillus casei Alleviated the Abnormal Increase of Cholestasis-Related Liver Indices During Tuberculosis Treatment: A Post Hoc Analysis of Randomized Controlled Trial 2021 · high-dose group · Patients receiving tuberculosis treatment; age range and sex not specified | 20 billion CFU | — | — |
| Regulation of Alcohol and Acetaldehyde Metabolism by a Mixture of Lactobacillus and Bifidobacterium Species in Human 2021 · Duolac ProAP4 · Men aged 19–65 years, healthy, BMI 18–25 kg/m², with prior hangover experience; participants were not homozygous for ALDH2*2 | 0.5 billion CFU | 15 days | — |
| Probiotic kefir consumption improves serum apolipoprotein A1 levels in metabolic syndrome patients: a randomized controlled clinical trial 2022 · probiotic kefir group · Adults with metabolic syndrome | 180 mL | 12 weeks | — |
| Carbon monoxide (CO) correlates with symptom severity, autoimmunity, and responses to probiotics treatment in a cohort of children with autism spectrum disorder (ASD): a post-hoc analysis of a randomized controlled trial 2022 · probiotics group · Children and young adults aged 3–25 with autism spectrum disorder (ASD) | 60 billion CFU | 16 weeks | — |
| Chronic consumption of probiotics, oats, and apples has differential effects on postprandial bile acid profile and cardiometabolic disease risk markers compared with an isocaloric control (cornflakes): a randomized trial 2023 · cornflakes with Lactobacillus reuteri · Adult volunteers, mean age 52 ± 12 years, with mean BMI 24.8 ± 3.4 kg/m² | 10 billion CFU | 8 weeks | — |
| Benefits of Probiotic Pretreatment on the Gut Microbiota and Minor Complications after Bowel Preparation for Colonoscopy: A Randomized Double-Blind, Placebo-Controlled Pilot Trial 2023 · active group · Adults aged 40–65 years undergoing colonoscopy for screening or post-polypectomy surveillance | 10 billion CFU | 30 days | — |
| Lactobacillus GG is associated with mucin genes expressions in type 2 diabetes mellitus: a randomized, placebo-controlled trial 2023 · probiotic group · Women aged 30–60 years with type 2 diabetes mellitus | 10 billion CFU | 8 weeks | — |
| Expanding CYLD protein in NF-κβ/TNF-α signaling pathway in response to Lactobacillus acidophilus in non-metastatic rectal cancer patients 2023 · L. acidophilus probiotic · Patients with non-metastatic rectal cancer; age and sex not specified | 1.5 g | 13 weeks | — |
| Impact of Extreme Prematurity, Chorioamnionitis, and Sepsis on Neonatal Monocyte Characteristics and Functions 2024 · L. reuteri group · Extremely preterm infants born at gestational weeks 23+0 to 27+6 with birthweight under 1,000 g | 0.125 billion CFU | — | — |
| Impact of Bifidobacterium animalis subsp. lactis BLa80 and Lacticaseibacillus rhamnosus LRa05 supplementation on the gut microbiota and metabolic health of alcohol-consuming individuals: a randomised, double-blind, placebo-controlled trial 2025 · intervention (maltodextrin + BLC) · healthy adults with alcohol-consuming habits | 20 billion CFU | 8 weeks | — |
| The impact of Bifidobacterium breve BBr60 (BBr60) on metabolic and gastrointestinal health in healthy adults: A combined in vitro metabolomic and randomized, double-blind, placebo-controlled study 2025 · BBr60 supplement · Healthy adults aged 19–45 | 10 billion CFU | 8 weeks | — |
| Efficacy of Probiotic VITA-PB2 from Fermented Foods on Alcohol Consumption and Hangover Symptoms: A Randomized, Double-Blind, Placebo-Controlled Trial 2025 · VITA-PB2 intervention · Healthy adults; age and sex ranges not specified. | 1 billion CFU | 1 day | — |
| Effect of Probiotics on the Gut Microbiota After Colonoscopy: A Multicenter, Randomized, Placebo-Controlled Clinical Study 2026 · probiotic group · Adults after colonoscopy; age and sex not specified | 1.5 g | 4 weeks | — |
| Effects of feeding premature infants with Lactobacillus GG on gut fermentation 1993 · Lactobacillus GG · Preterm infants | 0.2 billion CFU | 2 weeks | — |
| The impact of fish oil and/or probiotics on serum fatty acids and the interaction with low-grade inflammation in pregnant women with overweight and obesity: secondary analysis of a randomised controlled trial 2024 · probiotics + placebo · Pregnant women with overweight or obesity, recruited in early pregnancy before 18 gestational weeks | 20 billion CFU | 150 days | 92 |
| The impact of fish oil and/or probiotics on serum fatty acids and the interaction with low-grade inflammation in pregnant women with overweight and obesity: secondary analysis of a randomised controlled trial 2024 · fish oil + probiotics · Pregnant women with overweight or obesity, recruited in early pregnancy before 18 gestational weeks | 20 billion CFU | 150 days | 91 |
| Evaluation of the intestinal colonization by microencapsulated probiotic bacteria in comparison with the same uncoated strains 2010 · Uncoated probiotic strains · Healthy volunteers; age and sex not reported | 10 billion CFU | 3 weeks | 44 |
| Evaluation of the intestinal colonization by microencapsulated probiotic bacteria in comparison with the same uncoated strains 2010 · Microencapsulated probiotic strains · Healthy volunteers; age and sex not reported | 2 billion CFU | 3 weeks | 44 |
| Probiotic Administration Increases Amino Acid Absorption from Plant Protein: a Placebo-Controlled, Randomized, Double-Blind, Multicenter, Crossover Study 2020 · Protein plus probiotic · Healthy men aged 18–35 years with normal body weight who were recreationally active | 10 billion CFU | 2 weeks | 15 |
| Synbiotic Supplementation Improves Response to Iron Supplementation in Female Athletes during Training 2022 · Daily synbiotic supplement plus iron · Female athletes with low iron status | 8 billion CFU | 8 weeks | 9 |
| Plasma phytoestrogens are not altered by probiotic consumption in postmenopausal women with and without a history of breast cancer 2004 · soy + probiotics (S+P) · Postmenopausal women, including breast cancer survivors and controls | 1 billion CFU | 6 weeks | — |
| Probiotic normalization of Candida albicans in schizophrenia: A randomized, placebo-controlled, longitudinal pilot study 2017 · Probiotics · Adults aged 18–65 with schizophrenia or schizoaffective disorder, treated as outpatients | 2 billion CFU | 14 weeks | — |
| The Effect of Lactobacillus plantarum 299v on Iron Status and Physical Performance in Female Iron-Deficient Athletes: A Randomized Controlled Trial 2020 · LpFe · Female athletes aged 16–40 years with low iron stores, non-anemic, and regularly training at least 5 hours per week | 10 billion CFU | 12 weeks | — |
| Effects of Lactobacillus rhamnosus HN001 in early life on the cumulative prevalence of allergic disease to 11 years 2018 · Bifidobacterium lactis HN019 (HN019) · Mothers from 35 weeks' gestation while breastfeeding and their infants from birth to age 2 years | 9 billion CFU | 2 years | — |
| The effect of Lactiplantibacillus plantarum 299v together with a low dose of iron on iron status in healthy pregnant women: A randomized clinical trial 2021 · Lp group · Healthy, non-anemic pregnant women aged 18–42 years, with singleton pregnancies and iron-replete status at enrollment | 20 billion CFU | — | 120 |
| Neonatal administration of Lactiplantibacillus plantarum ATCC 202195 with or without fructooligosaccharide in Bangladesh: a placebo-controlled randomized trial 2025 · LP1 + FOS · Newborn infants aged 0–4 days at enrollment, generally healthy, born in two public hospitals in Dhaka, Bangladesh | 1 billion CFU | 1 day | 103 |
| Neonatal administration of Lactiplantibacillus plantarum ATCC 202195 with or without fructooligosaccharide in Bangladesh: a placebo-controlled randomized trial 2025 · LP7 + FOS · Newborn infants aged 0–4 days at enrollment, generally healthy, born in two public hospitals in Dhaka, Bangladesh | 1 billion CFU | 7 days | 103 |
| Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study 2021 · Bi group (Bifidobacterium) · Adults aged 18–70 with newly diagnosed hyperglycemia | 1.4 g | 16 weeks | 100 |
| Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study 2022 · Prob+BBR · Adults aged 20–70 years, both sexes, with newly diagnosed type 2 diabetes | 4 g | 12 weeks | 98 |
| Efficacy of the Synbiotic Supplementation on the Metabolic Factors in Patients with Metabolic Syndrome: A Randomized, Triple-Blind, Placebo-Controlled Trial 2022 · synbiotic · Adults with metabolic syndrome; age range and sex distribution not specified | 1 billion CFU | 12 weeks | 65 |
| Effects of synbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlled clinical trial 2014 · synbiotic food · Adults aged 35–70 with diabetes | 0.03 billion CFU | 6 weeks | 62 |
| Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease 2020 · synbiotic treatment · Adults with proven nonalcoholic fatty liver disease (NAFLD); ages and sex distribution not specified for this arm | 10 billion CFU | 1 year | 55 |
| Effect of synbiotic supplementation on immune parameters and gut microbiota in healthy adults: a double-blind randomized controlled trial 2023 · Synbiotic · Healthy adults aged 18–65 years; 66% female in this arm; no stated disease | 0.225 billion CFU | 8 weeks | 53 |
| Effects of beta-carotene fortified synbiotic food on metabolic control of patients with type 2 diabetes mellitus: A double-blind randomized cross-over controlled clinical trial 2016 · beta-carotene fortified synbiotic food · Patients with type 2 diabetes mellitus | 0.03 billion CFU | 6 weeks | 51 |
| Novel probiotic preparation with in vivo gluten-degrading activity and potential modulatory effects on the gut microbiota 2024 · probiotic group · Healthy men and women aged 18–65 years, with normal BMI, following a gluten-free diet during the challenge | 6 billion CFU | 32 days | 50 |
| Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study 2021 · BB group (berberine and Bifidobacterium) · Adults aged 18–70 with newly diagnosed hyperglycemia | 1.4 g | 16 weeks | 49 |
| Limosilactobacillus reuteri DSM 17938 supplementation and SARS-CoV-2 specific antibody response in healthy adults: a randomized, triple-blinded, placebo-controlled trial 2023 · active treatment (probiotic) · Healthy adults aged 18–60 years without prior SARS-CoV-2 infection or seropositivity | 0.2 billion CFU | 26 weeks | 48 |
| Impact of Synbiotic Intake on Liver Metabolism in Metabolically Healthy Participants and Its Potential Preventive Effect on Metabolic-Dysfunction-Associated Fatty Liver Disease (MAFLD): A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial 2024 · synbiotic (SYN) · Men aged 20–60 years, metabolically healthy, with BMI 20–34 kg/m² | 2 billion CFU | 7 weeks | 45 |
| Probiotics Support Resilience of the Oral Microbiota during Resolution after Experimental Gingivitis-A Randomized, Double-Blinded, Placebo-Controlled Trial 2023 · Probiotics group · Systemically and orally healthy adults aged 19–33 years | 2 billion CFU | 4 weeks | 40 |
| Gut microbiota of preterm infants supplemented with probiotics: sub-study of the ProPrems trial 2018 · Probiotic · Very preterm infants born before 32 weeks’ gestation and weighing less than 1500 g | 1 billion CFU | 9 weeks | 38 |
| Probiotic treatment induces changes in intestinal microbiota but does not alter SCFA levels in peritoneal dialysis patients-a randomized, placebo-controlled trial 2024 · probiotics (PR) group · Adults over 18 with stable continuous ambulatory peritoneal dialysis for more than 3 months | 60 billion CFU | 12 weeks | 38 |
| Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial 2014 · S. boulardii group · Patients with diarrhea-dominant irritable bowel syndrome | 750 mg | 6 weeks | 37 |
| Probiotics Partly Suppress the Impact of Sugar Stress on the Oral Microbiota-A Randomized, Double-Blinded, Placebo-Controlled Trial 2023 · probiotic group · Systemically and orally healthy adults aged 19–31 years | 2 billion CFU | 4 weeks | 36 |
| Effects of maternal allergy and supplementation with ω-3 fatty acid and probiotic on human milk oligosaccharides 2025 · OL (ω-3 PUFA + L. reuteri) · Pregnant women with a family history of allergies who intended to breastfeed for the first 3 months; maternal age median about 30 years | 2 billion CFU | 230 days | 36 |
| Probiotic effects of orally administered Lactobacillus salivarius WB21-containing tablets on periodontopathic bacteria: a double-blinded, placebo-controlled, randomized clinical trial 2009 · test group · Healthy volunteers without severe periodontitis; age and sex not specified | 2.01 billion CFU | 8 weeks | 34 |
| A combination of calcium phosphate and probiotics beneficially influences intestinal lactobacilli and cholesterol metabolism in humans 2012 · LPC37 plus CaP · Healthy, moderately hypercholesterolemic men and women | 10 billion CFU | 4 weeks | 32 |
| Evaluation of Lactocare® Synbiotic Administration on the Serum Electrolytes and Trace Elements Levels in Psoriasis Patients: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial Study 2022 · treatment group · Adults aged 18–60 with mild to moderate psoriasis | 2 billion CFU | 12 weeks | 32 |
| The effects of probiotic and selenium co-supplementation on parameters of mental health, hormonal profiles, and biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome 2018 · Probiotic plus selenium group · Women aged 18–40 with polycystic ovary syndrome (PCOS) | 8 billion CFU | 12 weeks | 30 |
| The effects of vitamin D and probiotic co-supplementation on glucose homeostasis, inflammation, oxidative stress and pregnancy outcomes in gestational diabetes: A randomized, double-blind, placebo-controlled trial 2019 · vitamin D plus probiotic · women with gestational diabetes; age not stated | 8 billion CFU | 6 weeks | 30 |
| Vitamin D and probiotic co-supplementation affects mental health, hormonal, inflammatory and oxidative stress parameters in women with polycystic ovary syndrome 2019 · vitamin D plus probiotic supplements · Women aged 18–40 with polycystic ovary syndrome | 8 billion CFU | 12 weeks | 30 |
| The effects of selenium plus probiotics supplementation on glycemic status and serum lipoproteins in patients with gestational diabetes mellitus: A randomized, double-blind, placebo-controlled trial 2022 · Probiotic plus selenium · Pregnant women with gestational diabetes mellitus | 8 billion CFU | 6 weeks | 30 |
| The effects of synbiotics on indoxyl sulphate level, constipation, and quality of life associated with constipation in chronic haemodialysis patients: a randomized controlled trial 2022 · Synbiotics · Adults over 18 years old with chronic kidney disease on haemodialysis and gastrointestinal complaints including constipation | 10 billion CFU | 60 days | 30 |
| Synergistic immunomodulatory effect of synbiotics pre- and postoperative resection of pancreatic ductal adenocarcinoma: a randomized controlled study 2024 · Synbiotics · Adults with pancreatic ductal adenocarcinoma undergoing pancreatoduodenectomy; age and sex not restricted | 25 billion CFU | 6 weeks | 30 |
| The effects of next generation probiotics on metabolic dysfunction-associated steatotic liver disease: a parallel, double-blind, randomized, placebo-controlled trial 2025 · LL001 · Adults with MASLD, mean age 47.0 years; 61% of participants were men | 9 billion CFU | 8 weeks | 29 |
| Effects of probiotic supplements on insulin resistance in gestational diabetes mellitus: A double-blind randomized controlled trial 2019 · probiotic group · Pregnant women aged 18–45 with newly diagnosed, diet-controlled gestational diabetes mellitus at 24–28 weeks of gestation | 2 billion CFU | 4 weeks | 28 |
| Effects of daily consumption of synbiotic bread on insulin metabolism and serum high-sensitivity C-reactive protein among diabetic patients: a double-blind, randomized, controlled clinical trial 2014 · synbiotic bread · Adults with type 2 diabetes mellitus | 0.3 billion CFU | 8 weeks | 27 |
| The Consumption of Synbiotic Bread Containing Lactobacillus sporogenes and Inulin Affects Nitric Oxide and Malondialdehyde in Patients with Type 2 Diabetes Mellitus: Randomized, Double-Blind, Placebo-Controlled Trial 2016 · Group A (synbiotic bread) · Patients with type 2 diabetes mellitus, aged 35–70 years; sex not specified | 0.3 billion CFU | 8 weeks | 27 |
| The effects of next generation probiotics on metabolic dysfunction-associated steatotic liver disease: a parallel, double-blind, randomized, placebo-controlled trial 2025 · PPKID7 · Adults with MASLD, mean age 47.0 years; 61% of participants were men | 9 billion CFU | 8 weeks | 27 |
| Synbiotic food consumption reduces levels of triacylglycerols and VLDL, but not cholesterol, LDL, or HDL in plasma from pregnant women 2014 · synbiotic food · Pregnant women aged 18–35 in their third trimester; primigravida | 0.02 billion CFU | 9 weeks | 26 |
| Beneficial effects of a new probiotic formulation on adipocytokines, appetite-regulating hormones, and metabolic parameters in obese women 2024 · intervention group · Obese women | 75 billion CFU | 12 weeks | 25 |
| The effects of next generation probiotics on metabolic dysfunction-associated steatotic liver disease: a parallel, double-blind, randomized, placebo-controlled trial 2025 · LH001 · Adults with MASLD, mean age 47.0 years; 61% of participants were men | 9 billion CFU | 8 weeks | 24 |
| Changes in Gut Microbiota and Systemic Inflammation after Synbiotic Supplementation in Patients with Systemic Lupus Erythematosus: A Randomized, Double-Blind, Placebo-Controlled Trial 2022 · synbiotic-supplemented group · Women aged 18–60 with systemic lupus erythematosus and gastrointestinal symptoms | 3 billion CFU | 60 days | 23 |
| Changes in peripheral immune populations during pregnancy and modulation by probiotics and ω-3 fatty acids 2020 · ω3 + L. reuteri · Pregnant women included at gestational week 20, with at least one parent or sibling with allergic disease history or symptoms | 2 billion CFU | 137 days | 22 |
| Probiotic-Reduced Inflammaging in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial 2025 · LpHEAL9 + Berries · Men and women aged 70 years or older with moderately elevated CRP (2–10 mg/L), otherwise healthy | 10 billion CFU | 4 weeks | 22 |
| Consumption of a new developed synbiotic yogurt improves oxidative stress status in adults with metabolic syndrome: a randomized controlled clinical trial 2024 · Intervention group · Adults aged 30–50 with metabolic syndrome and BMI 25–35 kg/m² | 0.2 billion CFU | 12 weeks | 22 |
| Oral Microbiota Shift after 12-Week Supplementation with Lactobacillus reuteri DSM 17938 and PTA 5289; A Randomized Control Trial 2015 · test group · Healthy adults aged 20–66 years | 0.4 billion CFU | 12 weeks | 21 |
| Potential reversal of epigenetic age using a diet and lifestyle intervention: a pilot randomized clinical trial 2021 · Treatment group · Men aged 50–72 without a history of recent or chronic disease | 0.04 billion CFU | 8 weeks | 21 |
| One-year application of probiotic strain Enterococcus faecium M-74 decreases serum cholesterol levels 2005 · E-group · Older adult volunteers; mean age 75.4 years | 2 billion CFU | 56 weeks | 20 |
| Effect of Bifidobacterium breve on the Intestinal Microbiota of Coeliac Children on a Gluten Free Diet: A Pilot Study 2016 · Probiotic group · Children aged 1–19 years with coeliac disease on a gluten-free diet | 2 billion CFU | 90 days | 20 |
| Interaction of orally administered Lactobacillus rhamnosus GG with skin and gut microbiota and humoral immunity in infants with atopic dermatitis 2011 · LGG-supplemented formula · Infants with atopic dermatitis | 3.4 billion CFU | 90 days | 19 |
| Acid production in dental plaque after exposure to probiotic bacteria 2012 · L. reuteri probiotic tablets · Healthy young adults, mean age 26 years, with moderate-to-high salivary mutans streptococci counts; 14 female and 4 male | 0.6 billion CFU | 2 weeks | 18 |
| Synbiotic Lactobacillus acidophilus NCFM and cellobiose does not affect human gut bacterial diversity but increases abundance of lactobacilli, bifidobacteria and branched-chain fatty acids: a randomized, double-blinded cross-over trial 2014 · synbiotic · Healthy volunteers; age and sex not reported. | 1 billion CFU | 3 weeks | 18 |
| Lactobacillus gasseri CECT 30648 shows probiotic characteristics and colonizes the vagina of healthy women after oral administration 2025 · Lg + Lc · Healthy premenopausal women aged 18–45 years | 1.5 billion CFU | 18 days | 18 |
| The Impact of Synbiotic Treatment on the Levels of Gut-Derived Uremic Toxins, Inflammation, and Gut Microbiome of Chronic Kidney Disease Patients-A Randomized Trial 2023 · intervention group · Adults aged 18 years or older with nondialyzed chronic kidney disease and eGFR 15–45 mL/minute | 32 billion CFU | 12 weeks | 17 |
| Effect of probiotic (VSL#3) and omega-3 on lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight adults: a randomized, controlled trial 2014 · Omega-3 capsule + VSL#3 capsule · Adults aged 40–60 of both sexes with BMI >25, apparently healthy and overweight | 113 billion CFU | 6 weeks | 15 |
| Probiotic Lactobacillus fermentum TSF331, Lactobacillus reuteri TSR332, and Lactobacillus plantarum TSP05 improved liver function and uric acid management-A pilot study 2024 · 3 Mix + PE0401 · Adults aged 18 or older with elevated AST, ALT, and uric acid levels and potential risk of MAFLD | 20.1 billion CFU | 60 days | 15 |
| Randomized pilot trial of a synbiotic dietary supplement in chronic HIV-1 infection 2012 · Synbiotic · Adult women with HIV-1 infection taking antiretroviral medication and with blood CD4 count >200 cells/μl | 10 billion CFU | 4 weeks | 14 |
| An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD) 2019 · Probiotics group · Adults with stable stage 3a chronic kidney disease (eGFR 45–60 ml/min/1.73 m²); ages over 18; men and women | 3.86 g | 111 days | 14 |
| The preterm gut microbiota and administration routes of different probiotics: a randomized controlled trial 2023 · C-LGG + Bb12 · Preterm neonates born at 25–35 weeks’ gestation, younger than 3 days at recruitment and admitted to the NICU | 2 billion CFU | — | 14 |
| Effect of probiotic administration during pregnancy on the functional diversity of the gut microbiota in healthy pregnant women 2024 · probiotic group (PG) · healthy pregnant women, recruited before 32 weeks of gestation | 0.01 billion CFU | — | 14 |
| Multi-Strain Probiotic Supplementation with a Product Containing Human-Native S. salivarius K12 in Healthy Adults Increases Oral S. salivarius 2021 · active · Healthy adults aged 21–45 years without diagnosed chronic metabolic disease or obesity | 18 billion CFU | 2 weeks | 13 |
| Effect of probiotic L. plantarum IS-10506 and zinc supplementation on humoral immune response and zinc status of Indonesian pre-school children 2014 · combination of probiotic and zinc · Indonesian children aged 12–24 months | 10 billion CFU | 90 days | 12 |
| Feasibility Study of Lactobacillus Plantarum 299v Probiotic Supplementation in an Urban Academic Facility among Diverse Pregnant Individuals 2023 · probiotic LP299V + prenatal vitamin with iron (PNVI) · Pregnant women with hemoglobin 10.0–12.0 g/dL at the initial prenatal visit; mean age 28.9 years | 10 billion CFU | — | 12 |
| Maternal-to-neonatal microbial transmission and impact of prenatal probiotics on neonatal gut development 2025 · probiotic group · Pregnant women with singleton first pregnancies, enrolled before 32 weeks’ gestation and delivering at term | 0.01 billion CFU | 53 days | 11 |
| Oral administration of Lactobacillus strains isolated from breast milk as an alternative for the treatment of infectious mastitis during lactation 2008 · probiotic group · Women with staphylococcal mastitis during lactation | 20 billion CFU | 4 weeks | 10 |
| Effects of Synbiotic Supplement on Human Gut Microbiota, Body Composition and Weight Loss in Obesity 2020 · synbiotic (treatment) group · Adult men and women, mean age 47.4 years, initially overweight or obese (mean BMI 33.5 kg/m²), enrolled in a weight-loss program; participants with gastrointestinal, autoimmune or metabolic diseases and relevant medications were excluded. | 15 billion CFU | 90 days | 10 |
| The preterm gut microbiota and administration routes of different probiotics: a randomized controlled trial 2023 · M-LGG + Bb12 · Mothers of preterm neonates born at 25–35 weeks’ gestation | 2 billion CFU | — | 10 |
| Effects of Lactobacillus salivarius-containing tablets on caries risk factors: a randomized open-label clinical trial 2014 · Short-term L. salivarius WB21 administration · Healthy dentists aged approximately 30 years, men and women | 2.01 billion CFU | 2 weeks | 8 |
| Pilot study of probiotic/colostrum supplementation on gut function in children with autism and gastrointestinal symptoms 2019 · Combination treatment (BCP + Bifidobacterium infantis) · Children aged 3.9–10.9 years with autism spectrum disorder and gastrointestinal symptoms | 20 billion CFU | 5 weeks | 8 |
| Probiotic consumption does not enhance the cholesterol-lowering effect of soy in postmenopausal women 2004 · soy protein isolate + probiotic capsules · postmenopausal women | 1 billion CFU | 6 weeks | — |
| Probiotic consumption does not enhance the cholesterol-lowering effect of soy in postmenopausal women 2004 · milk protein isolate + probiotic · postmenopausal women | 1 billion CFU | 6 weeks | — |
| Effect of chewing gums containing xylitol or probiotic bacteria on salivary mutans streptococci and lactobacilli 2007 · A, probiotic gum group · Healthy young adults aged 21–24 years | 0.6 billion CFU | 3 weeks | — |
| Effect of chewing gums containing xylitol or probiotic bacteria on salivary mutans streptococci and lactobacilli 2007 · C, probiotic + xylitol gum group · Healthy young adults aged 21–24 years | 0.3 billion CFU | 3 weeks | — |
| In school-aged children a combination of galacto-oligosaccharides and Lactobacillus GG increases bifidobacteria more than Lactobacillus GG on its own 2008 · LGG plus GOS · Healthy school-aged children | 6.5 billion CFU | 3 weeks | — |
| The influence of Lactobacillus rhamnosus LC705 together with Propionibacterium freudenreichii ssp. shermanii JS on potentially carcinogenic bacterial activity in human colon 2008 · Bacterial capsules · Healthy men; age not reported | 40 billion CFU | 4 weeks | — |
| Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial 2011 · Lactobacillus GG · Healthy adults aged 18–49 years | 20 billion CFU | 4 weeks | — |
| The triglyceride-lowering effect of supplementation with dual probiotic strains, Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032: Reduction of fasting plasma lysophosphatidylcholines in nondiabetic and hypertriglyceridemic subjects 2015 · probiotic group · participants with hypertriglyceridemia but without diabetes; age and sex not specified | 10 billion CFU | 12 weeks | — |
| Clinical application of probiotics in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study 2017 · probiotic group · Adults with type 2 diabetes mellitus | 2 billion CFU | 6 weeks | — |
| Consumption of dairy yogurt with the polysaccharide rhamnogalacturonan from the peel of the Korean citrus hallabong enhances immune function and attenuates the inflammatory response 2016 · test group · Nondiabetic, nonobese subjects; age and sex not specified | 50 mg | 8 weeks | — |
| Influence of Synbiotics on Selected Oxidative Stress Parameters 2017 · synbiotic group · Healthy volunteers aged 20–35 years, both sexes | 0.4 billion CFU | 7 weeks | — |
| Early gut mycobiota and mother-offspring transfer 2017 · probiotic milk · pregnant women, from 36 weeks of gestation until 3 months after birth; healthy pregnant women and their offspring were included in the cohort | 150 billion CFU | — | — |
| Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics 2018 · IVS-1 + GOS · Women and men aged 18–65 years with obesity (BMI 30.0–40.0 kg/m²) | 1 billion CFU | 3 weeks | — |
| Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics 2018 · BB-12 + GOS · Women and men aged 18–65 years with obesity (BMI 30.0–40.0 kg/m²) | 1 billion CFU | 3 weeks | — |
| A synbiotic supplement for inflammation and oxidative stress and lipid abnormalities in hemodialysis patients 2019 · synbiotic group · Hemodialysis patients; age and sex not reported | 100 mg | 8 weeks | — |
| Lactobacillus reuteri DSM 17938 and Agave Inulin in Children with Cerebral Palsy and Chronic Constipation: A Double-Blind Randomized Placebo Controlled Clinical Trial 2020 · Synbiotic group · Children aged 14–60 months with cerebral palsy (gross motor function levels IV or V) and chronic constipation | 0.1 billion CFU | 4 weeks | — |
| The Impacts of Fish Oil and/or Probiotic Intervention on Low-Grade Inflammation, IGFBP-1 and MMP-8 in Pregnancy: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial 2020 · fish oil + probiotics · Overweight or obese pregnant women at increased risk for gestational diabetes | 10 billion CFU | — | — |
| The effect of Bacillus coagulans Unique IS-2 supplementation on plasma amino acid levels and muscle strength in resistance trained males consuming whey protein: a double-blind, placebo-controlled study 2022 · supplemental group · Resistance-trained males, mean age 21.08 ± 2.84 years | 2 billion CFU | 60 days | — |
| The effect of synbiotic adjunct therapy on clinical and paraclinical outcomes in hospitalized COVID-19 patients: A randomized placebo-controlled trial 2023 · intervention group · Hospitalized patients with confirmed COVID-19 infection; age and sex not specified | 2 billion CFU | 2 weeks | — |
| Probiotic Supplementation, Hepatic Fibrosis, and the Microbiota Profile in Patients with Nonalcoholic Steatohepatitis: A Randomized Controlled Trial 2023 · PROs · Patients with NASH; median age 58 years; sex not specified | 2 billion CFU | 26 weeks | — |
| Multi-species synbiotic supplementation increased fecal short chain fatty acids and anti-inflammatory cytokine interleukin-10 in adult men with dyslipidemia; A randomized, double-blind, clinical trial 2024 · synbiotic group · Adult men with dyslipidemia | 60 billion CFU | 12 weeks | — |
| Effects of multi-species synbiotic supplementation on circulating miR-27a, miR-33a levels and lipid parameters in adult men with dyslipidaemia; a randomised, double-blind, placebo-controlled clinical trial 2025 · synbiotic · adult men with dyslipidaemia | 60 billion CFU | 12 weeks | — |
| Effect of combination of Beta Glucan and Lactobacillus rhamnosus HerizI on white blood cell counts and serum levels of IL-4 and IL-12 in women with breast cancer undergoing chemotherapy: A randomized double-blind placebo-controlled clinical trial 2024 · intervention group · Women with breast cancer receiving chemotherapy | 0.02 billion CFU | 3 weeks | — |
| Beneficial Effects of Synbiotics on the Gut Microbiome in Individuals with Low Fiber Intake: Secondary Analysis of a Double-Blind, Randomized Controlled Trial 2024 · synbiotic (SYN) group · Male non-smokers aged 20–60 without stated disease; secondary analysis stratified participants by low or high baseline fiber intake | 2 billion CFU | 7 weeks | — |
| Do Herbal Supplements and Probiotics Complement Antibiotics and Diet in the Management of SIBO? A Randomized Clinical Trial 2024 · Intervention group, CH4-SIBO or mixed SIBO · Adults with diagnosed methane SIBO or mixed hydrogen and methane SIBO | 250 mg | 90 days | 88 |
| Comparison of the kinetics of intestinal colonization by associating 5 probiotic bacteria assumed either in a microencapsulated or in a traditional, uncoated form 2012 · uncoated probiotic strains · healthy volunteers | 25 billion CFU | 3 weeks | 53 |
| Comparison of the kinetics of intestinal colonization by associating 5 probiotic bacteria assumed either in a microencapsulated or in a traditional, uncoated form 2012 · microencapsulated probiotic strains · healthy volunteers | 5 billion CFU | 3 weeks | 53 |
| The impact of synbiotic on serum sCD163/sTWEAK, paraoxonase 1, and lipoproteins in patients with chronic heart failure: a randomized, triple-blind, controlled trial 2024 · synbiotic group · Adults aged 30–70 with chronic heart failure, LVEF <40%, and NYHA class I–III | 30.4 billion CFU | 10 weeks | 45 |
| Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study 2008 · probiotic plus standard therapy · Adult men aged 18 or older admitted with alcohol-related psychosis and alcohol-induced liver injury | 0.99 billion CFU | 5 days | 32 |
| Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes 2013 · multispecies probiotic supplement · Adults aged 35–70 with type 2 diabetes | 39.2 billion CFU | 8 weeks | 27 |
| Synbiotic Bacillus megaterium DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study 2024 · SynΩ3 group · Healthy men and women aged 30–75 years, selected as at-risk individuals with omega-3 index ≤6.5% and elevated AGEs and/or hsCRP | 2 billion CFU | 4 weeks | 24 |
| The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial 2015 · probiotics group · Peritoneal dialysis patients with chronic kidney disease; age and sex not reported | 4 billion CFU | 26 weeks | 21 |
| Effects of Multispecies Probiotic Supplementation on Serum Bone Turnover Markers in Postmenopausal Women with Osteopenia: A Randomized, Double-Blind, Placebo-Controlled Trial 2024 · multispecies probiotic group · Postmenopausal women aged 45–70 with osteopenia | 8 billion CFU | 12 weeks | 20 |
| Effect and Tolerability of a Nutritional Supplement Based on a Synergistic Combination of β-Glucans and Selenium- and Zinc-Enriched Saccharomyces cerevisiae (ABB C1(®)) in Volunteers Receiving the Influenza or the COVID-19 Vaccine: A Randomized, Double-Blind, Placebo-Controlled Study 2021 · ABB C1® group, COVID-19-vaccine cohort · Men and women aged 18 years or older receiving COVID-19 vaccine, recruited from long-stay centers or as healthcare workers at the study centers | 233 mg | 5 weeks | 18 |
| Soluble fibre supplementation with and without a probiotic in adults with asthma: A 7-day randomised, double blind, three way cross-over trial 2019 · inulin+probiotic · Adults with doctor-diagnosed, stable asthma; median age 43 years, range 19–82; both sexes | 25 billion CFU | 7 days | 14 |
| Effect and Tolerability of a Nutritional Supplement Based on a Synergistic Combination of β-Glucans and Selenium- and Zinc-Enriched Saccharomyces cerevisiae (ABB C1(®)) in Volunteers Receiving the Influenza or the COVID-19 Vaccine: A Randomized, Double-Blind, Placebo-Controlled Study 2021 · ABB C1® group, influenza-vaccine cohort · Men and women aged 60 years or older receiving influenza vaccine and requiring hospitalization or ambulatory follow-up by palliative support teams | 233 mg | 30 days | 14 |
| An Innovative Synbiotic Formulation Decreases Free Serum Indoxyl Sulfate, Small Intestine Permeability and Ameliorates Gastrointestinal Symptoms in a Randomized Pilot Trial in Stage IIIb-IV CKD Patients 2021 · Synbiotic (arm S), CKD patients · Adults aged 30–65 with stage IIIb–IV chronic kidney disease, not on dialysis | 4.8 billion CFU | 60 days | 13 |
| An Innovative Synbiotic Formulation Decreases Free Serum Indoxyl Sulfate, Small Intestine Permeability and Ameliorates Gastrointestinal Symptoms in a Randomized Pilot Trial in Stage IIIb-IV CKD Patients 2021 · Synbiotic (arm S), healthy volunteers · Healthy adults aged 35–60 | 4.8 billion CFU | 60 days | 12 |
| Modulation of miR-29a and miR-29b Expression and Their Target Genes Related to Inflammation and Renal Fibrosis by an Oral Nutritional Supplement with Probiotics in Malnourished Hemodialysis Patients 2024 · ONS + probiotics (ONS-PR) · Adults over 18 years with malnutrition undergoing hemodialysis or hemodiafiltration | 5 billion CFU | 26 weeks | 10 |
| Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation 2010 · AKSB · Adults with calcium oxalate nephrolithiasis and mild hyperoxaluria of unknown cause | 10 billion CFU | 4 weeks | — |
| Probiotic supplementation restores normal microbiota composition and function in antibiotic-treated and in caesarean-born infants 2018 · treatment group · Pregnant mothers whose infants were at increased allergy risk (at least one parent with diagnosed allergic disease), and their infants | 12.2 billion CFU | 26 weeks | — |
| Potential Modulation of Inflammation by Probiotic and Omega-3 Supplementation in Elderly with Chronic Low-Grade Inflammation-A Randomized, Placebo-Controlled Trial 2022 · Active treatment group · Adults aged 65–80 with low-grade inflammation (hs-CRP 1.5–6 mg/L) and BMI 18.5–27 kg/m² | 10 billion CFU | 8 weeks | — |
| Effects of a Synbiotic on Plasma Immune Activity Markers and Short-Chain Fatty Acids in Children and Adults with ADHD-A Randomized Controlled Trial 2023 · Synbiotic 2000 · Children and adults aged 5–55 with ADHD | 400 billion CFU | 9 weeks | — |
| The effects of vitamin D and probiotic co-supplementation on glucose homeostasis, inflammation, oxidative stress and pregnancy outcomes in gestational diabetes: A randomized, double-blind, placebo-controlled trial 2019 · probiotic · women with gestational diabetes; age not stated | 8 billion CFU | 6 weeks | 29 |